


**CUMULATIVE  
SUPPLEMENT 7  
JULY 2017**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2017**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**Cumulative Supplement 7  
July 2017**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition .....	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 7**  
**July 2017**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                   FDA/CDER Orange Book Staff  
                                   Office of Generic Drugs  
                                   7620 Standish Place  
                                   Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.



## New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130	18391	18711		
	2646	2688	2708		
	(14.6%)	(14.6%)	(14.5%)		
MULTISOURCE	15484	15703	16003		
	(85.4%)	(85.4%)	(85.5%)		
THERAPEUTICALLY EQUIVALENT	15335	15581	15882		
	(84.7%)	(84.7%)	(84.9%)		
NOT THERAPEUTICALLY EQUIVALENT	129	122	121		
	(0.7%)	(0.7%)	(0.6%)		
EXCEPTIONS <sup>1</sup>	73	73	73		
	(0.4%)	(0.4%)	(0.4%)		
NEW MOLECULAR ENTITIES APPROVED	7	14	17		
NUMBER OF APPLICANTS	1051	1053	1050		

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
AB	AUROBINDO PHARMA LTD	EQ	600MG BASE; 300MG	A206151	001	Mar 28, 2017	Mar	NEWA	
AB	CIPLA LTD	EQ	600MG BASE; 300MG	A091144	001	Mar 28, 2017	Mar	NEWA	
AB	LUPIN LTD	EQ	600MG BASE; 300MG	A204990	001	Mar 28, 2017	Mar	NEWA	

ABALOPARATIDE

SOLUTION; SUBCUTANEOUS		TYMLOS							
+!	RADIUS HEALTH INC		3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr	NEWA	

ABIRATERONE ACETATE

TABLET; ORAL		ZYTIGA							
+	JANSSEN BIOTECH		500MG	N202379	002	Apr 14, 2017	May	NEWA	

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL		ACAMPROSATE CALCIUM							
AB	ZYDUS PHARMS USA INC		333MG	A205995	001	May 26, 2017	May	NEWA	

ACETAMINOPHEN

SOLUTION; IV (INFUSION)		ACETAMINOPHEN							
AP	CUSTOPHARM INC		1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan	CAHN	

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL		BUTALBITAL AND ACETAMINOPHEN							
AA	TEDOR PHARMA INC		300MG; 50MG	A207635	001	Jun 05, 2017	May	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
>A>	AB	TEDOR PHARMA INC	300MG; 50MG; 40MG	A206615	001	Aug 04, 2017	Jul	NEWA	
TABLET; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA		ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	Apr	CTNA	
AA		MALLINCKRODT INC	325MG; 50MG; 40MG	A087804	001	Jan 24, 1985	Mar	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>A>		@ ALLIED PHARMA INC	120MG/5ML; 12MG/5ML	A086366	001		Jul	CAHN	
>D>		@ ROXANE	120MG/5ML; 12MG/5ML	A086366	001		Jul	CAHN	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA	ABHAI LLC		300MG; 5MG	A209036	001	Jun 21, 2017	Jun	NEWA	
AA			300MG; 7.5MG	A209036	002	Jun 21, 2017	Jun	NEWA	
AA			300MG; 10MG	A209036	003	Jun 21, 2017	Jun	NEWA	
AA			325MG; 5MG	A209037	001	Jun 21, 2017	Jun	NEWA	
AA			325MG; 7.5MG	A209037	002	Jun 21, 2017	Jun	NEWA	
AA			325MG; 10MG	A209037	003	Jun 21, 2017	Jun	NEWA	
AA	AMNEAL PHARMS NY		300MG; 5MG	A206869	001	Jun 23, 2017	Jun	NEWA	
AA	LANNETT HOLDINGS INC		300MG; 5MG	A207171	001	Jun 20, 2017	Jun	NEWA	
AA			300MG; 7.5MG	A207171	002	Jun 20, 2017	Jun	NEWA	
AA			300MG; 10MG	A207171	003	Jun 20, 2017	Jun	NEWA	
AA			325MG; 5MG	A207172	001	Jun 22, 2017	Jun	NEWA	
AA			325MG; 7.5MG	A207172	002	Jun 22, 2017	Jun	NEWA	
AA			325MG; 10MG	A207172	003	Jun 22, 2017	Jun	NEWA	
AA	MALLINCKRODT INC		300MG; 5MG	A206718	001	Mar 31, 2017	Mar	NEWA	
AA			300MG; 7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA	
AA			300MG; 10MG	A206718	003	Mar 31, 2017	Mar	NEWA	
AA	!	MIKART	300MG; 7.5MG	A040658	002	Mar 24, 2006	May	CHRS	
AA			300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1	
AA	!		300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS	
AA			300MG; 10MG	A040658	003	Jun 23, 2004	Apr	CMS1	

## TABLET;ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	UPSHER-SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Jun	CAHN
AA		325MG;5MG	A206484	001	Mar 24, 2017	Mar	NEWA
AA		325MG;7.5MG	A206484	002	Mar 24, 2017	Jun	CAHN
AA		325MG;7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
AA		325MG;10MG	A206484	003	Mar 24, 2017	Jun	CAHN
AA		325MG;10MG	A206484	003	Mar 24, 2017	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## TABLET;ORAL

## OXYCODONE AND ACETAMINOPHEN

AA	AMNEAL PHARMS	325MG;5MG	A040777	001	Nov 27, 2007	May	CAHN
AA	ASCENT PHARMS INC	325MG;2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
AA		325MG;5MG	A207419	002	Mar 22, 2017	Mar	NEWA
AA		325MG;7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
AA		325MG;10MG	A207419	004	Mar 22, 2017	Mar	NEWA
AA	NOVEL LABS INC	325MG;2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
AA		325MG;5MG	A204407	002	Feb 24, 2017	Feb	NEWA
AA		325MG;7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
AA		325MG;10MG	A204407	004	Feb 24, 2017	Feb	NEWA
PERCOCET							
AA	! VINTAGE PHARMS LLC	325MG;7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
AA	!	325MG;10MG	A040330	004	Nov 23, 2001	Jan	CMS1

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

## TABLET;ORAL

## TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
AB	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	Apr	NEWA

ACETAZOLAMIDE

## TABLET;ORAL

## ACETAZOLAMIDE

>A>	AB	SUN PHARM INDS	125MG	A089753	002	Jun 22, 1988	Jul	CMS1
-----	----	----------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

## INJECTABLE;INJECTION

## ACETAZOLAMIDE SODIUM

AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun	NEWA
----	----------------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

## SOLUTION;IRRIGATION, URETHRAL

## ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	250MG/100ML	N017656	001		Feb	CAHN
----	-----------------	-------------	---------	-----	--	-----	------

ACETOHEXAMIDE

## TABLET;ORAL

## ACETOHEXAMIDE

@ WATSON LABS TEVA

250MG

A071893 001 Nov 25, 1987 May CAHN

@

500MG

A071894 001 Nov 25, 1987 May CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

## CAPSULE;ORAL

## SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG;60MG

N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

## CAPSULE;ORAL

## ACYCLOVIR

AB BOSCOGEN 200MG A075090 001 Jan 26, 1999 May CAHN

@ CHARTWELL MOLECULES

200MG

A074872 001 Apr 22, 1997 Jan CAHN

@ MYLAN

200MG

A074727 001 Apr 22, 1997 Jun DISC

## ZOVIRAX

AB +! MYLAN PHARMS INC 200MG N018828 001 Jan 25, 1985 Jan CAHN

## OINTMENT;TOPICAL

## ACYCLOVIR

&gt;A&gt; AB GLENMARK PHARMS LTD 5% A205510 001 Jul 31, 2017 Jul NEWA

&gt;A&gt; AB TOLMAR 5% A206437 001 Jul 31, 2017 Jul NEWA

	SUSPENSION; ORAL						
	ZOVIRAX						
AB	+	MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan CAHN
	TABLET; BUCCAL						
	SITAVIG						
	+	EPI HLTH	50MG	N203791	001	Apr 12, 2013	Jun CAHN
	TABLET; ORAL						
	ACYCLOVIR						
	@	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997	Jan CAHN
	@		800MG	A074834	002	Apr 24, 1997	Jan CAHN
AB		HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	Apr CMFD
AB			800MG	A074891	002	Oct 31, 1997	Apr CMFD
AB		MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar CAHN
AB			800MG	A075211	002	Sep 28, 1998	Mar CAHN
	ZOVIRAX						
AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan CAHN
AB	+		800MG	N020089	002	Apr 30, 1991	Jan CAHN
	<u>ACYCLOVIR SODIUM</u>						
	INJECTABLE; INJECTION						
	ACYCLOVIR SODIUM						
	@	ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN
AP	!	HIKMA PHARMS	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar CTEC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar NEWA
AP			EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar NEWA
AP		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May NEWA
AP			EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May NEWA
	<u>ADENOSINE</u>						
	INJECTABLE; INJECTION						
	ADENOSINE						
AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
	@		3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN
	<u>ALBENDAZOLE</u>						
	TABLET; ORAL						
	ALBENZA						
	+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun CAHN
	<u>ALBUTEROL SULFATE</u>						
	AEROSOL, METERED; INHALATION						
	PROVENTIL-HFA						
BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN
	SOLUTION; INHALATION						
	ALBUTEROL SULFATE						
>A>	AN	SUN PHARMA GLOBAL	EQ 0.083% BASE	A207857	001	Jul 21, 2017	Jul NEWA
	<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>						
	SOLUTION; INHALATION						
	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE						
>A>	AN	SUN PHARMA GLOBAL	EQ 0.083% BASE; 0.17%	A207875	001	Aug 07, 2017	Jul NEWA
	AN	WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb CAHN
	<u>ALENDRONATE SODIUM</u>						
	TABLET; ORAL						
	ALENDRONATE SODIUM						
	@	UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Jun CAHN
	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Jun CAHN
	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Jun CAHN
	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Jun CAHN
	@		EQ 70MG BASE	A075871	005	Apr 22, 2009	Jun CAHN
	<u>ALLOPURINOL</u>						
	TABLET; ORAL						
	ZYLOPRIM						
>A>	AB	+ CASPER PHARMA LLC	100MG	N016084	001		Jul CAHN
>A>	AB	+	300MG	N016084	002		Jul CAHN
>D>	AB	+ SEBELA IRELAND LTD	100MG	N016084	001		Jul CAHN
>D>	AB	+	300MG	N016084	002		Jul CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May	CAHN
AB		EQ 1MG BASE	A206647	002	Dec 22, 2016	May	CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May	CAHN
----	------------	---	---------	-----	--------------	-----	------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May	CAHN
----	------------	--	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr	CAHN
AB		0.5MG	A074342	002	Oct 31, 1993	Apr	CAHN
AB		1MG	A074342	003	Oct 31, 1993	Apr	CAHN
AB		2MG	A074342	004	Oct 31, 1993	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan	CAHN
AB		1MG	A090871	002	Jun 07, 2011	Jan	CAHN
AB		2MG	A090871	003	Jun 07, 2011	Jan	CAHN
AB		3MG	A090871	004	Jun 07, 2011	Jan	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	May	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	May	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	May	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	May	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	May	CAHN

SUPPOSITORY; URETHRAL

MUSE

+!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar	CAHN
+!		0.25MG	N020700	002	Nov 19, 1996	Mar	CAHN
+!		0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN
+!		1MG	N020700	004	Nov 19, 1996	Mar	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun	NEWA
AB	HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May	NEWA
AB	LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May	NEWA
AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May	NEWA
AB	USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun	CAHN

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May	CAHN

SYMMETREL

+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD
---	---	-------------	----------	---------	-----	--	-----	------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May	NEWA
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun	CAHN

AMCINONIDECREAM; TOPICAL  
CYCLOCORT+ @ ASTELLAS 0.025%  
+ @ 0.1%N018116 001  
N018116 002Jun CRLD  
Jun CRLDLOTION; TOPICAL  
CYCLOCORT

+ @ ASTELLAS 0.1%

N019729 001 Jun 13, 1988

Jun CRLD

OINTMENT; TOPICAL  
CYCLOCORT

+ @ ASTELLAS 0.1%

N018498 001

Jun CRLD

AMIFOSTINEINJECTABLE; INJECTION  
AMIFOSTINE>A> AP MYLAN LABS LTD 500MG/VIAL  
AP SUN PHARMA GLOBAL 500MG/VIALA204363 001 Jul 17, 2017  
A077126 001 Mar 14, 2008Jul NEWA  
Apr CAHNAMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>A> AB WINDLAS HLTHCARE 5MG  
>D> AB ZYDUS PHARMS USA INC 5MGA204180 001 Aug 07, 2015  
A204180 001 Aug 07, 2015Jul CAHN  
Jul CAHNAMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

ICU MEDICAL INC 10% (10GM/100ML)

N017673 003

Feb CAHN

AMINOSYN 10% (PH6)

ICU MEDICAL INC 10% (10GM/100ML)

N017673 008 Nov 18, 1985

Feb CAHN

AMINOSYN 3.5%

ICU MEDICAL INC 3.5% (3.5GM/100ML)

N017789 004

Feb CAHN

AMINOSYN 5%

ICU MEDICAL INC 5% (5GM/100ML)

N017673 001

Feb CAHN

AMINOSYN 7%

ICU MEDICAL INC 7% (7GM/100ML)

N017673 002

Feb CAHN

AMINOSYN 7% (PH6)

ICU MEDICAL INC 7% (7GM/100ML)

N017673 006 Nov 18, 1985

Feb CAHN

AMINOSYN 8.5%

ICU MEDICAL INC 8.5% (8.5GM/100ML)

N017673 004

Feb CAHN

AMINOSYN 8.5% (PH6)

ICU MEDICAL INC 8.5% (8.5GM/100ML)

N017673 007 Nov 18, 1985

Feb CAHN

AMINOSYN II 10%

ICU MEDICAL INC 10% (10GM/100ML)

N019438 005 Apr 03, 1986

Feb CAHN

AMINOSYN II 10% IN PLASTIC CONTAINER

ICU MEDICAL INC 10% (10GM/100ML)

N020015 001 Dec 19, 1991

Feb CAHN

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU MEDICAL INC 15% (15GM/100ML)

N020041 001 Dec 19, 1991

Feb CAHN

AMINOSYN II 3.5%

@ ICU MEDICAL INC 3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

Feb CAHN

AMINOSYN II 5%

@ ICU MEDICAL INC 5% (5GM/100ML)

N019438 002 Apr 03, 1986

Feb CAHN

AMINOSYN II 7%

ICU MEDICAL INC 7% (7GM/100ML)

N019438 003 Apr 03, 1986

Feb CAHN

AMINOSYN II 8.5%

ICU MEDICAL INC 8.5% (8.5GM/100ML)

N019438 004 Apr 03, 1986

Feb CAHN

AMINOSYN-HBC 7%

ICU MEDICAL INC 7% (7GM/100ML)

N019374 001 Jul 12, 1985

Feb CAHN

AMINOSYN-HF 8%

ICU MEDICAL INC 8% (8GM/100ML)

A020345 001 Apr 04, 1996

Jun CAHN

AMINOSYN-PF 10%

ICU MEDICAL INC 10% (10GM/100ML)

N019492 002 Oct 17, 1986

Feb CAHN

AMINOSYN-PF 7%

ICU MEDICAL INC 7% (7GM/100ML)

N019398 001 Sep 06, 1985

Feb CAHN

AMINOSYN-RF 5.2%

ICU MEDICAL INC 5.2% (5.2GM/100ML)

N018429 001

Apr CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC

3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML N017789 003

Feb CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC

3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML N017789 005

Feb CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC

10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 004 Apr 03, 1986 Apr CAHN

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC

7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 006 Apr 03, 1986 Apr CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC

8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 005 Apr 03, 1986 Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC

3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML N019437 007 Apr 03, 1986 Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC

7%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017789 002

Feb CAHN

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC

8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017673 005

Feb CAHN

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION; ORAL

GLEOLAN

+! NXDC

1.5GM/VIAL

N208630 001 Jun 06, 2017 Jun NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MAYNE PHARMA INC

200MG

A075389 001 Jan 25, 2001 Jan CAHN

@ MYLAN

200MG

A075188 001 Feb 24, 1999 Mar DISC

AB ! SANDOZ

200MG

A075315 001 Dec 23, 1998 Mar CHRS

AB TARO PHARM

100MG

A075424 002 Dec 18, 2002 Mar CAHN

AB

200MG

A075424 001 Mar 30, 2001 Mar CAHN

AB

300MG

A076362 002 Dec 02, 2003 Mar CAHN

AB

400MG

A076362 001 Nov 29, 2002 Mar CAHN

CORDARONE

+ @ WYETH PHARMS INC

200MG

N018972 001 Dec 24, 1985 Jan DISC

PACERONE

AB UPSHER-SMITH LABS

100MG

A075135 002 Apr 12, 2005 Jun CAHN

AB

200MG

A075135 001 Apr 30, 1998 Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

+ @ ASTRAZENECA

10MG

N012703 001

Mar CRLD

+ @

25MG

N012703 003

Mar CRLD

+ @

50MG

N012703 004

Mar CRLD

+ @

75MG

N012703 005

Mar CRLD

+ @

100MG

N012703 006

Mar CRLD

+ @

150MG

N012703 007

Mar CRLD



AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN
--------------------	--------------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar CAHN
	@	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar CAHN
	@	EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar CAHN
	@	EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC
AB	UPSHER-SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun CAHN
AB		EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun CAHN
AB		EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>A>	AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017	Jul NEWA
>A>	AB		EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017	Jul NEWA
>A>	AB		EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017	Jul NEWA
>A>	AB		EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017	Jul NEWA
>A>	AB	ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017	Jul NEWA
>A>	AB		EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017	Jul NEWA
>A>	AB		EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017	Jul NEWA
>A>	AB		EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017	Jul NEWA
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May NEWA
AB			EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May NEWA
AB			EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May NEWA
AB			EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May NEWA
AB		GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Jun NEWA
AB			EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Jun NEWA
AB			EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Jun NEWA
AB			EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Jun NEWA
AB		JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May NEWA
AB			EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May NEWA
AB			EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May NEWA
AB			EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May NEWA
AB		TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr CAHN
AB			EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr CAHN
AB			EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr CAHN
AB			EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
----	----------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

+ @ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
-------------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Jun CAHN
@	50MG	A072944	001	Jun 28, 1991	Jun CAHN
@	100MG	A072878	001	Jun 28, 1991	Jun CAHN
@	150MG	A072879	001	Jun 28, 1991	Jun CAHN
@ WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb CAHN
@	50MG	A072419	001	May 11, 1989	Feb CAHN
@	100MG	A072420	001	May 11, 1989	Feb CAHN
@	150MG	A072421	001	May 11, 1989	Feb CAHN

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXIL

@ DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Feb	DISC
@	400MG/5ML	N050760	002	Apr 15, 1999	Feb	DISC

TABLET;ORAL

AMOXIL

+ @ DR REDDYS LABS INC	500MG	N050754	002	Jul 10, 1998	Mar	DISC
+ @	875MG	N050754	001	Jul 10, 1998	Mar	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

TEVA	125MG	A064013	002	Sep 11, 1995	Feb	CTEC
!	250MG	A064013	001	Dec 22, 1992	Feb	CTEC
AMOXIL						
+ @ DR REDDYS LABS INC	125MG	N050542	002		Feb	DISC
+ @	250MG	N050542	001		Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AUGMENTIN '200'

+ @ DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb	DISC
AUGMENTIN '400'						
+ @ DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb	DISC
AUGMENTIN ES-600						
+ @ DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb	DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb	CHRS
AB	!	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb	CHRS
		AUGMENTIN '250'						
		+ @ DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb	DISC
		AUGMENTIN '500'						
		+ @ DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb	CTEC
!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb	CTEC
AUGMENTIN '200'						
+ @ DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb	DISC
AUGMENTIN '400'						
+ @ DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

+ SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jun	NEWA
+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jun	NEWA
+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jun	NEWA
+	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jun	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ALVOGEN MALTA	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017	Jul	NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017	Jul	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017	Jul	NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017	Jul	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017	Jul	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017	Jul	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017	Jul	NEWA
	AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May	CAHN
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May	CAHN
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	CAHN
	AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May	CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@	WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A 062692	001	Jun 24, 1986	Jan CAHN
@		EQ 250MG BASE/VIAL	A 062692	002	Jun 24, 1986	Jan CAHN
@		EQ 500MG BASE/VIAL	A 062692	003	Jun 24, 1986	Jan CAHN
@		EQ 1GM BASE/VIAL	A 062692	004	Jun 24, 1986	Jan CAHN
@		EQ 2GM BASE/VIAL	A 062692	005	Jun 24, 1986	Jan CAHN
@		EQ 10GM BASE/VIAL	A 062692	006	Jun 24, 1986	Jan CAHN
	PENBRITIN-S					
+ @	WYETH AYERST	EQ 125MG BASE/VIAL	N 050072	001		Jun CRLD
+ @		EQ 250MG BASE/VIAL	N 050072	002		Jun CRLD
+ @		EQ 500MG BASE/VIAL	N 050072	003		Jun CRLD
+ @		EQ 1GM BASE/VIAL	N 050072	004		Jun CRLD
+ @		EQ 2GM BASE/VIAL	N 050072	005		Jun CRLD
+ @		EQ 4GM BASE/VIAL	N 050072	006		Jun CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

>A>	AP	ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 201406	001	Dec 07, 2015	Jul CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 201406	002	Dec 07, 2015	Jul CAHN
>D>	AP	ANTIBIOTICS SA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 201406	001	Dec 07, 2015	Jul CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 201406	002	Dec 07, 2015	Jul CAHN
	AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065074	001	Mar 19, 2002	Jan CAHN
	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065074	002	Mar 19, 2002	Jan CAHN
	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 065076	001	Mar 19, 2002	Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 0.5MG BASE	A 076811	001	Apr 18, 2005	May DISC
AB		EQ 0.5MG BASE	A 076811	001	Apr 18, 2005	Mar CAHN
@		EQ 0.5MG BASE	A 077613	001	Jun 27, 2006	May DISC
@		EQ 1MG BASE	A 076811	002	Apr 18, 2005	May DISC
AB		EQ 1MG BASE	A 076811	002	Apr 18, 2005	Mar CAHN
@		EQ 1MG BASE	A 077613	002	Jun 27, 2006	May DISC
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A 209151	001	Jun 30, 2017	Jun NEWA
AB		EQ 1MG BASE	A 209151	002	Jun 30, 2017	Jun NEWA
@	UPSHER-SMITH LABS	EQ 0.5MG BASE	A 076683	001	Apr 18, 2005	Jun CAHN
@		EQ 1MG BASE	A 076683	002	Apr 18, 2005	Jun CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@	WATSON LABS TEVA	1MG	A 078984	001	Jun 28, 2010	May CAHN	
AB	+!	ASTRAZENECA PHARMS	1MG	N 020541	001	Dec 27, 1995	May CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N 203049	002	Sep 30, 2016	Feb NEWA	
AP	+!	NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N 020883	001	Jun 30, 2000	Jun CAHN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A 205570	001	May 22, 2017	May NEWA	
AP	+!	SANDOZ	125MG/125ML (1MG/ML)	N 022485	001	May 09, 2011	May CFTG

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

AB	ORCHID HLTHCARE	2MG	A 202683	001	May 23, 2017	May NEWA
AB		5MG	A 202683	002	May 23, 2017	May NEWA
AB		10MG	A 202683	003	May 23, 2017	May NEWA
AB		15MG	A 202683	004	May 23, 2017	May NEWA
AB		20MG	A 202683	005	May 23, 2017	May NEWA
AB		30MG	A 202683	006	May 23, 2017	May NEWA
AB	SANTOS BIOTECH	2MG	A 091279	001	Jan 09, 2017	May CAHN

<u>TABLET; ORAL</u>								
<u>ARIPIPIRAZOLE</u>								
AB		5MG	A091279	002	Jan 09, 2017	May	CAHN	
AB		10MG	A091279	003	Jan 09, 2017	May	CAHN	
AB		15MG	A091279	004	Jan 09, 2017	May	CAHN	
AB		20MG	A091279	005	Jan 09, 2017	May	CAHN	
AB		30MG	A091279	006	Jan 09, 2017	May	CAHN	
<u>ARIPIPIRAZOLE LAUROXIL</u>								
SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR								
ARISTADA								
+	ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun	NEWA	
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE</u>								
INJECTABLE; INJECTION								
SEPTOCAINE								
AP	+!	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun	CFTG
ULTACAN								
AP		HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun	NEWA
ULTACAN FORTE								
AP		HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun	NEWA
<u>ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K</u>								
INJECTABLE; IV (INFUSION)								
INFUVITE PEDIATRIC								
+	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;1.7MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	May	CAHN	
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)								
+	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;1.7MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004	May	CAHN	
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>								
TABLET; ORAL								
FIORINAL								
+	@ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CRLD	
<u>ASPIRIN; DIPYRIDAMOLE</u>								
CAPSULE, EXTENDED RELEASE; ORAL								
ASPIRIN AND DIPYRIDAMOLE								
AB		AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	May	CAHN
AB		IMPAX LABS INC	25MG;200MG	A206964	001	Jan 18, 2017	Jan	NEWA
AB		PAR PHARM INC	25MG;200MG	A207944	001	Jan 18, 2017	Jan	NEWA
AB		SANDOZ INC	25MG;200MG	A206739	001	Jan 18, 2017	Jan	NEWA
<u>ATENOLOL</u>								
TABLET; ORAL								
ATENOLOL								
@	WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May	CAHN	
<u>ATOMOXETINE HYDROCHLORIDE</u>								
CAPSULE; ORAL								
ATOMOXETINE HYDROCHLORIDE								
AB		APOTEX INC	10MG	A078983	001	May 30, 2017	May	NEWA
AB			18MG	A078983	002	May 30, 2017	May	NEWA
AB			25MG	A078983	003	May 30, 2017	May	NEWA
AB			40MG	A078983	004	May 30, 2017	May	NEWA
AB			60MG	A078983	005	May 30, 2017	May	NEWA
AB			80MG	A078983	006	May 30, 2017	May	NEWA
AB			100MG	A078983	007	May 30, 2017	May	NEWA
AB		AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May	NEWA
AB			18MG	A079016	002	May 30, 2017	May	NEWA
AB			25MG	A079016	003	May 30, 2017	May	NEWA
AB			40MG	A079016	004	May 30, 2017	May	NEWA
AB			60MG	A079016	005	May 30, 2017	May	NEWA

CAPSULE;ORAL							
ATOMOXETINE HYDROCHLORIDE							
AB		80MG		A079016	006	May 30, 2017	May NEWA
AB		100MG		A079016	007	May 30, 2017	May NEWA
AB	GLENMARK PHARMS LTD	10MG		A079019	001	May 30, 2017	May NEWA
AB		18MG		A079019	002	May 30, 2017	May NEWA
AB		25MG		A079019	003	May 30, 2017	May NEWA
AB		40MG		A079019	004	May 30, 2017	May NEWA
AB		60MG		A079019	005	May 30, 2017	May NEWA
AB		80MG		A079019	006	May 30, 2017	May NEWA
AB		100MG		A079019	007	May 30, 2017	May NEWA
AB	TEVA PHARMS USA	10MG		A079022	001	May 30, 2017	May NEWA
AB		18MG		A079022	002	May 30, 2017	May NEWA
AB		25MG		A079022	003	May 30, 2017	May NEWA
AB		40MG		A079022	004	May 30, 2017	May NEWA
AB		60MG		A079022	005	May 30, 2017	May NEWA
AB		80MG		A079022	006	May 30, 2017	May NEWA
AB		100MG		A079022	007	May 30, 2017	May NEWA
STRATTERA							
AB	+ LILLY	10MG		N021411	002	Nov 26, 2002	May CFTG
AB	+	18MG		N021411	003	Nov 26, 2002	May CFTG
AB	+	25MG		N021411	004	Nov 26, 2002	May CFTG
AB	+	40MG		N021411	005	Nov 26, 2002	May CFTG
AB	+!	60MG		N021411	006	Nov 26, 2002	May CFTG
AB	+	80MG		N021411	007	Feb 14, 2005	May CFTG
AB	+	100MG		N021411	008	Feb 14, 2005	May CFTG
<u>ATORVASTATIN CALCIUM</u>							
TABLET;ORAL							
ATORVASTATIN CALCIUM							
AB	TEVA PHARMS USA	EQ 10MG BASE		A205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE		A205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE		A205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE		A205300	004	Mar 27, 2017	Mar NEWA
<u>ATORVASTATIN CALCIUM; EZETIMIBE</u>							
TABLET;ORAL							
EZETIMIBE AND ATORVASTATIN CALCIUM							
	WATSON LABS TEVA	EQ 10MG BASE;10MG		A206084	001	Apr 26, 2017	Apr NEWA
		EQ 20MG BASE;10MG		A206084	002	Apr 26, 2017	Apr NEWA
		EQ 40MG BASE;10MG		A206084	003	Apr 26, 2017	Apr NEWA
	!	EQ 80MG BASE;10MG		A206084	004	Apr 26, 2017	Apr NEWA
<u>ATOVAQUONE</u>							
SUSPENSION;ORAL							
ATOVAQUONE							
AB	PADDOCK LLC	750MG/5ML		A207833	001	Apr 28, 2017	Apr NEWA
<u>ATRACURIUM BESYLATE</u>							
INJECTABLE;INJECTION							
ATRACURIUM BESYLATE							
AP	MYLAN LABS LTD	10MG/ML		A206096	001	Jun 22, 2017	Jun NEWA
	@ WATSON PHARMS TEVA	10MG/ML		A074945	001	Jul 28, 1998	Feb CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	MYLAN LABS LTD	10MG/ML		A206001	001	Apr 07, 2017	Mar NEWA
TRACRIUM							
+	@ HOSPIRA	10MG/ML		N018831	002	Jun 20, 1985	Apr CMS1
TRACRIUM PRESERVATIVE FREE							
+	@ HOSPIRA	10MG/ML		N018831	001	Nov 23, 1983	Apr CMS1
<u>ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE</u>							
TABLET;ORAL							
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
AA	ANI PHARMS INC	0.025MG;2.5MG		A086727	001		Jun CMFD
<u>AVIBACTAM SODIUM; CEFTAZIDIME</u>							
POWDER;IV (INFUSION)							
AVYCAZ							
+	! CEREXA	EQ 0.5GM BASE;2GM/VIAL		N206494	001	Feb 25, 2015	May CAHN

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun	NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR

VIDAZA

AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR
----	------------	------------	---------	-----	--------------	-----	------

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

>A>	+ @ CASPER PHARMA LLC	EQ 100MG BASE/VIAL	N017391	001		Jul	CAHN
>D>	+ @ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001		Jul	CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb	CAHN
----	------------	-------	---------	-----	--------------	-----	------

OPTIVAR

AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar	CAHN
----	------------------------	-------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

ASTELIN

AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar	CAHN
----	------------------------	-----------------------	---------	-----	--------------	-----	------

ASTEPRO

	@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar	CAHN
--	-----------------------	-----------------------	---------	-----	--------------	-----	------

AB	+!	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar	CAHN
----	----	------------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb	CAHN
AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun	CAHN
AB		EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar	NEWA

>A>	AB	ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Jul	NEWA
-----	----	----------------------	-----------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr	NEWA
----	------------	-------------------------------------	---------	-----	--------------	-----	------

DYMISTA

AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Apr	CFTG
	+!	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Mar	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

AZITHROMYCIN

	@ MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007	Jun	DISC
	@	EQ 500MG BASE	A065366	001	May 30, 2007	May	DISC

ZITHROMAX

AB	+ PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr	CRLD
AB	+	EQ 500MG BASE	N050784	001	May 24, 2002	Apr	CRLD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

CORTISPORIN

+!	MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N050168	002	May 04, 1984	Feb	CAHN
----	----------------	---	---------	-----	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOSPORIN

AT	+ CASPER PHARMA LLC	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050417	001		Apr	CMFD
----	---------------------	--	---------	-----	--	-----	------

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar	CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar	CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar	CAHN

GABLOFEN

	+!	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar	CRLD
AP		PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr	CAHN
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Apr	CAHN
	+!		1MG/ML	N022462	004	Jun 22, 2012	Apr	CAHN
AP			2MG/ML	N022462	003	Nov 19, 2010	Apr	CAHN

TABLET; ORAL

BACLOFEN

	@	MYLAN	10MG	A077181	001	Jul 29, 2005	May	DISC
AB		OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr	CMS1
AB		USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun	CAHN
AB			20MG	A074584	002	Aug 19, 1996	Jun	CAHN

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

>D>	BX	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul	CTEC
>A>	AB		750MG	A077806	001	Dec 28, 2007	Jul	CTEC
	BX		750MG	A077806	001	Dec 28, 2007	Apr	CTEC

BIARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

	+!	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr	CPOT
--	----	--------	--------------------	---------	-----	--------------	-----	------

E-Z-PAQUE

	+!	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr	NEWA
--	----	--------	--------------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

LIQUID E-Z-PAQUE

	+!	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar	NEWA
--	----	--------	-------------------	---------	-----	--------------	-----	------

VARIBAR NECTAR

>A>	+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017	Jul	NEWA
-----	----	--------	------------------	---------	-----	--------------	-----	------

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
AB			10MG	A076820	002	Feb 03, 2006	Apr	CAHN
AB			20MG	A076820	003	Feb 03, 2006	Apr	CAHN
AB			40MG	A076820	004	Feb 03, 2006	Apr	CAHN

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

LOTENSIN HCT

	+ @	US PHARMS HOLDINGS I	5MG; 6.25MG	N020033	001	May 19, 1992	May	DISC
--	-----	----------------------	-------------	---------	-----	--------------	-----	------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

AB	+	KING PHARMS LLC	5MG; 40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+!		5MG; 80MG	N018647	002	May 25, 1983	Mar	CAHN

BENZONATATE

CAPSULE; ORAL

TESSALON

AA	+	PFIZER	100MG	N011210	001		Apr	CRLD
----	---	--------	-------	---------	-----	--	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		TOLMAR	5%; EQ 1% BASE	A204087	001	Jun 27, 2017	Jun	NEWA
----	--	--------	----------------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

	BENZPHETAMINE HYDROCHLORIDE						
	@ EPIC PHARMA LLC	50MG	A 040714	001	Oct 29, 2007	May	CAHN
AA	TWI PHARMS INC	50MG	A 040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

	BENZTROPINE MESYLATE						
AA	EPIC PHARMA LLC	0.5MG	A 072264	001	Feb 27, 1989	May	CAHN
AA		1MG	A 072265	001	Feb 27, 1989	May	CAHN
AA		2MG	A 072266	001	Feb 27, 1989	May	CAHN
	OXFORD PHARMS	0.5MG	A 040706	002	Feb 14, 2008	May	CMS1
		1MG	A 040706	003	Feb 14, 2008	May	CMS1
AA	! UPSHER-SMITH LABS	0.5MG	A 040103	001	Dec 12, 1996	Feb	CAHN
AA	!	1MG	A 040103	002	Dec 12, 1996	Feb	CAHN
AA	!	2MG	A 040103	003	Dec 12, 1996	Feb	CAHN
AA	! USL PHARMA	0.5MG	A 040103	001	Dec 12, 1996	Jun	CAHN
AA	!	1MG	A 040103	002	Dec 12, 1996	Jun	CAHN
AA	!	2MG	A 040103	003	Dec 12, 1996	Jun	CAHN

BETAINE HYDROCHLORIDEFOR SOLUTION;ORAL  
CYSTADANE

>A>	+!	ORPHAN EUROPE	1GM/SCOOPFUL	N 020576	001	Oct 25, 1996	Jul	CAHN
>D>	+!	RARE DIS THERAP	1GM/SCOOPFUL	N 020576	001	Oct 25, 1996	Jul	CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

	BETAMETHASONE DIPROPIONATE						
AB	! FOUGERA PHARMS INC	EQ 0.05% BASE	A 070275	001	Aug 12, 1985	Jan	CAHN
	@ TARO	EQ 0.05% BASE	A 074272	001	Sep 30, 1994	Apr	CAHN
	DIPROSONE						
	+ @ SCHERING	EQ 0.05% BASE	N 017781	001		Jan	CRLD
	OINTMENT;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
AB	TARO	EQ 0.05% BASE	A 074271	001	Sep 15, 1994	Apr	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

	BETAMETHASONE VALERATE						
AB	PERRIGO UK FINCO	0.12%	A 078337	001	Nov 26, 2012	Apr	CAHN
AB	RICONPHARMA LLC	0.12%	A 207144	001	May 24, 2017	May	NEWA
AB	TARO PHARM	0.12%	A 208204	001	May 24, 2017	May	NEWA
	LUXIQ						
AB	+! MYLAN PHARMS INC	0.12%	N 020934	001	Feb 28, 1999	Jan	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

	BETAXOLOL HYDROCHLORIDE						
AT	TELIGENT	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Apr	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

	BETHANECHOL CHLORIDE						
	@ IMPAX LABS	5MG	A 040721	001	Nov 01, 2006	Jan	CMS1
	@	10MG	A 040721	002	Nov 01, 2006	Jan	CMS1
	@	25MG	A 040721	003	Nov 01, 2016	Jan	CMS1
AA	LANNETT HOLDINGS INC	5MG	A 040677	002	Mar 27, 2008	May	CMS1
AA		10MG	A 040677	003	Mar 27, 2008	May	CMS1
AA		25MG	A 040677	004	Mar 27, 2008	May	CMS1
AA	UPSHER-SMITH LABS	5MG	A 040633	001	Jun 01, 2005	Jun	CAHN
AA		10MG	A 040634	001	Jun 01, 2005	Jun	CAHN
AA		25MG	A 040635	001	Jun 01, 2005	Jun	CAHN
AA		50MG	A 040636	001	Jun 01, 2005	Jun	CAHN



BETRIXABANCAPSULE;ORAL  
BEVYXXA

	+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017	Jun NEWA
	+	!	80MG	N208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		SANTOS BIOTECH	50MG	A091011	001	Jun 10, 2015	May CAHN
AB		WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009	May CAHN
		CASODEX					
AB	+	! ASTRAZENECA PHARMS	50MG	N020498	001	Oct 04, 1995	May CAHN

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC  
BIMATOPROST

AT		SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar CAHN
----	--	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

>A>	+	@ CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG	N050719	001	Aug 15, 1996	Jul CAHN
>D>	+	@ SEBELA IRELAND LTD	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG	N050719	001	Aug 15, 1996	Jul CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan NEWA
AB			10MG	A204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

		@ WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May CAHN
		@	5MG;6.25MG	A075469	002	Sep 25, 2000	May CAHN
		@	10MG;6.25MG	A075469	003	Sep 25, 2000	May CAHN
		ZIAC					
AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan CAHN
AB	+	!	10MG;6.25MG	N020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP		APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun NEWA
AP		DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May NEWA

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

		@ WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan CAHN
--	--	------------------------	---------	---------	-----	--------------	----------

BRIGATINIB

TABLET;ORAL

ALUNBRIG

	+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr NEWA
	+	!	90MG	N208772	002	Apr 28, 2017	Apr NEWA

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC  
BRIMONIDINE TARTRATE

AT		SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb CAHN
AT			0.2%	A078075	001	Jan 30, 2008	Mar CAHN
		QOLIANA					
AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar CAHN

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC  
BROMFENAC SODIUM

AT1		AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN
AT1	!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
AT2	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS

BROMPHENIRAMINE MALEATETABLET;ORAL  
BROMPHENIRAMINE MALEATE  
@ UPSHER-SMITH LABS 4MG

A083215 001 Jun CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDESYRUP;ORAL  
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TARO PHARM	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
----	--	------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDECAPSULE;ORAL  
BUDESONIDE

>A>	AB	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Jul	NEWA
	AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr	NEWA

BUMETANIDEINJECTABLE;INJECTION  
BUMETANIDE

AP	!	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar	CAHN
AP		WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN

BUMEX

+ @ VALIDUS PHARMS 0.25MG/ML

N018226 001 Feb 28, 1983 Jun CAHN

TABLET;ORAL

BUMEX

AB	+	VALIDUS PHARMS	0.5MG	N018225	002	Feb 28, 1983	Jun	CAHN
AB	+		1MG	N018225	001	Feb 28, 1983	Jun	CAHN
AB	+		2MG	N018225	003	Jun 14, 1985	Jun	CAHN

BUPRENORPHINE HYDROCHLORIDEFILM;BUCCAL  
BELBUCA

+ BDSI EQ 0.075MG BASE

N207932 001 Oct 23, 2015 Jan CAHN

+ EQ 0.15MG BASE

N207932 002 Oct 23, 2015 Jan CAHN

+ EQ 0.3MG BASE

N207932 003 Oct 23, 2015 Jan CAHN

+ EQ 0.45MG BASE

N207932 004 Oct 23, 2015 Jan CAHN

+ EQ 0.6MG BASE

N207932 005 Oct 23, 2015 Jan CAHN

+ EQ 0.75MG BASE

N207932 006 Oct 23, 2015 Jan CAHN

+! EQ 0.9MG BASE

N207932 007 Oct 23, 2015 Jan CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar	NEWA
AB			EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May	CAHN
----	--	---------------	-------------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May	CAHN
----	--	---------------	---------------------------	---------	-----	--------------	-----	------

ZUBSOLV

+ OREXO US INC EQ 5.7MG BASE;EQ 1.4MG BASE

N204242 002 Jul 03, 2013 Jan CHRS

+! EQ 11.4MG BASE;EQ 2.9MG BASE

N204242 004 Dec 11, 2014 Jan CHRS

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL  
BUPROPION HYDROCHLORIDE

AB3		ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun	NEWA
AB3			300MG	A207224	002	Jun 30, 2017	Jun	NEWA
AB3		JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun	NEWA
AB3			300MG	A207459	002	Jun 30, 2017	Jun	NEWA
AB3		LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar	NEWA
AB3			300MG	A090693	002	Apr 06, 2017	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL							
BUPROPION HYDROCHLORIDE							
AB3	SCIENGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar	NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar	NEWA
FORFIVO XL							
+!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan	CAHN
<u>BUSPIRONE HYDROCHLORIDE</u>							
TABLET;ORAL							
BUSPIRONE HYDROCHLORIDE							
AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May	NEWA
AB		7.5MG	A208829	002	May 24, 2017	May	NEWA
AB		10MG	A208829	003	May 24, 2017	May	NEWA
AB		15MG	A208829	004	May 24, 2017	May	NEWA
AB		30MG	A208829	005	May 24, 2017	May	NEWA
	@ MYLAN	5MG	A075467	001	Feb 28, 2002	Jun	DISC
	@	10MG	A075467	003	Feb 28, 2002	Jun	DISC
	@	15MG	A075467	004	Feb 28, 2002	Jun	DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr	CAHN
AB		10MG	A202330	002	Aug 25, 2014	Apr	CAHN
AB		15MG	A202330	003	Aug 25, 2014	Apr	CAHN
AB		30MG	A202330	004	Aug 25, 2014	Apr	CAHN
<u>BUSULFAN</u>							
INJECTABLE;INJECTION							
BUSULFAN							
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar	NEWA
AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun	NEWA
<u>BUTABARBITAL SODIUM</u>							
TABLET;ORAL							
BUTISOL SODIUM							
	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar	CAHN
+!		30MG	N000793	004		Mar	CAHN
	@	50MG	N000793	003		Mar	CAHN
	@	100MG	N000793	005		Mar	CAHN
<u>BUTORPHANOL TARTRATE</u>							
INJECTABLE;INJECTION							
BUTORPHANOL TARTRATE PRESERVATIVE FREE							
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan	CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan	CAHN
<u>CALCIPOTRIENE</u>							
AEROSOL, FOAM;TOPICAL							
SORILUX							
+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan	CAHN
OINTMENT;TOPICAL							
CALCIPOTRIENE							
!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May	CAHN
<u>CALCITONIN SALMON</u>							
SPRAY, METERED;NASAL							
CALCITONIN-SALMON							
AB	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr	CHRS
	MIACALCIN						
+ @	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr	DISC
<u>CALCITONIN SALMON RECOMBINANT</u>							
SPRAY, METERED;NASAL							
FORTICAL							
	@ UPSHER-SMITH LABS	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun	CAHN
<u>CALCITRIOL</u>							
CAPSULE;ORAL							
CALCITRIOL							
AB	AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May	NEWA
AB		0.5MCG	A203289	001	Jun 14, 2017	May	NEWA
INJECTABLE;INJECTION							
CALCIJEX							
+ @	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May	CRLD
+ @		0.002MG/ML	N018874	002	Sep 25, 1986	May	CRLD

INJECTABLE; INJECTION  
CALCITRIOL

! AKORN 0.001MG/ML A078066 001 Jan 29, 2008 May CHRS

CALCIUM ACETATE

## CAPSULE; ORAL

AB CHARTWELL RX 667MG A091312 001 Jun 01, 2012 Mar CAHN

## TABLET; ORAL

AB ! PADDOCK LLC 667MG A091561 001 Apr 13, 2011 Apr CHRS  
ELIPHOS

AB CYPRESS PHARM 667MG A078502 001 Nov 25, 2008 Apr CHRS

CALCIUM CHLORIDE

## INJECTABLE; INJECTION

## CALCIUM CHLORIDE 10%

>A> AP LUITPOLD PHARMS INC 100MG/ML A209088 001 Jul 27, 2017 Jul NEWA

## CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

>D> +! HOSPIRA 100MG/ML N021117 001 Jan 28, 2000 Jul CFTG

>A> AP +! 100MG/ML N021117 001 Jan 28, 2000 Jul CFTG

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

## DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 30MG/100ML; 60 0MG/100ML; 310MG/100ML N017608 001 Feb CAHN

## POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 005 Oct 17, 1988 Feb CAHN

## @ 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 006 Oct 17, 1988 Feb CAHN

## POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 007 Oct 17, 1988 Feb CAHN

## POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 002 Oct 17, 1988 Feb CAHN

AP 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 008 Oct 17, 1988 Feb CAHN

## POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 003 Oct 17, 1988 Feb CAHN

## POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 004 Oct 17, 1988 Feb CAHN

## POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ ICU MEDICAL INC 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML N019685 001 Oct 17, 1988 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## RINGER'S IN PLASTIC CONTAINER

AP ICU MEDICAL INC 33MG/100ML; 30MG/100ML; 860MG/100ML N018251 001 Feb CAHN

## SOLUTION; IRRIGATION

## RINGER'S IN PLASTIC CONTAINER

AT ICU MEDICAL INC 33MG/100ML; 30MG/100ML; 860MG/100ML N017635 001 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

## LACTATED RINGER'S IN PLASTIC CONTAINER

AP ICU MEDICAL INC 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML N017641 001 Feb CAHN

## SOLUTION; IRRIGATION

## LACTATED RINGER'S IN PLASTIC CONTAINER

AT +! ICU MEDICAL INC 20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML N019416 001 Jan 17, 1986 Feb CAHN

CALCIUM GLUCONATESOLUTION;IV (INFUSION)  
CALCIUM GLUCONATE

+	!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Jun	NEWA
+	!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Jun	NEWA
+	!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Jun	NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB		ALEMVIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017	Jun	NEWA
----	--	--------------------	------	---------	-----	--------------	-----	------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		MYLAN PHARMS INC	16MG;12.5MG	A090704	001	Dec 04, 2012	May	CAHN
AB			32MG;12.5MG	A090704	002	Dec 04, 2012	May	CAHN
AB			32MG;25MG	A090704	003	Dec 04, 2012	May	CAHN

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb	NEWA
AB			500MG	A204741	002	Feb 28, 2017	Feb	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	May	CAHN
	@		25MG	A074677	002	May 30, 1997	May	CAHN
	@		50MG	A074677	001	May 30, 1997	May	CAHN
	@		100MG	A074677	003	May 30, 1997	May	CAHN
AB		MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar	CAHN
AB			25MG	A074434	002	Feb 13, 1996	Mar	CAHN
AB			50MG	A074434	003	Feb 13, 1996	Mar	CAHN
AB	!		100MG	A074434	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

EQUETRO

+		VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004	Jun	CAHN
+			200MG	N021710	002	Dec 10, 2004	Jun	CAHN
+	!		300MG	N021710	003	Dec 10, 2004	Jun	CAHN

SOLUTION;IV (INFUSION)

CARNEXIV

+	!	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan	CAHN
---	---	---------------------	----------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

TERIL

AB		TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN
----	--	------------	-----------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

>A>		IDT AUSTRALIA LTD	10MG;100MG	A073587	002	Jun 29, 1995	Jul	CMS1
>A>			25MG;250MG	A073587	003	Jun 29, 1995	Jul	CMS1

CARBOPLATIN

INJECTABLE;INJECTION

CARBOPLATIN

@ WATSON LABS TEVA

@

@

	@	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May	CAHN
	@		150MG/VIAL	A076162	002	Oct 14, 2004	May	CAHN
	@		450MG/VIAL	A076162	003	Oct 14, 2004	May	CAHN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA

INJECTABLE; IV (INFUSION)  
CARBOPLATIN

AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr NEWA

CARISOPRODOL

CAPSULE; ORAL  
SOMA

	@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar CAHN
--	-----------------------	-------	---------	-----	--	----------

TABLET; ORAL

CARISOPRODOL

	@ EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May CAHN
AA	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr NEWA
	@ WATSON LABS TEVA	350MG	A086179	001		May CAHN
	SOMA					
AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar CAHN
AA	+	350MG	N011792	001		Mar CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
CARTEOLOL HYDROCHLORIDE

AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar CAHN
	OCUPRESS					
	+ @ NOVARTIS	1%	N019972	001	May 23, 1990	May DISC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

>D>	AB	PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007	Jul DISC
>A>		@	3.125MG	A078240	001	Oct 30, 2007	Jul DISC
>D>	AB		6.25MG	A078240	002	Oct 30, 2007	Jul DISC
>A>		@	6.25MG	A078240	002	Oct 30, 2007	Jul DISC
>D>	AB		12.5MG	A078240	003	Oct 30, 2007	Jul DISC
>A>		@	12.5MG	A078240	003	Oct 30, 2007	Jul DISC
>D>	AB		25MG	A078240	004	Oct 30, 2007	Jul DISC
>A>		@	25MG	A078240	004	Oct 30, 2007	Jul DISC

CASPOFUNGIN ACETATE

POWDER; IV (INFUSION)  
CANCIDAS

AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar CDFR
AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar CDFR

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL  
CEFADROXIL

>A>	AB	CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jul NEWA
-----	----	--------------------	---------------	---------	-----	--------------	----------

CEFDINIR

CAPSULE; ORAL  
OMNICEF

	+ @ ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan CRLD
--	------------	-------	---------	-----	--------------	----------

FOR SUSPENSION; ORAL

OMNICEF

	+ @ ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
	+ @	250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan NEWA
	SUPRAX					
AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG

CEFOTETAN DISODIUMINJECTABLE; INJECTION  
CEFOTAN

AP	+	TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr	CAHN
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr	CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr	CAHN
CEFOTAN IN PLASTIC CONTAINER								
	@	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr	CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr	CAHN

CEFOXITIN SODIUMINJECTABLE; INJECTION  
CEFOXITIN

AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan	CAHN

CEFPROZILTABLET; ORAL  
CEFPROZIL

AB		AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan	CAHN
AB			500MG	A065340	002	May 24, 2007	Jan	CAHN

CEFTAZIDIMEINJECTABLE; INJECTION  
FORTAZ

AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUMINJECTABLE; INJECTION  
FORTAZ IN PLASTIC CONTAINER

@ TELIGENT

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989 May CAHN

+! EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 May CAHN

+! EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 May CAHN

CEFTRIAZONE SODIUMINJECTABLE; INJECTION  
CEFTRIAZONE SODIUM

AP		SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan	NEWA
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER								
	+	@ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan	CRLD
	+	@	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan	CRLD
	+	@	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB		AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan	CAHN
AB			EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan	CAHN
AB			EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan	CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION  
ZINACEF

AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May	CAHN
ZINACEF IN PLASTIC CONTAINER								
	@	TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May	CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May	CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS								
ZINACEF								
AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May	CAHN

CELECOXIB

	CAPSULE;ORAL						
	CELECOXIB						
AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar	NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar	NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar	NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar	NEWA

CEPHALEXIN

	CAPSULE;ORAL						
	CEPHALEXIN						
AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan	CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan	CAHN

CEPHAPIRIN SODIUM

	INJECTABLE;INJECTION						
	CEPHAPIRIN SODIUM						
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan	CAHN
	@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan	CAHN
	@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan	CAHN

CETIRIZINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	ZERVIAE						
	+! NICOX OPTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May	NEWA
	SYRUP;ORAL						
	CETIRIZINE HYDROCHLORIDE						
AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr	CAHN

CEVIMELINE HYDROCHLORIDE

	CAPSULE;ORAL						
	CEVIMELINE HYDROCHLORIDE						
AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May	CAHN

CHENODIOL

	TABLET;ORAL						
	CHENIX						
	+ @ LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb	CAHN

CHLORAMPHENICOL SODIUM SUCCINATE

	INJECTABLE;INJECTION						
	CHLOROMYCETIN						
	+ @ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar	CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE

	CAPSULE;ORAL						
	CHLORDIAZEPOXIDE HYDROCHLORIDE						
	@ UPSHER-SMITH LABS	5MG	A084678	001		Jun	CAHN
	@	10MG	A084041	001		Jun	CAHN
	@	25MG	A084679	002		Jun	CAHN
	@ USL PHARMA	10MG	A084623	001		Apr	DISC

CHLORHEXIDINE GLUCONATE

	SOLUTION;DENTAL						
	PERIOGARD						
AT	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	May	CAHN

CHLORPHENESIN CARBAMATE

	TABLET;ORAL						
	MAOLATE						
	@ PAMLAB LLC	400MG	N014217	002		Mar	CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

	SOLUTION;ORAL						
	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE						
AA	ACELLA PHARMS LLC	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017	May	NEWA



CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE  
 AA BIO-PHARM INC 4MG/5ML; 5MG/5ML; 60MG/5ML A206660 001 May 15, 2017 May NEWA

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

USL PHARMA 10MG A083386 001 Jun CAHN  
 10MG A083386 001 May CTEC  
 ! 25MG A084112 001 Jun CAHN  
 ! 25MG A084112 001 May CHRS  
 50MG A084113 001 Jun CAHN  
 50MG A084113 001 May CTEC  
 ! 100MG A084114 001 Jun CAHN  
 ! 100MG A084114 001 May CHRS  
 200MG A084115 001 Jun CAHN  
 200MG A084115 001 May CTEC

THORAZINE

@ GLAXOSMITHKLINE 10MG N009149 002 May CRLD  
 @ 25MG N009149 007 May CRLD  
 @ 50MG N009149 013 May CRLD  
 @ 100MG N009149 018 May CRLD  
 @ 200MG N009149 020 May CRLD

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC 250MG A087353 001 Jan CAHN  
 @ WATSON LABS TEVA 100MG A088852 001 Sep 26, 1984 May CAHN  
 @ 250MG A088826 001 Sep 26, 1984 May CAHN

GLUCAMIDE

>D> @ ANI PHARMS INC 250MG A088641 001 Oct 11, 1984 Jul CMFD  
 >A> AB 250MG A088641 001 Oct 11, 1984 Jul CMFD

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB RICONPHARMA LLC 25MG A206904 001 Mar 30, 2017 Mar NEWA  
 AB 50MG A206904 002 Mar 30, 2017 Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB ZYDUS PHARMS USA INC EQ 4GM RESIN/SCOOPFUL A202902 001 Apr 25, 2017 Apr NEWA  
 PREVALITE  
 AB UPSHER-SMITH LABS EQ 4GM RESIN/PACKET A073263 001 Feb 22, 1996 Jun CAHN  
 AB EQ 4GM RESIN/SCOOPFUL A073263 002 Oct 30, 1997 Jun CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

>D> AP UNIV TX MD ANDERSON 4-33.1mCi/ML A205690 001 Oct 29, 2015 Jul CPOT  
 >A> 4-100mCi/ML A205690 001 Oct 29, 2015 Jul CPOT

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB ALEMBIC PHARMS LTD EQ 45MG FENOFIBRIC ACID A208705 001 May 12, 2017 May NEWA  
 AB EQ 135MG FENOFIBRIC ACID A208705 002 May 12, 2017 May NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

>A> +! ASTRAZENECA PHARMS 0.08MG/INH N021658 002 Jan 10, 2008 Jul CAHN  
 >A> +! 0.16MG/INH N021658 003 Jan 10, 2008 Jul CAHN  
 >D> +! TAKEDA GMBH 0.08MG/INH N021658 002 Jan 10, 2008 Jul CAHN  
 >D> +! 0.16MG/INH N021658 003 Jan 10, 2008 Jul CAHN

AEROSOL, METERED; NASAL

ZETONNA

>A> +! ASTRAZENECA PHARMS 0.037MG/INH N202129 001 Jan 20, 2012 Jul CAHN

	AEROSOL, METERED;NASAL ZETONNA							
>D>	+! TAKEDA GMBH	0.037MG/INH	N202129	001	Jan 20, 2012	Jul	CAHN	
	SPRAY, METERED;NASAL OMNARIS							
>A>	+! ASTRAZENECA PHARMS	0.05MG/INH	N022004	001	Oct 20, 2006	Jul	CAHN	
>D>	+! TAKEDA GMBH	0.05MG/INH	N022004	001	Oct 20, 2006	Jul	CAHN	

CICLOPIROX

	CREAM;TOPICAL CICLOPIROX							
AB	PERRIGO NEW YORK	0.77%	A077364	001	Mar 03, 2006	Apr	CAHN	
	SHAMPOO;TOPICAL CICLOPIROX							
AT	PERRIGO CO	1%	A078594	001	Feb 16, 2010	Apr	CAHN	

CILOSTAZOL

	TABLET;ORAL CILOSTAZOL							
	@ EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May	CAHN	
	@	100MG	A077022	001	Nov 23, 2004	May	CAHN	
	@ MYLAN	50MG	A077323	002	Apr 20, 2006	May	DISC	
	@	100MG	A077323	001	Apr 20, 2006	May	DISC	
	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar	DISC	
	@	100MG	A077019	002	Nov 23, 2004	Mar	DISC	
	@ PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar	DISC	
	@	100MG	A077898	002	Oct 29, 2007	Mar	DISC	
	PLETAL							
	+ @ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan	CRLD	
	+ @	100MG	N020863	002	Jan 15, 1999	Jan	CRLD	

CIMETIDINE

	TABLET;ORAL CIMETIDINE							
	@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan	CAHN	
	@	300MG	A074281	002	May 17, 1994	Jan	CAHN	
	@	400MG	A074281	003	May 17, 1994	Jan	CAHN	
	@	800MG	A074329	001	May 17, 1994	Jan	CAHN	
	@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar	CAHN	
	@	300MG	A074250	002	Jun 29, 1995	Mar	CAHN	
	@	400MG	A074250	003	Jun 29, 1995	Mar	CAHN	
	@	800MG	A074250	004	Jun 29, 1995	Mar	CAHN	
	@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun	CAHN	
	@	300MG	A074506	002	Jan 24, 1996	Jun	CAHN	
	@	400MG	A074506	003	Jan 24, 1996	Jun	CAHN	
	@	800MG	A074506	004	Jan 24, 1996	Jun	CAHN	

CIMETIDINE HYDROCHLORIDE

	SOLUTION;ORAL CIMETIDINE HYDROCHLORIDE							
AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May	CAHN	

CIPROFLOXACIN

	INJECTABLE;INJECTION CIPRO							
	+ @ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb	DISC	
	+ @	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb	DISC	
	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER							
	+ @ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb	DISC	
	+ @	400MG/200ML	N019857	002	Dec 26, 1990	Feb	DISC	
	CIPROFLOXACIN							
AP	! CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb	CHRS	
AP	!	400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb	CHRS	
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	! HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb	CHRS	
AP	!	400MG/200ML	A077753	002	Mar 18, 2008	Feb	CHRS	

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

AT	AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar	CAHN
AT	TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr	CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar	CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar	CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar	CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar	CAHN

CISATRACURIUM BESYLATEINJECTABLE;INJECTION  
CISATRACURIUM BESYLATE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun	NEWA
	CISATRACURIUM BESYLATE	PRESERVATIVE FREE					
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun	NEWA
AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun	NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan	NEWA

CISPLATININJECTABLE;INJECTION  
CISPLATIN

AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar	NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar	CRLD
	PLATINOL						
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar	CRLD
	+ @	50MG/VIAL	N018057	002		Mar	CRLD
	PLATINOL-AQ						
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar	CRLD

CITALOPRAM HYDROBROMIDECAPSULE;ORAL  
CITALOPRAM HYDROBROMIDE

@ MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar	DISC
@	EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar	DISC
@	EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar	DISC

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan	CAHN
----	----------------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@ EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May	CAHN
@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May	CAHN
@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May	CAHN
@ MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun	DISC
@	EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun	DISC
@	EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun	DISC
@ MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May	DISC
@	EQ 20MG BASE	A077037	002	Nov 05, 2004	May	DISC
@	EQ 40MG BASE	A077037	003	Nov 05, 2004	May	DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Mar	CAHN
----	--------------------	--	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

@ MYLAN	250MG	A065195	001	Mar 11, 2005	May	DISC
@	500MG	A065195	002	Mar 11, 2005	May	DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb	DISC	
!	TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb	CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 150MG BASE	A 065194	001	Mar 22, 2004	May	CAHN
AB		EQ 300MG BASE	A 065194	002	Mar 22, 2004	May	CAHN
	@ MYLAN PHARMS INC	EQ 75MG BASE	A 091225	001	May 31, 2011	May	DISC
	@	EQ 150MG BASE	A 091225	002	May 31, 2011	May	DISC
	@	EQ 300MG BASE	A 091225	003	May 31, 2011	May	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A 206958	001	May 05, 2017	Apr	NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A 206958	001	May 05, 2017	Jun	CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A 090902	001	Jul 07, 2010	Apr	CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

AT	+! MYLAN PHARMS INC	1%	N 050801	001	Oct 22, 2004	Jan	CAHN
----	---------------------	----	----------	-----	--------------	-----	------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP	SAGENT PHARMS	EQ 150MG BASE/ML	A 090109	001	Sep 30, 2011	Apr	CAHN
AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A 065206	001	Sep 24, 2004	Jan	CAHN

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

>A>	AP	BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A 208084	001	Jun 28, 2017	Jul	CAHN
>A>	AP		EQ 12MG BASE/ML	A 208084	002	Jun 28, 2017	Jul	CAHN
>A>	AP		EQ 18MG BASE/ML	A 208084	003	Jun 28, 2017	Jul	CAHN
>D>	AP	CELERITY PHARMS	EQ 6MG BASE/ML	A 208084	001	Jun 28, 2017	Jul	CAHN
	AP		EQ 6MG BASE/ML	A 208084	001	Jun 28, 2017	Jun	NEWA
>D>	AP		EQ 12MG BASE/ML	A 208084	002	Jun 28, 2017	Jul	CAHN
	AP		EQ 12MG BASE/ML	A 208084	002	Jun 28, 2017	Jun	NEWA
>D>	AP		EQ 18MG BASE/ML	A 208084	003	Jun 28, 2017	Jul	CAHN
	AP		EQ 18MG BASE/ML	A 208084	003	Jun 28, 2017	Jun	NEWA

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N 208083	001	Apr 20, 2017	May	CAHN
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N 208083	002	Apr 20, 2017	May	CAHN
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N 208083	003	Apr 20, 2017	May	CAHN
+!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N 208083	001	Apr 20, 2017	Apr	NEWA
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N 208083	002	Apr 20, 2017	Apr	NEWA
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N 208083	003	Apr 20, 2017	Apr	NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS INC	EQ 1% BASE	A 064159	001	Jun 05, 1997	Jan	CAHN
----	--------------------	------------	----------	-----	--------------	-----	------

SWAB;TOPICAL

CLINDETS

AT	PERRIGO CO	EQ 1% BASE	A 064136	001	Sep 30, 1996	Apr	CAHN
----	------------	------------	----------	-----	--------------	-----	------

CLOBAZAM

SUSPENSION;ORAL

ONFI

+!	LUNDBECK PHARMS LLC	2.5MG/ML	N 203993	001	Dec 14, 2012	Jan	CAHN
----	---------------------	----------	----------	-----	--------------	-----	------

TABLET;ORAL

ONFI

	@ LUNDBECK PHARMS LLC	5MG	N 202067	001	Oct 21, 2011	Jan	CAHN
	+	10MG	N 202067	002	Oct 21, 2011	Jan	CAHN
	+!	20MG	N 202067	003	Oct 21, 2011	Jan	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

>A>	AB1	INGENUS PHARMS LLC	0.05%	A 206805	001	Jul 31, 2017	Jul	NEWA
	AB1	+! MYLAN PHARMS INC	0.05%	N 021142	001	May 26, 2000	Jan	CAHN

AEROSOL, FOAM;TOPICAL							
OLUX E							
AB2	+!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
AB1		MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
	@		0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN
GEL;TOPICAL							
CLOBETASOL PROPIONATE							
AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN
AB		TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb NEWA
OINTMENT;TOPICAL							
CLOBETASOL PROPIONATE							
AB		GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar NEWA
AB1		MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	May CMFD
	@		0.05%	A075057	001	Aug 12, 1998	Jan CAHN
AB		TARO	0.05%	A074248	001	Jul 12, 1996	Apr CAHN
TEMOVATE							
	+ @	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CRLD
SOLUTION;TOPICAL							
CLOBETASOL PROPIONATE							
AT		TARO	0.05%	A075224	001	Nov 16, 1998	Apr CAHN
SPRAY;TOPICAL							
CLOBETASOL PROPIONATE							
AT		AKORN	0.05%	A207218	001	Apr 28, 2017	Apr NEWA
AT		ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb NEWA
<u>CLOFARABINE</u>							
INJECTABLE;IV (INFUSION)							
CLOFARABINE							
AP		ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr NEWA
CLOLAR							
AP	+!	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr CFTG
<u>CLOFIBRATE</u>							
CAPSULE;ORAL							
CLOFIBRATE							
	@	USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun CAHN
<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
CLOMIPRAMINE HYDROCHLORIDE							
AB		SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB			50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB			75MG	A074953	003	Jun 25, 1997	Feb CMFD
<u>CLONAZEPAM</u>							
TABLET;ORAL							
CLONAZEPAM							
	@	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@		1MG	A074940	002	Oct 30, 1997	Mar DISC
	@		2MG	A074940	003	Oct 30, 1997	Mar DISC
AB		PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB			1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB			2MG	A077856	003	Jun 28, 2006	Feb CAHN
<u>CLONIDINE HYDROCHLORIDE</u>							
TABLET;ORAL							
CLONIDINE HYDROCHLORIDE							
>A>		CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Jul CMS1
>A>			0.2MG	A071785	003	Apr 05, 1988	Jul CMS1
	@		0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB		PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
AB			0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
AB			0.3MG	A077901	003	Mar 09, 2007	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL							
CLONIDINE HYDROCHLORIDE							
AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

AB1		0.1MG	A203320	001	May 15, 2015	Apr	CAHN
	@	0.2MG	A202792	002	May 15, 2015	Apr	CAHN
	@	0.2MG	A203320	002	May 15, 2015	Apr	CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL  
CLOPIDOGREL BISULFATE

>A>	AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012	Jul	CAHN
>D>	AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Jul	CAHN
	AB		EQ 75MG BASE	A078004	001	May 17, 2012	Mar	CAHN
	AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL  
CLORAZEPATE DIPOTASSIUM

AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN
AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN
AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN

CLOTRIMAZOLE

SOLUTION;TOPICAL  
CLOTRIMAZOLE

AT	!	TARO	1%	A074580	001	Jul 29, 1996	Apr	CAHN
		LOTRIMIN						
>D>		@ SCHERING PLOUGH	1%	N017613	001		Jul	CRLD
>A>		+ @	1%	N017613	001		Jul	CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL  
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE  
@ PHARM ASSOC 10MG/5ML;6.25MG/5ML

A089647	001	Dec 22, 1988	May	CAHN
---------	-----	--------------	-----	------

CODEINE SULFATE

SOLUTION;ORAL  
CODEINE SULFATE  
@ WEST-WARD PHARMS INT 30MG/5ML

N202245	001	Jun 30, 2011	Jan	CAHN
---------	-----	--------------	-----	------

TABLET;ORAL  
CODEINE SULFATE

AB	+	WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan	CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jan	CAHN
AB	+	!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN

CORTICOTROPIN

INJECTABLE;INJECTION  
PURIFIED CORTROPHIN GEL

@ ANI PHARMS INC	40 UNITS/ML	N008975	001		May	CAHN
@	80 UNITS/ML	N008975	002		May	CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION  
CORTROPHIN-ZINC

@ ANI PHARMS INC	40 UNITS/ML	N009854	001		May	CAHN
------------------	-------------	---------	-----	--	-----	------

CORTISONE ACETATE

TABLET;ORAL  
CORTONE

+ @ MERCK	25MG	N007750	003		Mar	CRLD
-----------	------	---------	-----	--	-----	------

COSYNTROPIN

SOLUTION;INTRAVENOUS  
COSYNTROPIN

@ SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	May	CAHN
--------------	-----------------------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE;ORAL  
GASTROCROM

AA	+	!	MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
----	---	---	---------------------	-----------	---------	-----	--------------	-----	------

SOLUTION; INHALATION								
CROMOLYN SODIUM								
>D>	AN	BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Jul	DISC
>A>		@	10MG/ML	A075585	001	Dec 21, 2000	Jul	DISC
	AN		10MG/ML	A075585	001	Dec 21, 2000	Feb	CAHN
INTAL								
		@ KING PHARMS LLC	10MG/ML	N018596	001	May 28, 1982	May	CAHN
<u>CYANOCOBALAMIN</u>								
INJECTABLE; INJECTION								
CYANOCOBALAMIN								
AP		MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May	NEWA
		DODEX						
		@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jun	CAHN
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>								
TABLET; ORAL								
CYCLOBENZAPRINE HYDROCHLORIDE								
AB		OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May	CMS1
AB		PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb	CAHN
AB			10MG	A077797	002	Feb 28, 2007	Feb	CAHN
AB		RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May	NEWA
AB			7.5MG	A208170	002	May 31, 2017	May	NEWA
AB			10MG	A208170	003	May 31, 2017	May	NEWA
		@ UPSHER-SMITH LABS	5MG	A072854	002	Feb 03, 2006	Jun	CAHN
		@	10MG	A072854	001	Nov 19, 1991	Jun	CAHN
<u>CYCLOPHOSPHAMIDE</u>								
CAPSULE; ORAL								
CYCLOPHOSPHAMIDE								
+		WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan	CAHN
+	!		50MG	N203856	002	Sep 16, 2013	Jan	CAHN
INJECTABLE; INJECTION								
CYTOXAN (LYOPHILIZED)								
+	@	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb	CRLD
+	@		1GM/VIAL	N012142	004	Aug 30, 1982	Feb	CRLD
+	@		2GM/VIAL	N012142	005	Aug 30, 1982	Feb	CRLD
<u>CYPROHEPTADINE HYDROCHLORIDE</u>								
SYRUP; ORAL								
CYPROHEPTADINE HYDROCHLORIDE								
>A>	AA	SILARX PHARMS INC	2MG/5ML	A203191	001	Jul 13, 2017	Jul	NEWA
		PERIACTIN						
+	@	MERCK	2MG/5ML	N013220	002		Jan	CRLD
TABLET; ORAL								
CYPROHEPTADINE HYDROCHLORIDE								
AA		APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan	NEWA
AA		IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb	CAHN
AA		SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May	CAHN
AA		ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May	NEWA
<u>CYSTEAMINE BITARTRATE</u>								
CAPSULE, DELAYED RELEASE; ORAL								
PROCYSBI								
+		HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar	CAHN
+	!		EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar	CAHN
<u>CYSTEAMINE HYDROCHLORIDE</u>								
SOLUTION/DROPS; OPHTHALMIC								
CYSTARAN								
+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb	CAHN
<u>CYTARABINE</u>								
INJECTABLE; INJECTION								
CYTARABINE								
AP		MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar	CTEC
	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar	CHRS
	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar	CHRS
	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar	CHRS

INJECTABLE; INJECTION  
CYTOSAR-U

@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar	DISC
@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar	DISC
@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar	DISC
@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar	DISC

DACARBAZINE

INJECTABLE; INJECTION  
DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS
		DTIC-DOME						
	+	@ BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr	DISC
	+	@	200MG/VIAL	N017575	002		Apr	DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL  
AMPYRA

AB	+	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
		DALFAMPRIDINE						
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION  
DANTROLENE SODIUM

AP		HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun	NEWA
----	--	--------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
XIGDUO XR

>A>	+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017	Jul	NEWA
-----	---	----------------	--------------------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL  
QTERN

	+	!	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb	NEWA
--	---	---	----------------	---------------------------	---------	-----	--------------	-----	------

DAPSONE

TABLET; ORAL  
DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar	NEWA
AB			100MG	A204380	002	Mar 23, 2017	Mar	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN

>A>	AB		MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017	Jul	NEWA
>A>	AB			EQ 15MG BASE	A207302	002	Jul 28, 2017	Jul	NEWA

DECITABINE

INJECTABLE; INTRAVENOUS  
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA
AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May	NEWA

DEFERASIROX

GRANULE; ORAL  
JADENU SPRINKLE

	+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May	NEWA
	+		180MG	N207968	002	May 18, 2017	May	NEWA
	+	!	360MG	N207968	003	May 18, 2017	May	NEWA

DEFLAZACORT

SUSPENSION; ORAL  
EMFLAZA

	+	!	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
	+	!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN



## TABLET;ORAL

## EMFLAZA

+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb	NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
+		36MG	N208684	004	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
+		36MG	N208684	004	Feb 09, 2017	Apr	CAHN

DELAFLOXACIN MEGLUMINE

## POWDER; IV (INFUSION)

## BAXDELA

+	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun	NEWA
---	---------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

BAXDELA

+	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun	NEWA
---	---------------------	---------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

## TABLET;ORAL

## DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESMETHYL PIROXICAM

## CAPSULE;ORAL

## PIROXICAM

## SUN PHARM INDS

10MG

A073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATE

## INJECTABLE; INJECTION

## DESMOPRESSIN ACETATE

>D>	AP	HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul	DISC
>A>		@	0.004MG/ML	A075220	001	Aug 28, 2000	Jul	DISC
>D>	AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul	DISC
>A>		@	0.004MG/ML	A074888	001	Oct 15, 1997	Jul	DISC

## SPRAY, METERED;NASAL

## NOCTIVA

+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar	NEWA
+		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar	NEWA

STIMATE

@	FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994	Jun	CAHN
---	--------------------	--------------	---------	-----	--------------	-----	------

STIMATE (NEEDS NO REFRIGERATION)

+	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Jun	CAHN
---	--------------------	--------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## DESMOPRESSIN ACETATE

AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May	NEWA
AB		0.1MG	A207880	001	May 26, 2017	May	CAHN
AB		0.2MG	A207880	002	May 26, 2017	May	NEWA
AB		0.2MG	A207880	002	May 26, 2017	May	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

## TABLET;ORAL-28

## DESOGESTREL AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG	A209170	001	Jun 05, 2017	May	NEWA
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar	NEWA

KALLIGA

AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG	A207081	001	May 17, 2017	May	NEWA
----	----------------------	---------------	---------	-----	--------------	-----	------

DESONIDE

## CREAM;TOPICAL

## DESONIDE

>A>	AB	GLENMARK PHARMS	0.05%	A209729	001	Jul 24, 2017	Jul	NEWA
-----	----	-----------------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DESONIDE

AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

		CREAM; TOPICAL							
		TOPICORT							
AB	!	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CAHN	
AB	!		0.25%	A073193	001	Nov 30, 1990	Apr	CAHN	
	+	@	0.25%	N017856	001		May	CAHN	
		TOPICORT LP							
	+	@	TARO	0.05%	N018309	001		May	CAHN
		GEL; TOPICAL							
		DESOXIMETASONE							
AB		RISING PHARMS INC	0.05%	A204675	001	Aug 12, 2016	May	CAHN	
		TOPICORT							
AB	!	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CAHN	
	+	@		N018586	001	Mar 29, 1982	May	CAHN	
	+	@	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD
		OINTMENT; TOPICAL							
		DESOXIMETASONE							
AB		RISING PHARMS INC	0.25%	A204272	001	Nov 30, 2016	May	CAHN	
		TOPICORT							
AB	+	!	TARO	0.05%	N018594	001	Jan 17, 1985	May	CAHN
AB	!			0.25%	A074286	001	Jun 07, 1996	Apr	CAHN
	+	@		0.25%	N018763	001	Sep 30, 1983	May	CAHN
		SPRAY; TOPICAL							
		DESOXIMETASONE							
AT		PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan	NEWA	
		TOPICORT							
AT	+	!	TARO	0.25%	N204141	001	Apr 11, 2013	Jan	CFTG

DESVENLAFAXINE SUCCINATE

		TABLET, EXTENDED RELEASE; ORAL							
		DESVENLAFAXINE SUCCINATE							
AB		ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May	CAHN	
AB			EQ 50MG BASE	A204065	002	Jul 29, 2016	May	CAHN	
AB			EQ 100MG BASE	A204065	003	Jul 29, 2016	May	CAHN	

DEUTETRABENAZINE

		TABLET; ORAL							
		AUSTEDO							
	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr	NEWA	
	+		9MG	N208082	002	Apr 03, 2017	Apr	NEWA	
	+	!	12MG	N208082	003	Apr 03, 2017	Apr	NEWA	

DEXAMETHASONE

		TABLET; ORAL							
		DEXAMETHASONE							
>A>	AB	LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017	Jul	NEWA	
>D>	BP	PAR PHARM	1.5MG	A088237	001	Apr 28, 1983	Jul	CAHN	
	BP		6MG	A088481	001	Nov 28, 1983	May	CHRS	
		@	UPSHER SMITH	0.75MG	A087534	001		Jun	CAHN
		@		1.5MG	A087533	001		Jun	CAHN
>A>	BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983	Jul	CAHN	

DEXAMETHASONE ACETATE

		INJECTABLE; INJECTION							
		DEXAMETHASONE ACETATE							
	@	WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001	May 24, 1982	May	CAHN	

DEXAMETHASONE SODIUM PHOSPHATE

		SOLUTION/DROPS; OPHTHALMIC, OTIC							
		DEXAMETHASONE SODIUM PHOSPHATE							
AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb	CAHN	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

		SUSPENSION/DROPS; OPHTHALMIC							
		MAXITROL							
AT		SANDOZ INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062341	001	May 22, 1984	Feb	CAHN	



<u>DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE</u>										
INJECTABLE; INJECTION										
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER										
	ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 37MG/100ML; 22MG/100ML; 526MG/100ML; 502MG/100ML	N017609	001					Feb	CAHN
<u>DEXTROSE; POTASSIUM CHLORIDE</u>										
INJECTABLE; INJECTION										
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML	N018371	001					Apr	CAHN
	POTASSIUM CHLORIDE	30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003					Apr	CAHN
	POTASSIUM CHLORIDE	40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002					Apr	CAHN
<u>DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>										
INJECTABLE; INJECTION										
	POTASSIUM CHLORIDE	10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983				Feb	CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988				Feb	CAHN
	POTASSIUM CHLORIDE	10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986				Jun	CAHN
		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988				Jun	CAHN
	POTASSIUM CHLORIDE	10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988				Feb	CAHN
AP		5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983				Feb	CAHN
	POTASSIUM CHLORIDE	10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988				Apr	CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988				Apr	CAHN
	POTASSIUM CHLORIDE	15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988				Feb	CAHN
	POTASSIUM CHLORIDE	15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988				Jun	CAHN
	POTASSIUM CHLORIDE	15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988				Feb	CAHN
AP		5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988				Apr	CAHN
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001					Feb	CAHN
		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988				Feb	CAHN
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988				Jun	CAHN
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983				Feb	CAHN
AP		5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988				Feb	CAHN
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988				Apr	CAHN
AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988				Apr	CAHN
	POTASSIUM CHLORIDE	20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986				Jun	CAHN
	POTASSIUM CHLORIDE	30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983				Feb	CAHN
	POTASSIUM CHLORIDE	30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986				Jun	CAHN
	POTASSIUM CHLORIDE	30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002					Feb	CAHN
	POTASSIUM CHLORIDE	30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988				Apr	CAHN
	POTASSIUM CHLORIDE	40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983				Feb	CAHN
	POTASSIUM CHLORIDE	40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988				Jun	CAHN
	POTASSIUM CHLORIDE	40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003					Feb	CAHN
	POTASSIUM CHLORIDE	40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988				Apr	CAHN
	POTASSIUM CHLORIDE	5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER								
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988				Feb	CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988				Feb	CAHN

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun	CAHN
		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN
AP		5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Apr	CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Apr	CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
+	ICU MEDICAL INC	5GM/100ML; 225MG/100ML	N017606	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
+	ICU MEDICAL INC	5GM/100ML; 300MG/100ML	N017799	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	5GM/100ML; 450MG/100ML	N017607	001		Feb	CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	5GM/100ML; 900MG/100ML	N017585	001		Feb	CAHN

DIAZEPAM

TABLET; ORAL

	DIAZEPAM						
@	UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun	CAHN
@		5MG	A070303	001	Dec 20, 1985	Jun	CAHN
@		10MG	A070304	001	Dec 20, 1985	Jun	CAHN
@	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb	CAHN
@		5MG	A070463	001	Feb 25, 1986	Feb	CAHN
@		10MG	A070464	001	Feb 25, 1986	Feb	CAHN

DICLOFENAC POTASSIUM

TABLET; ORAL

	DICLOFENAC POTASSIUM						
@	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May	CAHN

DICLOFENAC SODIUM

SOLUTION; TOPICAL

	DICLOFENAC SODIUM							
AT	ACTAVIS LABS UT INC	2%	A207238	001	May 15, 2017	May	NEWA	
>D>	AT	APOTEX INC	1.5%	A202027	001	May 27, 2014	Jul	CHRS
>A>	AT	!	1.5%	A202027	001	May 27, 2014	Jul	CHRS
>A>	AT	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Jul	NEWA
AT	AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar	CAHN
	PENNSAID							
AT	+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	May	CFTG
	+ @	NUVO PHARMS INC	1.5%	N020947	001	Nov 04, 2009	Apr	CAHN
	+ @	NUVO RES INC	1.5%	N020947	001	Nov 04, 2009	Feb	DISC

SOLUTION/DROPS; OPHTHALMIC

	DICLOFENAC SODIUM							
AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb	CAHN	
	TABLET, DELAYED RELEASE; ORAL							
	DICLOFENAC SODIUM							
	@	ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr	CAHN
	@		75MG	A074986	002	Feb 26, 1999	Apr	CAHN
	TABLET, EXTENDED RELEASE; ORAL							
	DICLOFENAC SODIUM							
	@	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr	DISC
AB	!	DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr	CHRS
	VOLTAREN-XR							
>D>	@	NOVARTIS	100MG	N020254	001	Mar 08, 1996	Jul	CRLD
>A>	+ @		100MG	N020254	001	Mar 08, 1996	Jul	CRLD

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM AND MISOPROSTOL						
AB	EAGLE PHARMS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN
AB		75MG; 0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN
AB	EXELA HOLDINGS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN
AB		75MG; 0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DICYCLOMINE HYDROCHLORIDE

AP LUITPOLD PHARMS INC 10MG/ML A208353 001 Feb 17, 2017 Feb NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL  
DIDANOSINE

@ MYLAN PHARMS INC 125MG A090788 001 Apr 08, 2010 May DISC  
@ 200MG A090788 002 Apr 08, 2010 May DISC  
@ 250MG A090788 003 Apr 08, 2010 May DISC  
@ 400MG A090788 004 Apr 08, 2010 May DISC

FOR SOLUTION; ORAL

>D> DIDANOSINE  
>D> AA AUROBINDO PHARMA 10MG/ML A078112 001 Mar 08, 2007 Jul DISC  
>A> @ 10MG/ML A078112 001 Mar 08, 2007 Jul DISC  
VIDEX  
>D> AA +! BRISTOL MYERS SQUIBB 10MG/ML N020156 001 Oct 09, 1991 Jul CTEC  
>A> +! BRISTOL-MYERS SQUIBB 10MG/ML N020156 001 Oct 09, 1991 Jul CTEC  
>D> TABLET, FOR SUSPENSION; ORAL  
>D> DIDANOSINE  
>D> AUROBINDO 100MG A077275 001 Aug 14, 2012 Jul DISC  
>A> @ 100MG A077275 001 Aug 14, 2012 Jul DISC  
>D> 150MG A077275 002 Aug 14, 2012 Jul DISC  
>A> @ 150MG A077275 002 Aug 14, 2012 Jul DISC  
>D> ! 200MG A077275 003 Aug 14, 2012 Jul DISC  
>A> @ 200MG A077275 003 Aug 14, 2012 Jul DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL  
NATAZIA

+! BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M N022252 001 May 06, 2010 Apr CTEC  
G, N/A

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL  
DIETHYLPROPION HYDROCHLORIDE  
@ EPIC PHARMA LLC 25MG

A040828 001 Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE

OINTMENT; TOPICAL  
DIFLORASONE DIACETATE

AB RICONPHARMA LLC 0.05% A207440 001 Feb 27, 2017 Feb NEWA  
AB ! TARO 0.05% A075331 001 May 14, 1999 Apr CAHN  
PSORCON  
+ @ PHARMACIA AND UPJOHN 0.05% N019260 001 Aug 28, 1985 Mar CRLD

DIFLUNISAL

TABLET; ORAL  
DIFLUNISAL

>A> @ ALLIED PHARMA INC 250MG A073562 001 Nov 27, 1992 Jul CAHN  
>A> @ 500MG A073563 001 Nov 27, 1992 Jul CAHN  
>D> @ ROXANE 250MG A073562 001 Nov 27, 1992 Jul CAHN  
>D> @ 500MG A073563 001 Nov 27, 1992 Jul CAHN  
AB ZYDUS PHARMS USA INC 500MG A203547 001 Jun 16, 2017 Jun NEWA

DIGOXIN

ELIXIR; ORAL  
DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE; INJECTION  
DIGOXIN

>D> AP EUROHLTH INTL SARL 0.25MG/ML A083391 001 Jul CAHN  
AP SANDOZ INC 0.25MG/ML A040481 001 Aug 21, 2003 Mar CAHN  
>A> AP WEST-WARD PHARMS INT 0.25MG/ML A083391 001 Jul CAHN  
LANOXIN  
AP +! COVIS PHARMA BV 0.25MG/ML N009330 002 May CAHN  
LANOXIN PEDIATRIC  
+! COVIS PHARMA BV 0.1MG/ML N009330 004 May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION  
DIHYDROERGOTAMINE MESYLATE

AP WEST-WARD PHARMS INT 1MG/ML A040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DILTIAZEM HYDROCHLORIDE

AB3 SUN PHARM INDS LTD 120MG A203023 001 Jun 08, 2017 May NEWA  
 AB3 180MG A203023 002 Jun 08, 2017 May NEWA  
 AB3 240MG A203023 003 Jun 08, 2017 May NEWA  
 AB3 300MG A203023 004 Jun 08, 2017 May NEWA  
 AB3 360MG A203023 005 Jun 08, 2017 May NEWA  
 >A> AB3 ZYDUS PHARMS USA INC 120MG A206534 001 Aug 08, 2017 Jul NEWA  
 >A> AB4 120MG A206641 001 Aug 11, 2017 Jul NEWA  
 >A> AB3 180MG A206534 002 Aug 08, 2017 Jul NEWA  
 >A> AB4 180MG A206641 002 Aug 11, 2017 Jul NEWA  
 >A> AB3 240MG A206534 003 Aug 08, 2017 Jul NEWA  
 >A> AB4 240MG A206641 003 Aug 11, 2017 Jul NEWA  
 >A> AB3 300MG A206534 004 Aug 08, 2017 Jul NEWA  
 >A> AB4 300MG A206641 004 Aug 11, 2017 Jul NEWA  
 >A> AB3 360MG A206534 005 Aug 08, 2017 Jul NEWA  
 >A> AB4 360MG A206641 005 Aug 11, 2017 Jul NEWA  
 >A> AB4 420MG A206641 006 Aug 11, 2017 Jul NEWA

INJECTABLE; INJECTION  
DILTIAZEM HYDROCHLORIDE

AP ! ATHENEX INC 5MG/ML A074617 001 Feb 28, 1996 Mar CAHN  
 AP WEST-WARD PHARMS INT 5MG/ML A078538 001 Dec 17, 2008 Jan CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ CHARTWELL MOLECULES 30MG A074093 001 Nov 05, 1992 Feb CAHN  
 @ 60MG A074093 002 Nov 05, 1992 Feb CAHN  
 @ 90MG A074093 003 Nov 05, 1992 Feb CAHN  
 @ 120MG A074093 004 Nov 05, 1992 Feb CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION  
DIMENHYDRINATE

@ WATSON LABS TEVA 50MG/ML A080615 001 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML A087513 001 Feb 10, 1982 May CAHN

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS TEVA 10MG/ML A080873 001 May CAHN  
 @ 50MG/ML A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ WATSON LABS TEVA 50MG/ML A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION  
DIPYRIDAMOLE

AP ! ATHENEX INC 5MG/ML A074939 001 Apr 13, 1998 Mar CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB CHARTWELL MOLECULES 250MG A091563 001 Dec 31, 2012 Jan CAHN  
 AB 500MG A091563 002 Dec 31, 2012 Jan CAHN  
 @ WATSON LABS TEVA 500MG A086890 001 May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM

AB PRINSTON INC EQ 125MG VALPROIC ACID A090210 001 Nov 30, 2009 Feb CAHN  
 AB EQ 250MG VALPROIC ACID A090210 002 Nov 30, 2009 Feb CAHN  
 AB EQ 500MG VALPROIC ACID A090210 003 Nov 30, 2009 Feb CAHN  
 AB UPSHER-SMITH LABS EQ 125MG VALPROIC ACID A078182 001 Jul 29, 2008 Jun CAHN  
 AB EQ 250MG VALPROIC ACID A078182 002 Jul 29, 2008 Jun CAHN

TABLET, DELAYED RELEASE;ORAL  
DIVALPROEX SODIUM

AB EQ 500MG VALPROIC ACID A078182 003 Jul 29, 2008 Jun CAHN

DOCETAXEL

INJECTABLE;INJECTION  
DOCETAXEL

AP ACTAVIS LLC 20MG/ML (20MG/ML) N203551 001 Apr 12, 2013 Feb CAHN  
 AP 80MG/4ML (20MG/ML) N203551 002 Apr 12, 2013 Feb CAHN  
 140MG/7ML (20MG/ML) N203551 003 Apr 12, 2013 Feb CAHN  
 AP DFB ONCOLOGY LTD 20MG/ML (20MG/ML) A206177 001 Jan 20, 2017 Jan NEWA  
 AP 80MG/4ML (20MG/ML) A206177 002 Jan 20, 2017 Jan NEWA  
 200MG/10ML (20MG/ML) A206177 003 Jan 20, 2017 Jan NEWA  
 + HOSPIRA INC 160MG/8ML (20MG/ML) N022234 007 Jan 24, 2017 Jan NEWA  
 >A> AP JIANGSU HENGRUI MED 20MG/ML (20MG/ML) A207252 001 Aug 09, 2017 Jul NEWA  
 ! 40MG/ML A203170 001 Feb 15, 2017 Jan NEWA  
 >A> AP 80MG/4ML (20MG/ML) A207252 002 Aug 09, 2017 Jul NEWA  
 >A> AP 160MG/8ML (20MG/ML) A207252 003 Aug 09, 2017 Jul NEWA  
 @ PFIZER LABS 20MG/2ML (10MG/ML) N202356 001 Mar 13, 2014 Jan DISC  
 @ 80MG/8ML (10MG/ML) N202356 002 Mar 13, 2014 Jan DISC  
 @ 130MG/13ML (10MG/ML) N202356 003 Mar 13, 2014 Jan DISC  
 @ 200MG/20ML (10MG/ML) N202356 004 Mar 13, 2014 Jan DISC

DOFETILIDE

CAPSULE;ORAL  
DOFETILIDE

AB MAYNE PHARMA INC 0.125MG A207058 001 Jun 06, 2016 Feb CAHN  
 AB 0.25MG A207058 002 Jun 06, 2016 Feb CAHN  
 AB 0.5MG A207058 003 Jun 06, 2016 Feb CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL  
DONEPEZIL HYDROCHLORIDE

AB ACI HEALTHCARE LTD 5MG A078662 001 May 31, 2011 Jun CAHN  
 AB 10MG A078662 002 May 31, 2011 Jun CAHN  
 AB ALLIED PHARMA INC 5MG A078662 001 May 31, 2011 Mar CAHN  
 AB 10MG A078662 002 May 31, 2011 Mar CAHN  
 AB ZHEJIANG HISUN PHARM 23MG A202410 001 Mar 24, 2017 Mar NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB AMNEAL PHARMS 10MG;14MG A208328 001 Jan 27, 2017 Jan NEWA  
 AB 10MG;28MG A208328 002 Jan 27, 2017 Jan NEWA  
 NAMZARIC  
 AB + FOREST LABS LLC 10MG;14MG N206439 001 Dec 23, 2014 Jan CFTG  
 AB +! 10MG;28MG N206439 002 Dec 23, 2014 Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
DOPAMINE HYDROCHLORIDE

@ TELIGENT 40MG/ML N018656 001 Jun 28, 1983 May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

AT SANDOZ INC EQ 2% BASE A078748 001 Nov 06, 2008 Mar CAHN  
 AT EQ 2% BASE A078981 001 Apr 13, 2009 Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT SANDOZ INC EQ 2% BASE;EQ 0.5% BASE A090604 001 Nov 18, 2009 Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION  
DOXAPRAM HYDROCHLORIDE

AP ATHENEX INC 20MG/ML A076266 001 Jan 10, 2003 Mar CAHN



DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun	NEWA
AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun	NEWA
AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun	NEWA
AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun	NEWA
AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun	NEWA
AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun	NEWA
AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun	NEWA
AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun	NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May	CAHN

CREAM;TOPICAL

ZONALON

+!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan	CAHN
----	------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb	NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb	NEWA
>A>	GLAND PHARMA LTD	2MG/ML	A209825	001	Aug 11, 2017	Jul	NEWA

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May	NEWA
AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>A>	AB	ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017	Jul	NEWA
>A>	AB		EQ 100MG BASE	A209165	002	Jul 28, 2017	Jul	NEWA

DOXYCYCLINE HYCLATE

>D>	CAPSULE, DELAYED RELEASE;ORAL							
>D>	DOXYCYCLINE HYCLATE							
>D>		MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005	Jul	DISC
>A>		@	EQ 75MG BASE	A065281	001	Dec 21, 2005	Jul	DISC
>D>		!	EQ 100MG BASE	A065281	002	Dec 21, 2005	Jul	DISC
>A>		@	EQ 100MG BASE	A065281	002	Dec 21, 2005	Jul	DISC

INJECTABLE;INJECTION

VIBRAMYCIN

+ @	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD
+ @		EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD

TABLET;ORAL

ACTICLATE

AB	+ AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG	
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG	
		DOXYCYCLINE HYCLATE						
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD
	@	EQ 50MG BASE	A062269	003			Jan	CAHN
AB	@	EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN	
	@ EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	May	CAHN	
AB	MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May	NEWA	
AB		EQ 150MG BASE	A208765	002	Jun 14, 2017	May	NEWA	

DRONABINOLSOLUTION;ORAL  
SYNDROS

+! INSYS DEV CO INC 5MG/ML N205525 001 Mar 23, 2017 Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

&gt;A&gt; AB PII 3MG;0.02MG A203291 001 Jul 18, 2017 Jul NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar	NEWA
AB		EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar	NEWA
AB		EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar	NEWA
AB	PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May	NEWA
AB		EQ 30MG BASE	A206653	002	May 18, 2017	May	NEWA
AB		EQ 60MG BASE	A206653	003	May 18, 2017	May	NEWA
AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr	CAHN
AB		EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr	CAHN
AB		EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr	CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May	CAHN
AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

@	MYLAN SPECIALITY LP	200MG	A084566	001		Mar	CAHN
@		400MG	A084566	002		Mar	CAHN

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL  
ECOZA

+! CHEMO RESEARCH SL 1% N205175 001 Oct 24, 2013 May CAHN

CREAM;TOPICAL

SPECTAZOLE

+ @ ALVOGEN MALTA 1% N018751 001 Dec 23, 1982 Mar CMS1

EDARAVONESOLUTION;IV (INFUSION)  
RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML) N209176 001 May 05, 2017 May NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

+ @ TELIGENT 10MG/ML N007959 001 Apr CAHN

TENSILON PRESERVATIVE FREE

+ @ TELIGENT 10MG/ML N007959 002 Apr CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A205152	001	Aug 11, 2017	Jul	NEWA
>A>	AB		EQ 40MG BASE	A205152	002	Aug 11, 2017	Jul	NEWA
	AB	TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun	NEWA
	AB		EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun	NEWA
	AB		EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun	NEWA
		RELPAK						
	AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun	CFTG
	AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun	CFTG

ELVITEGRAVIRTABLET;ORAL  
VITEKTA

+ @	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	May	DISC
+ @		150MG	N203093	002	Sep 24, 2014	May	DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL  
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May	NEWA
	TRUVADA						
AB	+! GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May	CFTG

ENALAPRIL MALEATESOLUTION;ORAL  
EPANED

>D>	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Jul	CRLD
>A>	+!	1MG/ML	N208686	001	Sep 20, 2016	Jul	CRLD

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET;ORAL  
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Jun	CAHN
@		10MG;25MG	A076116	002	Sep 19, 2001	Jun	CAHN

ENALAPRILATINJECTABLE;INJECTION  
ENALAPRILAT

AP	! ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN
	VASOTEC						
	+ @ BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar	CRLD

ENTACAPONETABLET;ORAL  
ENTACAPONE

AB	MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May	NEWA
	@ MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May	DISC

ENTECAVIRTABLET;ORAL  
ENTECAVIR

AB	SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May	NEWA
AB		1MG	A206672	002	May 11, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun	NEWA
AB		1MG	A206745	002	Jun 23, 2017	Jun	NEWA

EPHEDRINE SULFATESOLUTION;INTRAVENOUS  
AKOVAZ

AP	+! FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar	CTEC
	EPHEDRINE SULFATE						
AP	AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar	NEWA
	SOLUTION;IV (INFUSION)						
	CORPHEDRA						
	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan	NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr	NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN

EPINEPHRINEINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS  
ADRENACLICK

BX	+! IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun	CAHN
BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun	CAHN
	TWINJECT 0.15						
	@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun	CAHN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS  
TWINJECT 0.3

@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS					
SYMJEPI					
+! ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@ BELMORA LLC	0.01MG/ML; 2%	A080504	004	Oct 19, 1983	Feb CAHN
@	0.02MG/ML; 2%	A080504	005	Oct 19, 1983	Feb CAHN
@ WEST-WARD PHARMS INT	0.01MG/ML; 1%	A080406	001		Mar CAHN
@	0.01MG/ML; 2%	A080406	002		Mar CAHN

EPLERENONE

TABLET; ORAL  
EPLERENONE

>A> AB	ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul NEWA
>A> AB		50MG	A206922	002	Jul 13, 2017	Jul NEWA
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATES

TABLET; ORAL  
ERGOLOID MESYLATES

!	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	May CHRS
HYDERGINE						
+	@ NOVARTIS	1MG	N017993	001		May DISC

ERYTHROMYCIN

GEL; TOPICAL  
E-GLADES

@ MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan CAHN	
ERYGEL						
AT	+! MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan CAHN
ERYTHROMYCIN						
AT	PERRIGO CO	2%	A063211	001	Jan 29, 1993	Apr CAHN
>A> AT	TELLIGENT PHARMA INC	2%	A208154	001	Jul 19, 2017	Jul NEWA

SOLUTION; TOPICAL  
A/T/S

@ TARO	2%	A062405	001	Nov 18, 1982	Apr CAHN
--------	----	---------	-----	--------------	----------

SWAB; TOPICAL  
ERYTHROMYCIN

@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan CAHN	
AT	! PERRIGO CO	2%	A064126	001	Jul 03, 1996	Apr CAHN

>D> ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

>D> GRANULE; ORAL

>D> ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

>D>	!	BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	A062759	001	May 20, 1988	Jul DISC
>A>	@		EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	A062759	001	May 20, 1988	Jul DISC

ESCITALOPRAM OXALATE

TABLET; ORAL  
ESCITALOPRAM OXALATE

AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017	May NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017	May NEWA

ESOMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE;ORAL  
NEXIUM

+ ASTRAZENECA PHARMS EQ 10MG BASE/PACKET N022101 001 Feb 27, 2008 May CRLD

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May	CHRS
AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May	CHRS
AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA
AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May	NEWA
AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May	NEWA

NEXIUM IV

	+	@	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May	DISC
	+	@		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May	DISC

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL  
ESTRADERM

	+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May	DISC
	+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May	DISC

VIVELLE

	@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May	DISC
	@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	DISC

GEL, METERED;TRANSDERMAL  
ELESTRIN

+! MYLAN SPECIALITY LP 0.06% (0.87GM/ACTIVATION) N021813 001 Dec 15, 2006 Mar CAHN

SPRAY;TRANSDERMAL  
EVAMIST

+! PERRIGO PHARMA INTL 1.53MG/SPRAY N022014 001 Jul 27, 2007 May CAHN

TABLET;VAGINAL  
ESTRADIOL

&gt;A&gt; AB TEVA PHARMS USA 10MCG A206388 001 Jul 21, 2017 Jul NEWA

ESTRADIOL ACETATETABLET;ORAL  
FEMTRACE

	+	@	APIL	0.45MG	N021633	001	Aug 20, 2004	Jun	DISC
	+	@		0.9MG	N021633	002	Aug 20, 2004	Jun	DISC
	+	@		1.8MG	N021633	003	Aug 20, 2004	Jun	DISC

ESTRADIOL VALERATEINJECTABLE; INJECTION  
ESTRADIOL VALERATE

	@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr	CAHN
	@		20MG/ML	A040628	002	Oct 04, 2007	Apr	CAHN
	@		40MG/ML	A040628	003	Oct 04, 2007	Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan	NEWA
AB			1MG;0.5MG	A207261	002	Feb 10, 2017	Jan	NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUWIA

TEVA BRANDED PHARM

			0.3MG	N021443	001	Dec 20, 2004	Apr	CAHN
			0.45MG	N021443	002	Dec 20, 2004	Apr	CAHN
	@		0.625MG	N021443	003	May 10, 2004	Apr	CAHN
			0.9MG	N021443	005	Apr 27, 2007	Apr	CAHN
	@		1.25MG	N021443	004	May 10, 2004	Apr	CAHN

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENESE

MONARCH PHARMS

			0.3MG	A084951	001		Jun	CAHN
			0.625MG	A084948	001		Jun	CAHN
			1.25MG	A084950	001		Jun	CAHN
	!		2.5MG	A084949	001		Jun	CAHN

ESTRONEINJECTABLE; INJECTION  
ESTRONE

@	WATSON LABS TEVA	5MG/ML	A085239	001		May	CAHN
---	------------------	--------	---------	-----	--	-----	------

ESTROPIPATETABLET; ORAL  
ESTROPIPATE

@	BARR	0.75MG	A040135	001	Nov 27, 1996	May	DISC
@		1.5MG	A040135	002	Nov 27, 1996	May	DISC
@		3MG	A040135	003	Nov 27, 1996	May	DISC
!	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	May	CHRS
AB		3MG	A081215	001	Sep 23, 1993	Feb	CAHN
	OGEN .625						
@	PHARMACIA AND UPJOHN	0.75MG	A083220	001		May	DISC
	OGEN 1.25						
@	PHARMACIA AND UPJOHN	1.5MG	A083220	002		May	DISC
	OGEN 2.5						
@	PHARMACIA AND UPJOHN	3MG	A083220	003		May	DISC

ETELCALCETIDESOLUTION; INTRAVENOUS  
PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb	NEWA
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb	NEWA
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb	NEWA

ETHACRYNIC ACIDTABLET; ORAL  
ETHACRYNIC ACID

>A>	AB	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Jul	NEWA
	AB	WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-21  
ZOVIA 1/35E-21

@	WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991	Mar	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL  
LO SIMPESE

AB	AUROBINDO PHARMA LTD	0.02MG,0.01MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr	NEWA
	SIMPESSE						
AB	AUROBINDO PHARMA LTD	0.03MG,0.01MG;0.15MG,N/A	A206851	001	Apr 07, 2017	Mar	NEWA
	TABLET; ORAL-28						
	ELIFEMME						
AB	LABS LEON FARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Feb	CAHN

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL  
XULANE

AB	!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	CAHN
----	---	--------------------	--------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

@	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988	Mar	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

NORETHINDRONE AND ETHINYL ESTRADIOL

@	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987	Mar	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May	CAHN
---	------------------	---------------------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.035MG;1MG	A206864	001	Apr 28, 2017	Apr	NEWA
AB	WATSON LABS TEVA	0.035MG;1MG	A070687	001	Jan 29, 1987	May	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988	May	CAHN

## TABLET, CHEWABLE;ORAL

## NEXESTA FE

AB	AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017	Jan NEWA
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	ACCORD HLTHCARE	0.035MG;0.4MG	A207066	001	Mar 29, 2017	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

## TABLET;ORAL

## AUROVELA 24 FE

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207504	001	Jun 15, 2017	Jun NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Jan NEWA

## TABLET;ORAL-21

## AUROVELA 1.5/30

AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207581	001	Jun 26, 2017	Jun NEWA
	AUROVELA 1/20					

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207506	001	Jun 16, 2017	Jun NEWA
----	----------------------	------------	---------	-----	--------------	----------

## TABLET;ORAL-28

## AUROVELA FE 1.5/30

AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207580	001	Jun 15, 2017	May NEWA
	AUROVELA FE 1/20					

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207505	001	Jun 16, 2017	Jun NEWA
	LOESTRIN FE 1/20					

>D>	AB	APIL	0.02MG;1MG	N017354	001	Jul CRLD
-----	----	------	------------	---------	-----	----------

>A>	AB	+	0.02MG;1MG	N017354	001	Jul CRLD
-----	----	---	------------	---------	-----	----------

ETHINYL ESTRADIOL; NORGESTREL

## TABLET;ORAL-28

## NORGESTREL AND ETHINYL ESTRADIOL

AB	MYLAN LABS LTD	0.05MG;0.5MG	A202875	001	May 08, 2017	Apr NEWA
	OGESTREL 0.5/50-28					

AB	!	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999	May CTEC
----	---	-------------	--------------	---------	-----	--------------	----------

ETHOSUXIMIDE

## SYRUP;ORAL

## ETHOSUXIMIDE

AA	PHARM ASSOC	250MG/5ML	A040253	001	Nov 22, 2000	May CAHN
	ZARONTIN					

AA	!	PARKE-DAVIS	250MG/5ML	A080258	001	Mar CAHN
----	---	-------------	-----------	---------	-----	----------

ETIDRONATE DISODIUM

## TABLET;ORAL

## DIDRONEL

	+ @	APIL	200MG	N017831	001	Jun DISC
--	-----	------	-------	---------	-----	----------

	+ @		400MG	N017831	002	Jun DISC
--	-----	--	-------	---------	-----	----------

## ETIDRONATE DISODIUM

		MYLAN	200MG	A075800	001	Jan 24, 2003	Jun CTEC
--	--	-------	-------	---------	-----	--------------	----------

	!		400MG	A075800	002	Jan 24, 2003	Jun CHRS
--	---	--	-------	---------	-----	--------------	----------

ETODOLAC

## CAPSULE;ORAL

## ETODOLAC

	@	CHARTWELL MOLECULES	200MG	A074842	001	Jul 17, 1997	Mar CAHN
--	---	---------------------	-------	---------	-----	--------------	----------

	@		300MG	A074842	002	Jul 17, 1997	Mar CAHN
--	---	--	-------	---------	-----	--------------	----------

	@	CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Jan CAHN
--	---	----------------------	-------	---------	-----	--------------	----------

	@		300MG	A074842	002	Jul 17, 1997	Jan CAHN
--	---	--	-------	---------	-----	--------------	----------

	@	ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998	Apr CAHN
--	---	----------------	-------	---------	-----	--------------	----------

## LODINE

>D>	@	WYETH PHARMS INC	300MG	N018922	003	Jan 31, 1991	Jul CRLD
-----	---	------------------	-------	---------	-----	--------------	----------

>A>	+ @		300MG	N018922	003	Jan 31, 1991	Jul CRLD
-----	-----	--	-------	---------	-----	--------------	----------

## TABLET;ORAL

## ETODOLAC

	@	CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan CAHN
--	---	---------------------	-------	---------	-----	--------------	----------

	@	MYLAN PHARMS INC	400MG	A075104	001	Feb 06, 1998	May DISC
--	---	------------------	-------	---------	-----	--------------	----------

AB			400MG	A075104	001	Feb 06, 1998	Mar CAHN
----	--	--	-------	---------	-----	--------------	----------

	@		500MG	A075104	002	Nov 20, 1998	May DISC
--	---	--	-------	---------	-----	--------------	----------

AB			500MG	A075104	002	Nov 20, 1998	Mar CAHN
----	--	--	-------	---------	-----	--------------	----------

ETOMIDATEINJECTABLE; INJECTION  
ETOMIDATE

AP	AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209058	001	Apr 18, 2017	Apr	NEWA
AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan	NEWA
AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan	CAHN

EXEMESTANETABLET; ORAL  
EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb	NEWA
>A> AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Jul	NEWA

EZETIMIBETABLET; ORAL  
EZETIMIBE

AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May	NEWA
AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May	NEWA
AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May	NEWA
AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May	NEWA
AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May	NEWA
AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May	NEWA

EZETIMIBE; SIMVASTATINTABLET; ORAL  
EZETIMIBE AND SIMVASTATIN

AB	DR REDDYS LABS INTL	10MG;10MG	A200909	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A200909	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A200909	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A200909	004	Apr 26, 2017	Apr	NEWA
AB	DR REDDYS LABS SA	10MG;10MG	A200909	001	Apr 26, 2017	May	CAHN
AB		10MG;20MG	A200909	002	Apr 26, 2017	May	CAHN
AB		10MG;40MG	A200909	003	Apr 26, 2017	May	CAHN
AB		10MG;80MG	A200909	004	Apr 26, 2017	May	CAHN
AB	IMPAX LABS INC	10MG;10MG	A201890	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A201890	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A201890	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A201890	004	Apr 26, 2017	Apr	NEWA
AB	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A202968	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A202968	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A202968	004	Apr 26, 2017	Apr	NEWA
	VYTORIN						
AB	+ MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Apr	CFTG
AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Apr	CFTG
AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Apr	CFTG
AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Apr	CFTG

FAMCICLOVIRTABLET; ORAL  
FAMCICLOVIR

AB	! TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan	CHRS
	FAMVIR						
	+ @ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan	DISC
	+ @	250MG	N020363	001	Apr 26, 1996	Jan	DISC
	+ @	500MG	N020363	002	Jun 29, 1994	Jan	DISC

FAMOTIDINEINJECTABLE; INJECTION  
FAMOTIDINE

AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN

TABLET; ORAL  
FAMOTIDINE

AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN
AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN



FELBAMATE

SUSPENSION;ORAL		FELBAMATE							
AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun	NEWA		
FELBATOL									
AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN		
TABLET;ORAL		FELBAMATE							
AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN		
AB		600MG	A202284	002	Nov 04, 2015	Feb	CAHN		
AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA		
AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA		
AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May	NEWA		
AB		600MG	A208970	002	May 30, 2017	May	NEWA		
FELBATOL									
AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN		
AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN		

FENOFIBRATE

CAPSULE;ORAL		FENOFIBRATE (MICRONIZED)							
AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA		
AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA		
AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA		
AB	! IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun	CHRS		
AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA		
AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA		
AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA		
AB	RHODES PHARMS	200MG	A075753	003	Apr 09, 2002	Jun	CHRS		
TABLET;ORAL		FENOFIBRATE							
AB	! IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS		
AB	RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS		

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION		FENOLDOPAM MESYLATE							
AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar	CAHN		

FENOPROFEN CALCIUM

TABLET;ORAL		FENOPROFEN CALCIUM							
	@ WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988	May	CAHN		

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL		FENTANYL-100							
AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar	CAHN		
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN		
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar	CAHN		
FENTANYL-12									
AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar	CAHN		
FENTANYL-25									
AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar	CAHN		
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN		
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar	CAHN		
FENTANYL-50									
AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar	CAHN		
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN		
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar	CAHN		
FENTANYL-75									
AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar	CAHN		
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN		
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar	CAHN		
SPRAY;SUBLINGUAL		SUBSYS							
+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May	CAHN		
+		0.2MG	N202788	002	Jan 04, 2012	May	CAHN		
+	!	0.4MG	N202788	003	Jan 04, 2012	May	CAHN		
+		0.6MG	N202788	004	Jan 04, 2012	May	CAHN		
+		0.8MG	N202788	005	Jan 04, 2012	May	CAHN		

	SPRAY;SUBLINGUAL								
	SUBSYS								
	+	1.2MG		N202788	006	Aug 30, 2012	May	CAHN	
	+	1.6MG		N202788	007	Aug 30, 2012	May	CAHN	
	<u>FESOTERODINE FUMARATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	FESOTERODINE FUMARATE								
AB	AUROBINDO PHARMA LTD	4MG		A205007	001	Feb 17, 2017	Feb	NEWA	
AB		8MG		A205007	002	Feb 17, 2017	Feb	NEWA	
	<u>FINASTERIDE</u>								
	TABLET;ORAL								
	FINASTERIDE								
AB	ACCORD HLTHCARE	1MG		A091643	001	Nov 05, 2013	Mar	CAHN	
AB	ACTAVIS TOTOWA TEVA	5MG		A077914	001	Mar 28, 2007	May	CAHN	
	<u>FLUCONAZOLE</u>								
	FOR SUSPENSION;ORAL								
	FLUCONAZOLE								
AB	AUROBINDO PHARMA LTD	50MG/5ML		A079150	001	Sep 18, 2009	Jan	CAHN	
AB		200MG/5ML		A079150	002	Sep 18, 2009	Jan	CAHN	
	INJECTABLE;INJECTION								
	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER								
	+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar	DISC	
	+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar	DISC	
	DIFLUCAN IN SODIUM CHLORIDE 0.9%								
	+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar	DISC	
	+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar	DISC	
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
	+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar	DISC	
	+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar	DISC	
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	CHRS	
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	CHRS	
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%								
		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan	CAHN	
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan	CAHN	
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan	CAHN	
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	!	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CHRS	
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CHRS	
AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan	CAHN	
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan	CAHN	
	TABLET;ORAL								
	FLUCONAZOLE								
AB	UNIQUE PHARM LABS	150MG		A076957	004	Feb 27, 2017	Feb	NEWA	
AB	ZYDUS PHARMS USA INC	50MG		A208963	001	Feb 16, 2017	Feb	NEWA	
AB		100MG		A208963	002	Feb 16, 2017	Feb	NEWA	
AB		150MG		A208963	003	Feb 16, 2017	Feb	NEWA	
AB		200MG		A208963	004	Feb 16, 2017	Feb	NEWA	
	<u>FLUCYDOSINE</u>								
	CAPSULE;ORAL								
	FLUCYDOSINE								
AB	NOVEL LABS INC	250MG		A204652	001	Jul 07, 2017	Jun	NEWA	
AB		500MG		A204652	002	Jul 07, 2017	Jun	NEWA	
	<u>FLUDARABINE PHOSPHATE</u>								
	INJECTABLE;INJECTION								
	FLUDARABINE PHOSPHATE								
AP	ACTAVIS LLC	50MG/2ML (25MG/ML)		A203738	001	Feb 28, 2017	Feb	NEWA	
	<u>FLUMAZENIL</u>								
	INJECTABLE;INJECTION								
	FLUMAZENIL								
AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)		A077071	001	May 03, 2005	Apr	CAHN	
AP		1MG/10ML (0.1MG/ML)		A077071	002	May 03, 2005	Apr	CAHN	
AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)		A076256	002	Oct 12, 2004	Jan	CAHN	
AP		0.5MG/5ML (0.1MG/ML)		A076787	002	Oct 12, 2004	Jan	CAHN	
AP		1MG/10ML (0.1MG/ML)		A076256	001	Oct 12, 2004	Jan	CAHN	
AP		1MG/10ML (0.1MG/ML)		A076787	001	Oct 12, 2004	Jan	CAHN	

FLUNISOLIDE

AEROSOL, METERED; INHALATION  
AEROSPAN HFA

+! MYLAN SPECIALITY LP 0.078MG/INH N021247 001 Jan 27, 2006 Mar CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL  
FLUOCINOLONE ACETONIDE

AT FOUGERA PHARMS INC 0.01% A088170 001 Dec 16, 1982 Jan CAHN  
AT 0.025% A088169 001 Dec 16, 1982 Jan CAHN  
@ TARO 0.01% A040035 001 Oct 31, 1994 Apr CAHN  
@ 0.025% A040042 001 Oct 31, 1994 Apr CAHN

OIL/DROPS; OTIC  
FLUOCINOLONE ACETONIDE

>A> AT PERRIGO ISRAEL 0.01% A202849 001 Jul 17, 2017 Jul NEWA

OINTMENT; TOPICAL  
FLUOCINOLONE ACETONIDE

AT FOUGERA PHARMS INC 0.025% A088168 001 Dec 16, 1982 Jan CAHN  
AT TARO 0.025% A040041 001 Sep 15, 1994 Apr CAHN

SOLUTION; TOPICAL  
FLUOCINOLONE ACETONIDE

AT FOUGERA PHARMS INC 0.01% A088167 001 Dec 16, 1982 Jan CAHN

FLUOCINONIDE

CREAM; TOPICAL  
FLUOCINONIDE

AB1 FOUGERA PHARMS INC 0.05% A073030 001 Oct 17, 1994 Jan CAHN  
AB PERRIGO ISRAEL 0.1% A090256 001 Jan 14, 2014 Apr CAHN  
AB1 TARO 0.05% A071500 001 Jun 10, 1987 Mar CMFD

FLUOCINONIDE EMULSIFIED BASE  
AB2 G AND W LABS INC 0.05% A074204 001 Jun 13, 1995 May CMFD

GEL; TOPICAL  
FLUOCINONIDE

AB FOUGERA PHARMS INC 0.05% A072933 001 Dec 30, 1994 Jan CAHN  
AB ! TARO 0.05% A074935 001 Jul 29, 1997 Apr CAHN

OINTMENT; TOPICAL  
FLUOCINONIDE

>A> AB NOVEL LABS INC 0.05% A207538 001 Jul 31, 2017 Jul NEWA  
AB ! TARO 0.05% A075008 001 Jun 30, 1999 Apr CAHN

SOLUTION; TOPICAL  
FLUOCINONIDE

>A> AT NOVEL LABS INC 0.05% A206003 001 Jul 21, 2017 Jul NEWA  
AT ! TARO 0.05% A074799 001 Dec 31, 1996 Apr CAHN

LIDEX

AT + CNTY LINE PHARMS 0.05% N018849 001 Apr 06, 1984 Mar CRLD

FLUOROURACIL

CREAM; TOPICAL  
FLUOROURACIL

AB MYLAN PHARMS INC 0.5% A203122 001 Apr 20, 2015 Jun CAHN

INJECTABLE; INJECTION  
FLUOROURACIL

AP SAGENT PHARMS 500MG/10ML (50MG/ML) A203608 001 May 11, 2017 May NEWA  
AP 1GM/20ML (50MG/ML) A203608 002 May 11, 2017 May NEWA  
>D> AP SANDOZ 2.5GM/50ML (50MG/ML) A091299 001 May 02, 2011 Jul DISC  
>A> @ 2.5GM/50ML (50MG/ML) A091299 001 May 02, 2011 Jul DISC  
>D> AP 5GM/100ML (50MG/ML) A091299 002 May 02, 2011 Jul DISC  
>A> @ 5GM/100ML (50MG/ML) A091299 002 May 02, 2011 Jul DISC  
+ @ SPECTRUM PHARMS 500MG/10ML (50MG/ML) N012209 001 Jan CRLD

SOLUTION; TOPICAL  
FLUOROURACIL

AT TARO PHARM 2% A076526 001 Nov 05, 2003 Mar CAHN  
AT 5% A076526 002 Nov 05, 2003 Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL  
FLUOXETINE HYDROCHLORIDE

@ MYLAN EQ 10MG BASE A075207 001 Jan 30, 2002 Jun DISC  
@ EQ 20MG BASE A075207 002 Jan 30, 2002 Jun DISC  
@ EQ 40MG BASE A075207 003 May 25, 2007 Jun DISC

	SOLUTION;ORAL							
	FLUOXETINE HYDROCHLORIDE							
AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A 079209	001	Mar 20, 2009	Jan	CAHN	
AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A 076015	001	Jan 30, 2002	May	CAHN	
	TABLET;ORAL							
	FLUOXETINE HYDROCHLORIDE							
AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A 208698	001	Apr 05, 2017	Mar	NEWA	
AB		EQ 20MG BASE	A 208698	002	Apr 05, 2017	Mar	NEWA	
	+! ALVOGEN	EQ 60MG BASE	N 202133	001	Oct 06, 2011	Jan	CAHN	
	<u>FLUOXYMESTERONE</u>							
	TABLET;ORAL							
	FLUOXYMESTERONE							
	! USL PHARMA	10MG	A 088342	001	Oct 21, 1983	Jun	CAHN	
	<u>FLUPHENAZINE HYDROCHLORIDE</u>							
	CONCENTRATE;ORAL							
	FLUPHENAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC	5MG/ML	A 073058	001	Aug 30, 1991	Jan	CAHN	
	! PHARM ASSOC	5MG/ML	A 074725	001	Sep 16, 1996	May	CAHN	
	ELIXIR;ORAL							
	FLUPHENAZINE HYDROCHLORIDE							
	! PHARM ASSOC	2.5MG/5ML	A 040146	001	Aug 21, 1996	May	CAHN	
	<u>FLURANDRENOLIDE</u>							
	CREAM;TOPICAL							
	FLURANDRENOLIDE							
AT	CINTEX SVCS	0.05%	A 205342	001	Apr 13, 2016	Jun	CAHN	
	LOTION;TOPICAL							
	FLURANDRENOLIDE							
AT	CINTEX SVCS	0.05%	A 205343	001	Dec 22, 2016	Jun	CAHN	
	<u>FLURAZEPAM HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	FLURAZEPAM HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	15MG	A 071717	002	Jul 31, 1991	Jan	CMS1	
	<u>FLUTAMIDE</u>							
	CAPSULE;ORAL							
	FLUTAMIDE							
	@ MYLAN	125MG	A 076224	001	May 09, 2003	Jun	DISC	
	<u>FLUTICASONE PROPIONATE</u>							
	POWDER;INHALATION							
	ARMONAIR RESPICLICK							
	+ TEVA PHARM	0.055MG/INH	N 208798	001	Jan 27, 2017	Jan	NEWA	
		0.113MG/INH	N 208798	002	Jan 27, 2017	Jan	NEWA	
	+!	0.232MG/INH	N 208798	003	Jan 27, 2017	Jan	NEWA	
	SPRAY, METERED;NASAL							
	FLONASE							
>D>	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N 020121	001	Oct 19, 1994	Jul	CRLD	
>A>	+ @	0.05MG/SPRAY	N 020121	001	Oct 19, 1994	Jul	CRLD	
	FLUTICASONE PROPIONATE							
>D>	AB WEST-WARD PHARMS INT	0.05MG/SPRAY	A 076504	001	Feb 22, 2006	Jul	CHRS	
>A>	AB !	0.05MG/SPRAY	A 076504	001	Feb 22, 2006	Jul	CHRS	
	<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE</u>							
	POWDER;INHALATION							
	AIRDUO RESPICLICK							
	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N 208799	001	Jan 27, 2017	Jan	NEWA	
		0.113MG/INH;EQ 0.014MG BASE/INH	N 208799	002	Jan 27, 2017	Jan	NEWA	
	+!	0.232MG/INH;EQ 0.014MG BASE/INH	N 208799	003	Jan 27, 2017	Jan	NEWA	
	<u>FLUVASTATIN SODIUM</u>							
	CAPSULE;ORAL							
	FLUVASTATIN SODIUM							
AB	! MYLAN PHARMS INC	EQ 40MG BASE	A 090595	002	Apr 11, 2012	May	CHRS	
	LESCOL							
	+ @ NOVARTIS	EQ 20MG BASE	N 020261	001	Dec 31, 1993	May	DISC	
	+ @	EQ 40MG BASE	N 020261	002	Dec 31, 1993	May	DISC	

FLUVOXAMINE MALEATE

		CAPSULE, EXTENDED RELEASE;ORAL							
		FLUVOXAMINE MALEATE							
AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr	CHRS	
		LUVOX CR							
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr	DISC	
	+	@	150MG	N022033	002	Feb 28, 2008	Apr	DISC	
		TABLET;ORAL							
		FLUVOXAMINE MALEATE							
		@ ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May	CAHN	
		@	50MG	A075900	002	Feb 23, 2006	May	CAHN	
		@	100MG	A075900	003	Feb 23, 2006	May	CAHN	
		@ UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Jun	CAHN	
AB			25MG	A075888	001	Nov 29, 2000	Jun	CAHN	
		@	50MG	A075887	002	Jan 05, 2001	Jun	CAHN	
AB			50MG	A075888	002	Nov 29, 2000	Jun	CAHN	
		@	100MG	A075887	003	Jan 05, 2001	Jun	CAHN	
AB	!		100MG	A075888	003	Nov 29, 2000	Jun	CAHN	

FOLIC ACID

		TABLET;ORAL							
		FOLIC ACID							
		@ CONTRACT PHARMACAL	1MG	A085061	001		Mar	DISC	

FORMOTEROL FUMARATE

		POWDER; INHALATION							
		FORADIL							
	+	@ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb	DISC	

FORMOTEROL FUMARATE; GLYCOPYRROLATE

		AEROSOL, METERED; INHALATION							
		BEVESPI AEROSPHERE							
	+	! ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar	CAHN	

FOSINOPRIL SODIUM

		TABLET;ORAL							
		FOSINOPRIL SODIUM							
		@ UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Jun	CAHN	
AB			10MG	A076483	001	Apr 23, 2004	Jun	CAHN	
		@	20MG	A076188	002	Oct 08, 2004	Jun	CAHN	
AB			20MG	A076483	002	Apr 23, 2004	Jun	CAHN	
		@	40MG	A076188	003	Oct 08, 2004	Jun	CAHN	
AB			40MG	A076483	003	Apr 23, 2004	Jun	CAHN	
		MONOPRIL							
	+	@ BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan	CRLD	
	+	@	20MG	N019915	003	May 16, 1991	Jan	CRLD	
	+	@	40MG	N019915	004	Mar 28, 1995	Jan	CRLD	

FOSPHENYTOIN SODIUM

		INJECTABLE; INJECTION							
		FOSPHENYTOIN SODIUM							
AP		FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun	CMFD	
		@ HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar	DISC	
AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan	CAHN	
AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan	CAHN	

FUROSEMIDE

		INJECTABLE; INJECTION							
		FUROSEMIDE							
		@ ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Jun	CAHN	
		TABLET;ORAL							
		FUROSEMIDE							
BX		IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Apr	CTEC	
BX			40MG	A078010	002	Sep 18, 2006	Apr	CTEC	
BX			80MG	A078010	003	Sep 18, 2006	Apr	CTEC	
AB		PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb	CAHN	
AB			40MG	A076796	002	Mar 26, 2004	Feb	CAHN	
AB			80MG	A076796	003	Mar 26, 2004	Feb	CAHN	
		@ SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May	DISC	
		@	40MG	A091258	002	Apr 01, 2014	May	DISC	
		@	80MG	A091258	003	Apr 01, 2014	May	DISC	

## TABLET;ORAL

## FUROSEMIDE

	@ WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985	May CAHN
	@	80MG	A070528	001	Jan 07, 1986	May CAHN
AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN
AB		40MG	N018823	002	Nov 10, 1983	Jan CAHN

GABAPENTIN

## CAPSULE;ORAL

## GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA

## TABLET;ORAL

## GABAPENTIN

AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
AB		800MG	A077662	002	Aug 18, 2006	May CAHN
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA

GALANTAMINE HYDROBROMIDE

## TABLET;ORAL

## GALANTAMINE HYDROBROMIDE

>D>	@ YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul CMFD
>A>	AB	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul CMFD
>D>	@	EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul CMFD
>A>	AB	EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul CMFD
>D>	@	EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul CMFD
>A>	AB	EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul CMFD

GANCICLOVIR

## SOLUTION;IV (INFUSION)

## GANCICLOVIR

+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
----	----------------------	----------------------	---------	-----	--------------	----------

GATIFLOXACIN

## SOLUTION/DROPS;OPHTHALMIC

## GATIFLOXACIN

AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
----	------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## GEMCITABINE HYDROCHLORIDE

AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA

GEMFIBROZIL

## TABLET;ORAL

## GEMFIBROZIL

AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN
----	-----------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

## TABLET;ORAL

## FACTIVE

AB	+! LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

GENTAMICIN SULFATE

## CREAM;TOPICAL

## GENTAMICIN SULFATE

	@ FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan DISC
AT	! PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
	@ TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

## OINTMENT;TOPICAL

## GENTAMICIN SULFATE

AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
----	--------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC  
GENTAMICIN SULFATE

AT	SANDOZ INC	EQ 0.3% BASE	A062196	001			Mar	CAHN
----	------------	--------------	---------	-----	--	--	-----	------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	@ EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005	May	CAHN
	@	2MG	A077274	002	Oct 06, 2005	May	CAHN
	@	4MG	A077274	003	Oct 06, 2005	May	CAHN
AB	PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb	CAHN
AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN
AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN
AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB	WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May	CAHN
AB		10MG	A074223	002	Feb 27, 1995	May	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	GLIPIZIDE						
AB	AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May	NEWA
AB		5MG	A206928	002	May 12, 2017	May	NEWA
AB		10MG	A206928	003	May 12, 2017	May	NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	2.5MG;250MG	A077507	001	Oct 27, 2005	May	CAHN
AB		2.5MG;500MG	A077507	002	Oct 27, 2005	May	CAHN
AB		5MG;500MG	A077507	003	Oct 27, 2005	May	CAHN
	METAGLIP						
	+ @ BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan	CRLD
	+ @	2.5MG;500MG	N021460	002	Oct 21, 2002	Jan	CRLD
	+ @	5MG;500MG	N021460	003	Oct 21, 2002	Jan	CRLD

>D> GLUTAMINE

&gt;D&gt; FOR SOLUTION;ORAL

&gt;D&gt; NUTRESTORE

>D>	+! EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAIN
-----	-----------------	------------	---------	-----	--------------	-----	------

GLUTETHIMIDE

TABLET;ORAL

GLUTETHIMIDE

@ UPSHER-SMITH LABS	500MG	A083234	002			Jun	CAHN
---------------------	-------	---------	-----	--	--	-----	------

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1	EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May	CAHN
AB1		2.5MG	A076257	002	Jun 27, 2002	May	CAHN
AB1		5MG	A076257	003	Jun 27, 2002	May	CAHN
AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN
AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN
AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb	CAHN
@	2.5MG;500MG	A076731	002	Nov 19, 2004	Feb	CAHN
@	5MG;500MG	A076731	003	Nov 19, 2004	Feb	CAHN

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	1.5GM/100ML	N018315	001		Feb	CAHN
----	-----------------	-------------	---------	-----	--	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION		GLYCOPYRROLATE					
AP	AMNEAL PHARMS CO	0.2MG/ML	A208973	001	Jun 15, 2017	Jun	NEWA
AP	SOMERSET THERAPS LLC	0.2MG/ML	A207639	001	Jun 23, 2017	Jun	NEWA
POWDER; INHALATION		SEEBRI					
+!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan	CAHN
TABLET; ORAL		GLYCOPYRROLATE					
	@ EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May	CAHN
	@	2MG	A040568	002	Dec 22, 2004	May	CAHN
AA	SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May	CAHN
AA		2MG	A091182	002	Feb 03, 2014	May	CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION		UTIBRON					
+!	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Jan	CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION		FACTREL					
	@ WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar	CAHN
	@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar	CAHN
	@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar	CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION		CHORIONIC GONADOTROPIN					
+!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan	CMFD

GOSERELIN ACETATE

IMPLANT; IMPLANTATION		ZOLADEX					
+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May	CAHN
+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May	CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC		NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN					
AT	AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar	CAHN
NEOSPORIN							
AT	! MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION		GRANISETRON HYDROCHLORIDE					
AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Mar	NEWA
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Mar	NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan	NEWA
AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078534	001	Apr 30, 2009	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar	CAHN
AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan	CAHN
TABLET; ORAL		GRANISETRON HYDROCHLORIDE					
	@ EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May	CAHN
AB	TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar	CAHN



GRISEOFULVIN, MICROSIZESUSPENSION; ORAL  
GRISEOFULVIN

AB	CHARTWELL RX	125MG/5ML	A065200	001	Mar 02, 2005	Jun	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

HALOBETASOL PROPIONATECREAM; TOPICAL  
HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr	CHRS
----	----------------	-------	---------	-----	--------------	-----	------

AB	+ SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr	CHRS
----	----------------------	-------	---------	-----	--------------	-----	------

AB	+!	0.05%	N019967	001	Dec 27, 1990	Mar	CAHN
----	----	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL  
HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A077721	001	Sep 07, 2006	Jun	CHRS
----	----------------	-------	---------	-----	--------------	-----	------

AB	PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AB	+ RANBAXY	0.05%	N019968	001	Dec 17, 1990	Jun	CHRS
----	-----------	-------	---------	-----	--------------	-----	------

HALOPERIDOLTABLET; ORAL  
HALOPERIDOL

	@ FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb	CAHN
--	---------------------	------	---------	-----	--------------	-----	------

HALOPERIDOL DECANOATEINJECTABLE; INJECTION  
HALOPERIDOL DECANOATE

AO	GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May	NEWA
----	------------------	-----------------	---------	-----	--------------	-----	------

AO		EQ 100MG BASE/ML	A205241	002	May 12, 2017	May	NEWA
----	--	------------------	---------	-----	--------------	-----	------

	@ SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar	CAHN
--	--------------	-----------------	---------	-----	--------------	-----	------

	@	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar	CAHN
--	---	------------------	---------	-----	--------------	-----	------

HALOPERIDOL LACTATECONCENTRATE; ORAL  
HALOPERIDOL

AA	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May	CAHN
----	-------------	----------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
HALOPERIDOL

	@ SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar	CAHN
--	--------------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUMINJECTABLE; INJECTION  
HEPARIN SODIUM

>D>	@ EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Jul	CAHN
-----	----------------------	----------------	---------	-----	--	-----	------

>D>	@	2,500 UNITS/ML	N017007	007		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>D>	@	5,000 UNITS/ML	N017007	002		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>D>	@	5,000 UNITS/0.5ML	N017007	010		Jul	CAHN
-----	---	-------------------	---------	-----	--	-----	------

>D>	@	7,500 UNITS/ML	N017007	003		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>D>	@	10,000 UNITS/ML	N017007	004		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

>D>	@	15,000 UNITS/ML	N017007	005		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

>D>	@	20,000 UNITS/ML	N017007	006		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

AP	GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA
----	------------------	----------------	---------	-----	--------------	-----	------

>A>	@ WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul	CAHN
-----	------------------------	----------------	---------	-----	--	-----	------

>A>	@	2,500 UNITS/ML	N017007	007		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>A>	@	5,000 UNITS/ML	N017007	002		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>A>	@	5,000 UNITS/0.5ML	N017007	010		Jul	CAHN
-----	---	-------------------	---------	-----	--	-----	------

>A>	@	7,500 UNITS/ML	N017007	003		Jul	CAHN
-----	---	----------------	---------	-----	--	-----	------

>A>	@	10,000 UNITS/ML	N017007	004		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

>A>	@	15,000 UNITS/ML	N017007	005		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

>A>	@	20,000 UNITS/ML	N017007	006		Jul	CAHN
-----	---	-----------------	---------	-----	--	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA
----	-----------	--------------------	---------	-----	--------------	-----	------

AA	BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA
----	---------------	--------------------	---------	-----	--------------	-----	------

AA	NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

AA	PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA
----	-------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL								
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE								
>A>	AA	AVANTHI INC	1.5MG;5MG	A207176	001	Aug 07, 2017	Jul	NEWA
		TUSSIGON						
	AA	! KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Feb	CAHN
<u>HYDRALAZINE HYDROCHLORIDE</u>								
TABLET;ORAL								
HYDRALAZINE HYDROCHLORIDE								
	AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May	NEWA
	AA		25MG	A205236	002	May 26, 2017	May	NEWA
	AA		50MG	A205236	003	May 26, 2017	May	NEWA
	AA		100MG	A205236	004	May 26, 2017	May	NEWA
		@ UPSHER-SMITH LABS	10MG	A083241	001		Jun	CAHN
		@	25MG	A083560	001		Jun	CAHN
		@	50MG	A083561	001		Jun	CAHN
<u>HYDROCHLOROTHIAZIDE</u>								
CAPSULE;ORAL								
HYDROCHLOROTHIAZIDE								
	AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
TABLET;ORAL								
HYDROCHLOROTHIAZIDE								
	AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
	AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN
		@ WATSON LABS TEVA	50MG	A083232	001		May	CAHN
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN</u>								
TABLET;ORAL								
IRBESARTAN AND HYDROCHLOROTHIAZIDE								
	AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar	CAHN
	AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar	CAHN
	AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CAHN
	AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May	NEWA
<u>HYDROCHLOROTHIAZIDE; LISINAPRIL</u>								
TABLET;ORAL								
LISINAPRIL AND HYDROCHLOROTHIAZIDE								
	AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May	NEWA
	AB		12.5MG;20MG	A204058	002	May 23, 2017	May	NEWA
	AB		25MG;20MG	A204058	003	May 23, 2017	May	NEWA
PRINZIDE								
		+ @ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan	CRLD
		+ @	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan	CRLD
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM</u>								
TABLET;ORAL								
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE								
>A>	AB	UNICHEM LABS LTD	12.5MG;50MG	A204832	001	Jul 21, 2017	Jul	NEWA
>A>	AB		12.5MG;100MG	A204832	002	Jul 21, 2017	Jul	NEWA
>A>	AB		25MG;100MG	A204832	003	Jul 21, 2017	Jul	NEWA
<u>HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE</u>								
TABLET;ORAL								
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE								
		@ CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar	CAHN
		@	12.5MG;15MG	A090096	002	Sep 25, 2008	Mar	CAHN
		@	25MG;15MG	A090096	003	Sep 25, 2008	Mar	CAHN
	AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan	CMS1
	AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Jan	CMS1
	AB		25MG;15MG	A202150	003	Mar 07, 2014	Jan	CMS1
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL</u>								
TABLET;ORAL								
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE								
	AB	ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr	NEWA
	AB		12.5MG;40MG	A204233	002	Apr 24, 2017	Apr	NEWA
	AB		25MG;40MG	A204233	003	Apr 24, 2017	Apr	NEWA
	AB	AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr	NEWA
	AB		12.5MG;40MG	A205391	002	Apr 24, 2017	Apr	NEWA
	AB		25MG;40MG	A205391	003	Apr 24, 2017	Apr	NEWA
	AB	PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr	NEWA

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		12.5MG;40MG	A207804	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A207804	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A200532	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A200532	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr	NEWA
AB		12.5MG;40MG	A206515	002	May 03, 2017	Apr	NEWA
AB		25MG;40MG	A206515	003	May 03, 2017	Apr	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

## QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun	CMS1
AB		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun	CMS1
AB		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun	CMS1
	@ SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Jun	DISC
	@	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Jun	DISC
	@	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Jun	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

	@ UPSHER SMITH	25MG;25MG	A087553	001		Jun	CAHN
--	----------------	-----------	---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

## TABLET; ORAL

## TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	ZYDUS PHARMS USA INC	12.5MG;40MG	A204221	001	Aug 15, 2017	Jul	NEWA
>A>	AB		12.5MG;80MG	A204221	002	Aug 15, 2017	Jul	NEWA
>A>	AB		25MG;80MG	A204221	003	Aug 15, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

## TABLET; ORAL

## VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A201662	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A201662	005	Mar 21, 2013	May	CAHN
AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A091519	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May	CAHN

HYDROCODONE BITARTRATE

## TABLET, EXTENDED RELEASE; ORAL

## VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan	NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan	NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan	NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan	NEWA

HYDROCORTISONE

## CREAM; TOPICAL

## HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan	CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan	CAHN
>D>		SYNACORT						
>D>	AT	MEDICIS	1%	A087458	001		Jul	DISC
>A>		@	1%	A087458	001		Jul	DISC
>D>	AT		2.5%	A087457	001		Jul	DISC
>A>		@	2.5%	A087457	001		Jul	DISC

## LOTION; TOPICAL

## STIE-CORT

	@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr	CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr	CAHN

	OINTMENT;TOPICAL							
	HYDROCORTISONE							
AT	!	FOUGERA PHARMS INC 2.5%	A081203	001	May 28, 1993	Jan	CAHN	
		HYDROCORTISONE IN ABSORBASE						
AT		CMP PHARMA INC 1%	A088138	001	Sep 06, 1985	Apr	CAHN	
		TABLET;ORAL						
		HYDROCORTISONE						
AB		PII 5MG	A207029	001	Apr 27, 2017	Apr	NEWA	
AB		10MG	A207029	002	Apr 27, 2017	Apr	NEWA	
AB		20MG	A207029	003	Apr 27, 2017	Apr	NEWA	
		<u>HYDROCORTISONE ACETATE</u>						
		AEROSOL, METERED;RECTAL						
		CORTIFOAM						
	+	MYLAN SPECIALITY LP 10%	N017351	001	Feb 10, 1982	Mar	CAHN	
		<u>HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
		CREAM;TOPICAL						
		CORTISPORIN						
	+	MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN	
		<u>HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE</u>						
		AEROSOL, METERED;TOPICAL						
		EPIFOAM						
BX		MYLAN SPECIALITY LP 1%;1%	A086457	001		Mar	CAHN	
		PROCTOFOAM HC						
BX		MYLAN SPECIALITY LP 1%;1%	A086195	001		Mar	CAHN	
		<u>HYDROCORTISONE VALERATE</u>						
		CREAM;TOPICAL						
		HYDROCORTISONE VALERATE						
AB	!	TARO 0.2%	A075042	001	Aug 25, 1998	Apr	CAHN	
		OINTMENT;TOPICAL						
		HYDROCORTISONE VALERATE						
	!	TARO 0.2%	A075043	001	Aug 25, 1998	Apr	CAHN	
		<u>HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
		SOLUTION/DROPS;OTIC						
		CORTISPORIN						
AT	+	MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr	CAHN	
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar	CAHN	
AT		SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN	
		SUSPENSION/DROPS;OPHTHALMIC						
		CORTISPORIN						
	@	MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr	CAHN	
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb	CAHN	
		SUSPENSION/DROPS;OTIC						
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Mar	CAHN	
AT		SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb	CAHN	
		<u>HYDROMORPHONE HYDROCHLORIDE</u>						
		INJECTABLE;INJECTION						
		DILAUDID						
AP	+	FRESENIUS KABI USA 1MG/ML	N019034	003	Apr 30, 2009	Jan	CAHN	
AP	+	2MG/ML	N019034	004	Apr 30, 2009	Jan	CAHN	
AP	+	4MG/ML	N019034	005	Apr 30, 2009	Jan	CAHN	
		DILAUDID-HP						
AP	+	FRESENIUS KABI USA 10MG/ML	N019034	001	Jan 11, 1984	Jan	CAHN	
	@	250MG/VIAL	N019034	002	Aug 04, 1994	Jan	CAHN	

	SOLUTION; ORAL						
	DILAUDID						
AA	+!	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992	Jun CAHN
	TABLET; ORAL						
	DILAUDID						
AB	+	PURDUE PHARM PRODS	4MG	N019892	002	Nov 09, 2007	May CAHN
AB	+!		8MG	N019892	001	Dec 07, 1992	May CAHN
AB	+	RHODES PHARMS	2MG	N019892	003	Nov 09, 2007	Jun CAHN
AB	+		4MG	N019892	002	Nov 09, 2007	Jun CAHN
AB	+!		8MG	N019892	001	Dec 07, 1992	Jun CAHN
	<u>HYDROXOCOBALAMIN</u>						
	INJECTABLE; INJECTION						
	HYDROXOCOBALAMIN						
	!	ACTAVIS LLC	1MG/ML	A085998	001		Feb CAHN
	<u>HYDROXYZINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	VISTARIL						
	+ @	PFIZER	25MG/ML	N011111	001		Jan CRLD
	+ @		50MG/ML	N011111	002		Jan CRLD
	TABLET; ORAL						
	HYDROXYZINE HYDROCHLORIDE						
	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan CMS1
	@		25MG	A087871	003	Dec 20, 1982	Jan CMS1
AB		NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar NEWA
AB			25MG	A207121	001	Mar 29, 2017	Mar NEWA
AB			50MG	A207122	001	Mar 29, 2017	Mar NEWA
AB		PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb CAHN
AB			25MG	A040574	001	May 27, 2005	Feb CAHN
AB			50MG	A040580	001	May 27, 2005	Feb CAHN
	@	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Apr DISC
	@		25MG	A040899	002	Jun 10, 2008	Apr DISC
	@		50MG	A040899	003	Jun 10, 2008	Apr DISC
	<u>IBANDRONATE SODIUM</u>						
	TABLET; ORAL						
	IBANDRONATE SODIUM						
	@	MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	May DISC
AB		WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May CAHN
	<u>IBUPROFEN</u>						
	SUSPENSION; ORAL						
	IBUPROFEN						
AB	!	ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May CAHN
AB		TARO	100MG/5ML	A209204	001	Jun 23, 2017	Jun NEWA
	MOTRIN						
	+ @	MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan CRLD
	TABLET; ORAL						
	IBUPROFEN						
	@	MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar CAHN
	<u>IBUPROFEN; OXYCODONE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	OXYCODONE HYDROCHLORIDE AND IBUPROFEN						
	@	WATSON LABS	400MG; 5MG	A078394	001	Nov 26, 2007	Jun DISC
BX			400MG; 5MG	A078394	001	Nov 26, 2007	Apr CTEC
	<u>ICOSAPENT ETHYL</u>						
	CAPSULE; ORAL						
	VASCEPA						
	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar NEWA
>D>	<u>IDOXURIDINE</u>						
>D>	SOLUTION/DROPS; OPHTHALMIC						
>D>	DENDRID						
>D>	+!	ALCON	0.1%	N014169	001		Jul DISC
>A>	+ @		0.1%	N014169	001		Jul DISC

IFOSFAMIDE; MESNAINJECTABLE; INTRAVENOUS  
IFOSFAMIDE/MESNA KIT

@	TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002	Mar	DISC
@		3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002	Mar	DISC

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

AB	MYLAN PHARMS INC	EQ 100MG BASE	A204644	001	Jun 21, 2017	Jun	NEWA
AB		EQ 400MG BASE	A204644	002	Jun 21, 2017	Jun	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	May	CMS1
		25MG	A040751	002	Feb 28, 2008	May	CMS1
>D> AB	PAR PHARM	10MG	A089422	001	Jul 14, 1987	Jul	DISC
>A>	@	10MG	A089422	001	Jul 14, 1987	Jul	DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

@	MYLAN PHARMS INC	EQ 75MG HCL	A202338	001	Jun 28, 2013	Jun	DISC
@		EQ 100MG HCL	A202338	002	Jun 28, 2013	Jun	DISC
@		EQ 125MG HCL	A202338	003	Jun 28, 2013	Jun	DISC
@		EQ 150MG HCL	A202338	004	Jun 28, 2013	Jun	DISC

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jan	CAHN
----	---------------------	---------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CAHN
@		50MG	A070651	001	Mar 05, 1986	Apr	CAHN
@		50MG	N018829	001	Aug 06, 1984	Feb	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	CHARTWELL RX	75MG	A200529	001	Nov 30, 2010	Jun	CAHN
AB	GLENMARK PHARMS LTD	75MG	A203501	001	Jun 22, 2017	Jun	NEWA
AB	NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr	NEWA
	@ WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb	DISC

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUM

>A> AP	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017	Jul	NEWA
--------	-------------	------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

SCANLUX-300

AP	MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Feb	CAHN

SCANLUX-370

AP	MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb	CAHN

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D> AN	BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001	Jul	DISC
>A>	@	0.02%	A075835	001	Oct 15, 2001	Jul	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

AP	INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May	NEWA
AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May	NEWA
>D>	AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul DISC
>A>	@		40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul DISC
>D>	AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul DISC
>A>	@		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul DISC
AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan	CAHN
AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan	CAHN
INJECTABLE, LIPOSOMAL; IV (INFUSION)							
ONIVYDE							
+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Apr	CAHN

ISONIAZID

INJECTABLE; INJECTION  
ISONIAZID

!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar	CAHN
SYRUP; ORAL							
ISONIAZID							
!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Apr	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

>A>	AP	NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jul NEWA
ISUPREL							
>D>	+!	HOSPIRA	0.2MG/ML	N010515	001		Jul CTEC
>A>	AP	+!	0.2MG/ML	N010515	001		Jul CTEC

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL  
ISOSORBIDE DINITRATE

@	WATSON LABS TEVA	5MG	A086031	001	Sep 29, 1987	May	CAHN
TABLET, EXTENDED RELEASE; ORAL							
ISOSORBIDE DINITRATE							
@	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb	CAHN

ISRADIPINE

CAPSULE; ORAL  
ISRADIPINE

AB	WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May	CAHN
AB	!	5MG	A077317	002	Jan 05, 2006	May	CAHN

ITRACONAZOLE

CAPSULE; ORAL  
ITRACONAZOLE

AB	ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May	NEWA
AB	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb	NEWA

KANAMYCIN SULFATE

INJECTABLE; INJECTION  
KANAMYCIN

@	WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan	CAHN
@		EQ 500MG BASE/2ML	A062324	002		Jan	CAHN
@		EQ 1GM BASE/3ML	A062324	003		Jan	CAHN

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL  
EXTINA

AT	+!	MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan CAHN
CREAM; TOPICAL							
NIZORAL							
+	@	JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May CRLD

KETOPROFEN

	CAPSULE;ORAL						
	KETOPROFEN						
	HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb	CAHN
AB		50MG	A074014	002	Jan 29, 1993	Feb	CAHN
AB		75MG	A074014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

	INJECTABLE; INJECTION						
	KETOROLAC TROMETHAMINE						
	@ SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
AP		30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	KETOROLAC TROMETHAMINE						
AT	SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN

L-GLUTAMINE

>A>	FOR SOLUTION;ORAL						
>A>	ENDARI						
>A>	+ EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul	NEWA
>A>	NUTRESTORE						
>A>	+! EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAIN

LABETALOL HYDROCHLORIDE

	INJECTABLE; INJECTION						
	LABETALOL HYDROCHLORIDE						
AP	SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN

LACOSAMIDE

	TABLET;ORAL						
	LACOSAMIDE						
AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	May	CAHN
AB		100MG	A204857	002	Sep 09, 2016	May	CAHN
AB		150MG	A204857	003	Sep 09, 2016	May	CAHN
AB		200MG	A204857	004	Sep 09, 2016	May	CAHN

LACTULOSE

	SOLUTION;ORAL						
	LACTULOSE						
AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May	CAHN

LAMIVUDINE

	TABLET;ORAL						
	LAMIVUDINE						
AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

	TABLET;ORAL						
	LAMIVUDINE AND ZIDOVUDINE						
AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr	NEWA
BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar	NEWA

LAMOTRIGINE

	TABLET;ORAL						
	LAMOTRIGINE						
	@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
	@	100MG	A078443	002	Feb 11, 2009	Mar	CAHN
	@	150MG	A078443	003	Feb 11, 2009	Mar	CAHN
	@	200MG	A078443	004	Feb 11, 2009	Mar	CAHN
	TABLET, CHEWABLE;ORAL						
	LAMOTRIGINE						
AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May	CAHN
AB		25MG	A079099	002	Feb 19, 2009	May	CAHN
	@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jun	DISC
	@	25MG	A076630	002	Jan 22, 2009	Jun	DISC
	TABLET, EXTENDED RELEASE;ORAL						
	LAMOTRIGINE						
AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr	CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan	CAHN



TABLET, EXTENDED RELEASE;ORAL  
LAMOTRIGINE

AB		100MG	A202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL  
FOSRENOL

>D>	+	SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
>A>	AB		EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
>D>	+		EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
>A>	AB		EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
>D>	+	!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG
>A>	AB	+	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG

## LANTHANUM CARBONATE

>A>	AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul NEWA
>A>	AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul NEWA
>A>	AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

AT		AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT		SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

LETROZOLE

TABLET;ORAL  
LETROZOLE

	@	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jun DISC
	@	LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Jun DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL  
KISQALI FEMARA CO-PACK (COPACKAGED)

	+	!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
--	---	---	----------------------	-----------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
AP			EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
AP			EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA

## TABLET;ORAL

## LEUCOVORIN CALCIUM

	@	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
	@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN

## WELLCOVORIN

	+	@	GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun CRLD
	+	@		EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun CRLD

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
LEVALBUTEROL HYDROCHLORIDE

AN		AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA
----	--	----------------------	---------------	---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE;IV (INFUSION)  
LEVETIRACETAM

>A>	AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jul CAHN
>D>	AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jul CAHN

## SOLUTION;ORAL

## LEVETIRACETAM

AA		ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar CAHN
AA		AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN

## TABLET;ORAL

## LEVETIRACETAM

AB		ACI HEALTHCARE LTD	250MG	A078042	001	Jan 15, 2009	Jun CAHN
AB			500MG	A078042	002	Jan 15, 2009	Jun CAHN
AB			750MG	A078042	003	Jan 15, 2009	Jun CAHN
AB			1GM	A078042	004	Jan 15, 2009	Jun CAHN
AB		ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar CAHN
AB			500MG	A078042	002	Jan 15, 2009	Mar CAHN

## TABLET;ORAL

AB	LEVETIRACETAM	750MG	A078042	003	Jan 15, 2009	Mar	CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar	CAHN
	ROWEEPRA						
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr	NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr	CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr	NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr	NEWA

## TABLET, EXTENDED RELEASE;ORAL

AB	LEVETIRACETAM	500MG	A204754	001	Aug 26, 2016	Mar	CAHN
AB	ECI PHARMS LLC	750MG	A204754	002	Aug 26, 2016	Mar	CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr	DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr	DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr	DISC
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb	CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
LEVOBUNOLOL HYDROCHLORIDE

>D>	AT	BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul	DISC
>A>		@	0.25%	A074307	001	Mar 04, 1994	Jul	DISC
	AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN

LEVOCARNITINEINJECTABLE;INJECTION  
CARNITOR

AP	+	LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar	CAHN
		SOLUTION;ORAL						
		CARNITOR						
		@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar	CAHN
AA	+		1GM/10ML	N019257	001	Apr 10, 1986	Mar	CAHN
		CARNITOR SF						
AA	+	LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar	CAHN
		TABLET;ORAL						
		CARNITOR						
AB	+	LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar	CAHN
		LEVOCARNITINE						
AB		IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDESOLUTION;ORAL  
LEVOCETIRIZINE DIHYDROCHLORIDE

AA		SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	May	NEWA	
		XYZAL							
>A>	AA	+	SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul	CAHN
>D>	AA	+	UCB INC	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul	CAHN
		TABLET;ORAL							
		LEVOCETIRIZINE DIHYDROCHLORIDE							
AB		ALLIED PHARMA INC	5MG	A204323	001	Dec 20, 2016	Apr	CAHN	
		XYZAL							
>A>	AB	+	SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul	CAHN
>D>	AB	+	UCB INC	5MG	N022064	001	May 25, 2007	Jul	CAHN

LEVOFLOXACIN

## INJECTABLE;INJECTION

## LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	@ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD
	+	@	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD
	+	@	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD
		LEVOFLOXACIN						
AP		SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
AP		ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May	NEWA

SOLUTION/DROPS;OPHTHALMIC  
LEVOFLOXACIN

AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN
TABLET;ORAL						
LEVOFLOXACIN						
>D>	AB	MYLAN	250MG	A076276	001	Jun 20, 2011 Jul DISC
>A>		@	250MG	A076276	001	Jun 20, 2011 Jul DISC
>D>	AB		500MG	A076276	002	Jun 20, 2011 Jul DISC
>A>		@	500MG	A076276	002	Jun 20, 2011 Jul DISC
		@	750MG	A077097	001	Jun 20, 2011 Jun DISC

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)  
LEVOLEUCOVORIN CALCIUM

AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
	+	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN  
@ SEPTODONT INC 0.05MG/ML;2%  
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN  
@ BELMORA LLC 0.05MG/ML;2%

A084697	001		May CAHN
A084850	002	Oct 21, 1983	Feb CAHN

LEVOTHYROXINE SODIUM

SOLUTION;ORAL  
TIROSINT-SOL

+	@	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
+	@		25MCG/ML	N206977	002	Dec 15, 2016	Jun DISC
+	@		50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
+	@		75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
+	@		88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC
+	@		100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
+	@		112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
+	@		125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
+	@		137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
+	@		150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
+	@		175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
+	@		200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL  
LEVOXYL

AB1,	+	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May CAHN
AB3							
AB1,	+		0.05MG	N021301	002	May 25, 2001	May CAHN
AB3							
AB1,	+		0.075MG	N021301	003	May 25, 2001	May CAHN
AB3							
AB1,	+		0.088MG	N021301	004	May 25, 2001	May CAHN
AB3							
AB1,	+		0.1MG	N021301	005	May 25, 2001	May CAHN
AB3							
AB1,	+		0.112MG	N021301	006	May 25, 2001	May CAHN
AB3							
AB1,	+		0.125MG	N021301	007	May 25, 2001	May CAHN
AB3							
AB1,	+		0.137MG	N021301	008	May 25, 2001	May CAHN
AB3							
AB1,	+		0.15MG	N021301	009	May 25, 2001	May CAHN
AB3							
AB1,	+		0.175MG	N021301	010	May 25, 2001	May CAHN
AB3							
AB1,	+		0.2MG	N021301	011	May 25, 2001	May CAHN
AB3							
	+	@	0.3MG	N021301	012	May 25, 2001	May CAHN

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
	XYLOCAINE						
	+ @ ASTRAZENECA	5%	N008048	001		Jan	CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

	@ BELMORA LLC	2%	A080504	001		Feb	CAHN
--	---------------	----	---------	-----	--	-----	------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

	+! TARO PHARMS	7%; 7%	N021717	001	Jun 29, 2006	May	CAHN
--	----------------	--------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINESS

	+ FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan	NEWA
--	-------------------	-------	---------	-----	--------------	-----	------

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	Jun	NEWA
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	Jun	NEWA
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb	NEWA
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb	NEWA

TABLET; ORAL

LINEZOLID

AB	ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	+ KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB	+	EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+!	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE; ORAL

VYVANSE

	+ SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan	NEWA
	+	20MG	N208510	002	Jan 28, 2017	Jan	NEWA
	+	30MG	N208510	003	Jan 28, 2017	Jan	NEWA
	+	40MG	N208510	004	Jan 28, 2017	Jan	NEWA
	+	50MG	N208510	005	Jan 28, 2017	Jan	NEWA
	+!	60MG	N208510	006	Jan 28, 2017	Apr	CHRS
	+	60MG	N208510	006	Jan 28, 2017	Jan	NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb	CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb	CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb	CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb	CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb	CAHN
AB		40MG	A075743	006	Jul 01, 2002	Feb	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan	CAHN
AB		300MG	A076243	001	Jun 27, 2002	Jan	CAHN
AB		600MG	A078763	001	Apr 15, 2008	Jan	CAHN
AB	+ WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+	300MG	N017812	001		Jan	CAHN
AB	+!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN

## TABLET;ORAL

	LITHIUM CARBONATE						
AB	+!	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	LITHIUM CARBONATE						
AB		UNIQUE PHARM LABS	450MG	A205663	001	Jun 05, 2017	May NEWA

LITHIUM CITRATE

## SYRUP;ORAL

	LITHIUM CITRATE						
AA	+!	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN

LORAZEPAM

## INJECTABLE;INJECTION

	LORAZEPAM						
AP		SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Mar NEWA
AP			2MG/ML	A200542	001	Apr 28, 2017	Apr NEWA
AP			4MG/ML	A200217	002	Apr 04, 2017	Mar NEWA
AP			4MG/ML	A200542	002	Apr 28, 2017	Apr NEWA
	@	WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar CAHN
	@		4MG/ML	A074496	002	Sep 28, 1998	Mar CAHN

## TABLET;ORAL

	LORAZEPAM						
AB		SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr CMS1
AB			1MG	A071141	003	Apr 21, 1987	Apr CMS1

LOSARTAN POTASSIUM

## TABLET;ORAL

	LOSARTAN POTASSIUM						
>D>	BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul CTEC
>A>	AB		25MG	A203835	001	Aug 12, 2015	Jul CTEC
>D>	BX		50MG	A203835	002	Aug 12, 2015	Jul CTEC
>A>	AB		50MG	A203835	002	Aug 12, 2015	Jul CTEC
>D>	BX		100MG	A203835	003	Aug 12, 2015	Jul CTEC
>A>	AB		100MG	A203835	003	Aug 12, 2015	Jul CTEC
	AB	UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun CAHN
	AB		50MG	A090544	002	Oct 06, 2010	Jun CAHN
	AB		100MG	A090544	003	Oct 06, 2010	Jun CAHN

LOVASTATIN

## TABLET;ORAL

	LOVASTATIN						
	@	MYLAN	10MG	A075935	001	Dec 17, 2001	Mar DISC
	@		20MG	A075935	002	Dec 17, 2001	Mar DISC
	@		40MG	A075935	003	Dec 17, 2001	Mar DISC

## TABLET, EXTENDED RELEASE;ORAL

	ALTOPREV						
	@	COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002	Apr CAHN
	+		20MG	N021316	002	Jun 26, 2002	Apr CAHN
	+		40MG	N021316	003	Jun 26, 2002	Apr CAHN
	+!		60MG	N021316	004	Jun 26, 2002	Apr CAHN

MAFENIDE ACETATE

## FOR SOLUTION;TOPICAL

	MAFENIDE ACETATE						
>A>	AT	RICONPHARMA LLC	5%	A206716	001	Jul 31, 2017	Jul NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE;INJECTION

	NORMOSOL-R IN PLASTIC CONTAINER						
		ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N017586	001		Feb CAHN

## SOLUTION;IRRIGATION

	PHYSIOSOL IN PLASTIC CONTAINER						
		ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982	Feb CAHN

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA
	SUPREP BOWEL PREP KIT					
AA	! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
	SUPREP BOWEL PREP KIT					
AA	! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN

MALATHIONLOTION;TOPICAL  
OVIDE

AT	! TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	--------------	------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
	MANNITOL 10% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
	MANNITOL 15% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
	MANNITOL 20% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN
	MANNITOL 5% IN PLASTIC CONTAINER					

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001		Feb CAHN
	SORBITOL-MANNITOL IN PLASTIC CONTAINER					

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

	@ WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988	May CAHN
	MAPROTILINE HYDROCHLORIDE					
	@	50MG	A072163	001	Jun 01, 1988	May CAHN

MEBENDAZOLETABLET, CHEWABLE;ORAL  
EMVERM

!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	May CHRS
	MECAMYLAMINE HYDROCHLORIDE					

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May CAHN
	MECLIZINE HYDROCHLORIDE					
AA	@	25MG	A201451	002	Feb 23, 2011	May CAHN
AA	@	50MG	A201451	003	Feb 23, 2011	May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

	@ WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987	May CAHN
	MECLOFENAMATE SODIUM					

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

AB	@ SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Jun DISC
	MEDROXYPROGESTERONE ACETATE					
AB		150MG/ML	A078711	001	May 20, 2009	Mar CAHN
AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN

## TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA	10MG	A088484	001	Jul 26, 1984	Jun CAHN
--------------	------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

## TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

AB	!	BARR	250MG	A076392	001	Dec 29, 2003	Apr CHRS
		@ SANDOZ	250MG	A076175	001	Feb 20, 2002	Apr DISC

MEGESTROL ACETATE

## SUSPENSION;ORAL

MEGACE

	+	@ BRISTOL MYERS SQUIBB	40MG/ML	N020264	001	Sep 10, 1993	Feb DISC
		MEGESTROL ACETATE					
AB		HI-TECH PHARMACAL	40MG/ML	A203960	001	Jun 09, 2017	May NEWA
AB	!	WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb CHRS

MELOXICAM

## TABLET;ORAL

MELOXICAM

@ SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006	Apr DISC
@	15MG	A077937	002	Jul 19, 2006	Apr DISC

MELPHALAN

## TABLET;ORAL

ALKERAN

AB	+	!	APOTEX INC	2MG	N014691	002		Mar CFTG
			MELPHALAN					
AB			ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar NEWA

MELPHALAN HYDROCHLORIDE

## INJECTABLE;INJECTION

ALKERAN

	+	@ APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	May DISC
		MELPHALAN HYDROCHLORIDE					
AP	!	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	May CHRS
AP		SAGENT PHARMS	EQ 50MG BASE/VIAL	A201379	001	Feb 28, 2017	Feb NEWA

MEMANTINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	May CAHN
AB			14MG	A205825	002	Oct 12, 2016	May CAHN
AB			21MG	A205825	003	Oct 12, 2016	May CAHN
AB			28MG	A205825	004	Oct 12, 2016	May CAHN
AB		ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	May NEWA
AB			14MG	A205784	002	Jun 09, 2017	May NEWA
AB			21MG	A205784	003	Jun 09, 2017	May NEWA
AB			28MG	A205784	004	Jun 09, 2017	May NEWA
>A>	AB	ZYDUS PHARMS USA INC	7MG	A203293	001	Aug 03, 2017	Jul NEWA
>A>	AB		14MG	A203293	002	Aug 03, 2017	Jul NEWA
>A>	AB		21MG	A203293	003	Aug 03, 2017	Jul NEWA
>A>	AB		28MG	A203293	004	Aug 03, 2017	Jul NEWA

## TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	May CAHN
AB			10MG	A090041	002	Apr 10, 2015	May CAHN
AB		STRIDES PHARMA	5MG	A202350	001	May 23, 2017	May NEWA
AB			10MG	A202350	002	May 23, 2017	May NEWA
AB		UPSHER-SMITH LABS	5MG	A090043	001	Jul 31, 2015	Jun CAHN
AB			10MG	A090043	002	Jul 31, 2015	Jun CAHN
AB		ZYDUS PHARMS USA INC	5MG	A090961	001	Jul 10, 2017	Jun NEWA
AB			10MG	A090961	002	Jul 10, 2017	Jun NEWA

MEPERIDINE HYDROCHLORIDE

## INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
AP			25MG/ML	A080455	007		Jan CAHN
AP			50MG/ML	A080445	002		Jan CAHN
AP			50MG/ML	A080455	008		Jan CAHN

## INJECTABLE; INJECTION

## MEPERIDINE HYDROCHLORIDE

AP		75MG/ML	A080445	003		Jan	CAHN
AP		75MG/ML	A080455	009		Jan	CAHN
AP		100MG/ML	A080445	004		Jan	CAHN
AP		100MG/ML	A080455	010		Jan	CAHN
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	!	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr CAHN
		@ MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar CAHN
AP		WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr CAHN

MEPIVACAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ISOCAINE HYDROCHLORIDE

AP	!	SEPTODONT INC	3%	A080925	001		May CAHN
MEPIVACAINE HYDROCHLORIDE							
		@ BELMORA LLC	3%	A083559	001		Feb CAHN

MERCAPTOPURINE

## TABLET; ORAL

## MERCAPTOPURINE

AB		DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun CAHN
----	--	-------------------	------	---------	-----	--------------	----------

MEROPENEM

## INJECTABLE; INJECTION

## MEROPENEM

AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA
		@ SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Jun DISC
		@	1GM/VIAL	A091201	002	Mar 29, 2011	Jun DISC
MERREM							
AP	+	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN

MESALAMINE

## ENEMA; RECTAL

## ROWASA

AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar CAHN
SFROWASA							

AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar CAHN
----	---	---------------------	----------	---------	-----	--------------	----------

## TABLET, DELAYED RELEASE; ORAL

## ASACOL HD

>D>	+	APIL	800MG	N021830	001	May 29, 2008	Jul CFTG
>A>	AB	+	800MG	N021830	001	May 29, 2008	Jul CFTG

## LIALDA

AB	+	SHIRE	1.2GM	N022000	001	Jan 16, 2007	May CFTG
----	---	-------	-------	---------	-----	--------------	----------

## MESALAMINE

>A>	AB	ZYDUS PHARMS USA INC	800MG	A203286	001	Jul 21, 2017	Jul NEWA
	AB		1.2GM	A091640	001	Jun 05, 2017	May NEWA

METAXALONE

## TABLET; ORAL

## METAXALONE

AB		ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017	Jun NEWA
		@ EPIC PHARMA LLC	640MG	N022503	001	Jun 01, 2015	May CAHN
		IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb CAHN

## SKELAXIN

		+ @ KING PHARMS	400MG	N013217	001		May CAHN
AB	+		800MG	N013217	003	Aug 30, 2002	May CAHN

METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## METFORMIN HYDROCHLORIDE

		@ MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002	May DISC
		@	850MG	A075969	002	Jan 29, 2002	May DISC
		@	1GM	A075969	003	Jan 29, 2002	May DISC
		@ WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002	Mar DISC
		@	850MG	A075961	002	Jan 25, 2002	Mar DISC
		@	1GM	A075961	003	Jan 25, 2002	Mar DISC



## TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE							
AB1	INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb	NEWA
AB		750MG	A202306	002	Feb 23, 2017	Feb	NEWA
AB1	TORRENT PHARMS LTD	500MG	A090014	001	Dec 30, 2009	Apr	CAHN

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

## TABLET;ORAL

## ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 1MG BASE	A077337	005	May 19, 2017	May	NEWA
--	------	-------------------	---------	-----	--------------	-----	------

METHADONE HYDROCHLORIDE

## CONCENTRATE;ORAL

## METHADOSE

AA	+!	MALLINCKRODT INC	10MG/ML	N017116	002		Apr	CAHN
		POWDER;FOR RX COMPOUNDING						
		METHADONE HYDROCHLORIDE						
		MALLINCKRODT INC	50GM/BOT	N006383	002		Apr	CAHN
			100GM/BOT	N006383	003		Apr	CAHN
			500GM/BOT	N006383	004		Apr	CAHN

## SYRUP;ORAL

## DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 10MG/30ML

N006134 004 Jan CAHN

## TABLET;ORAL

## DOLOPHINE HYDROCHLORIDE

AA	+!	WEST-WARD PHARMS INT	5MG	N006134	002	Jan	CAHN	
AA	+!		10MG	N006134	010	Jan	CAHN	
		METHADONE HYDROCHLORIDE						
AA		EPIC PHARMA LLC	5MG	A090065	001	Aug 18, 2015	May	CAHN
AA			10MG	A090065	002	Aug 18, 2015	May	CAHN

## TABLET, FOR SUSPENSION;ORAL

## METHADONE HYDROCHLORIDE

AA	+!	WEST-WARD PHARMS INT	40MG	N017058	001		Jan	CAHN
----	----	----------------------	------	---------	-----	--	-----	------

METHENAMINE HIPPURATE

## TABLET;ORAL

## METHENAMINE HIPPURATE

AB		IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb	CAHN
----	--	----------------	-----	---------	-----	--------------	-----	------

METHIMAZOLE

## TABLET;ORAL

## METHIMAZOLE

@ ECI PHARMS LLC 15MG

A040619 003 Jul 12, 2005 May CAHN

## TAPAZOLE

AB		KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb	CAHN
AB			10MG	A040320	002	Mar 31, 2000	Feb	CAHN

METHOCARBAMOL

## SOLUTION;IM-IV

## METHOCARBAMOL

AP		LUITPOLD PHARMS INC	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017	Jun	NEWA
AP		RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan	NEWA
AP		RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar	CAHN
>A>	AP	SAGENT PHARMS	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017	Jul	NEWA
>A>	AP	SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017	Jul	NEWA

## TABLET;ORAL

## METHOCARBAMOL

AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan	NEWA
AA			750MG	A203550	002	Feb 08, 2017	Jan	NEWA
>A>	AA	BEXIMCO PHARMS USA	500MG	A208507	001	Jul 21, 2017	Jul	NEWA
>A>	AA		750MG	A208507	002	Jul 21, 2017	Jul	NEWA
		@ UPSHER SMITH	500MG	A087453	001		Jun	CAHN
		@	750MG	A087454	001		Jun	CAHN

METHOTREXATE

## SOLUTION;SUBCUTANEOUS

## OTREXUP PFS

>A>								
>A>	+	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jul	NEWA
>A>	+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jul	NEWA
>A>	+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jul	NEWA
>A>	+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jul	NEWA

	SOLUTION;SUBCUTANEOUS						
>A>	OTREXUP PFS						
>A>	+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jul	NEWA
>A>	+	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jul	NEWA
	RASUVO						
	@ MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun	DISC
	<u>METHOTREXATE SODIUM</u>						
	INJECTABLE;INJECTION						
	METHOTREXATE SODIUM PRESERVATIVE FREE						
AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr	CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr	CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr	CMS1
	SOLUTION;ORAL						
	XATMEP						
	+!	SILVERGATE PHARMS EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr	NEWA
	TABLET;ORAL						
	METHOTREXATE SODIUM						
>D>	AB	HQ SPCLT PHARMA EQ 2.5MG BASE	A201749	001	May 21, 2015	Jul	CAHN
>A>	AB	ORION CORP ORION EQ 2.5MG BASE	A201749	001	May 21, 2015	Jul	CAHN
	AB	ZYDUS PHARMS USA INC EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan	NEWA
	<u>METHYLDOPATE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	METHYLDOPATE HYDROCHLORIDE						
	!	LUITPOLD 50MG/ML	A071279	001	Oct 02, 1987	Jan	CTEC
	<u>METHYLPHENIDATE</u>						
	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL						
	COTEMPLA XR-ODT						
	+	NEOS THERAPS INC 8.6MG	N205489	001	Jun 19, 2017	Jun	NEWA
	+	17.3MG	N205489	002	Jun 19, 2017	Jun	NEWA
	+	25.9MG	N205489	003	Jun 19, 2017	Jun	NEWA
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>						
	CAPSULE, EXTENDED RELEASE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb	CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb	CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb	CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb	CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb	CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb	CAHN
	!	MAYNE PHARMA 60MG	A078458	004	Jun 23, 2016	Feb	CHRS
	RITALIN LA						
	+	@ NOVARTIS 60MG	N021284	005	Oct 27, 2014	Feb	DISC
	TABLET;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr	NEWA
AB		10MG	A206932	002	May 11, 2017	Apr	NEWA
AB		20MG	A206932	003	May 11, 2017	Apr	NEWA
AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb	CAHN
AB		10MG	A091159	002	Mar 12, 2014	Feb	CAHN
AB		20MG	A091159	003	Mar 12, 2014	Feb	CAHN
AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb	NEWA
AB		10MG	A207587	002	Mar 03, 2017	Feb	NEWA
AB		20MG	A207587	003	Mar 03, 2017	Feb	NEWA
	TABLET, CHEWABLE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan	NEWA
AB		5MG	A204954	002	Jan 26, 2017	Jan	NEWA
AB		10MG	A204954	003	Jan 26, 2017	Jan	NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
>A>	AB	IMPAX LABS INC 18MG	A208607	001	Jul 14, 2017	Jul	NEWA
>A>	AB	27MG	A208607	002	Jul 14, 2017	Jul	NEWA
>A>	AB	36MG	A208607	003	Jul 14, 2017	Jul	NEWA
>A>	AB	54MG	A208607	004	Jul 14, 2017	Jul	NEWA
>A>	AB	OSMOTICA 18MG	A205327	001	Jul 28, 2017	Jul	NEWA
>A>	AB	27MG	A205327	002	Jul 28, 2017	Jul	NEWA

TABLET, EXTENDED RELEASE;ORAL						
METHYLPHENIDATE HYDROCHLORIDE						
>A>	AB		36MG	A205327	003	Jul 28, 2017 Jul NEWA
>A>	AB		54MG	A205327	004	Jul 28, 2017 Jul NEWA
>A>			72MG	A205327	005	Jul 28, 2017 Jul NEWA
RITALIN-SR						
AB	+	NOVARTIS	20MG	N018029	001	Mar 30, 1982 Feb CRLD
<u>METHYLPREDNISOLONE ACETATE</u>						
INJECTABLE;INJECTION						
METHYLPREDNISOLONE ACETATE						
>D>	AB	SANDOZ	40MG/ML	A040794	001	Mar 05, 2009 Jul CAHN
>D>	AB		80MG/ML	A040794	002	Mar 05, 2009 Jul CAHN
	AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009 Mar CAHN
>A>	AB		40MG/ML	A040794	001	Mar 05, 2009 Jul CAHN
	AB		80MG/ML	A040719	002	Jan 29, 2009 Mar CAHN
>A>	AB		80MG/ML	A040794	002	Mar 05, 2009 Jul CAHN
<u>METHYLTESTOSTERONE</u>						
TABLET;ORAL						
ANDROID 10						
		@ VALEANT PHARMS NORTH	10MG	A086450	001	May CAHN
<u>METIPRANOLOL HYDROCHLORIDE</u>						
SOLUTION/DROPS;OPHTHALMIC						
METIPRANOLOL						
AT		SANDOZ INC	0.3%	A075720	001	Aug 06, 2001 Feb CAHN
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>						
SOLUTION;ORAL						
METOCLOPRAMIDE HYDROCHLORIDE						
AA		PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991 May CAHN
TABLET;ORAL						
METOCLOPRAMIDE HYDROCHLORIDE						
		@ SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997 May DISC
<u>METOPROLOL SUCCINATE</u>						
TABLET, EXTENDED RELEASE;ORAL						
TOPROL-XL						
AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001 Jan CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992 Jan CAHN
AB	+	!	EQ 100MG TARTRATE	N019962	002	Jan 10, 1992 Jan CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992 Jan CAHN
<u>METOPROLOL TARTRATE</u>						
INJECTABLE;INJECTION						
METOPROLOL TARTRATE						
AP		SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007 Mar CAHN
AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003 Jan CAHN
TABLET;ORAL						
METOPROLOL TARTRATE						
>A>	AB	SUN PHARM INDS	50MG	A073654	003	Dec 21, 1993 Jul CMS1
<u>METRONIDAZOLE</u>						
CAPSULE;ORAL						
METRONIDAZOLE						
AB		ALEMBIC PHARMS LTD	375MG	A079065	001	Jun 23, 2009 May CAHN
GEL;TOPICAL						
METRONIDAZOLE						
AB		TARO PHARM	1%	A204651	001	Mar 14, 2017 Feb NEWA
INJECTABLE;INJECTION						
METRONIDAZOLE						
		@ WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984 May CAHN
METRONIDAZOLE IN PLASTIC CONTAINER						
AP		MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017 Apr NEWA
TABLET;ORAL						
METRONIDAZOLE						
		@ CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983 Jun CAHN
		@	500MG	N018930	001	Aug 18, 1983 Jun CAHN
AB		ORIT LABS LLC	250MG	A208681	001	Jun 20, 2017 Jun NEWA
AB			500MG	A208681	002	Jun 20, 2017 Jun NEWA

TABLET, EXTENDED RELEASE;ORAL									
METRONIDAZOLE									
AB	ALEMBIC PHARMS LTD	750MG		A090222	001	May 05, 2010	May	CAHN	
<u>MICONAZOLE NITRATE</u>									
SUPPOSITORY;VAGINAL									
MICONAZOLE NITRATE									
AB	ACTAVIS PHARMA	200MG		A073508	001	Nov 19, 1993	May	CAHN	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE</u>									
OINTMENT;TOPICAL									
VUSION									
+!	MYLAN PHARMS INC	0.25%;81.35%;15%		N021026	001	Feb 16, 2006	Jan	CAHN	
<u>MIDAZOLAM HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
MIDAZOLAM HYDROCHLORIDE									
	FRESENIUS KABI USA	EQ 5MG BASE/ML		A208878	001	Mar 28, 2017	Mar	NEWA	
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML		A075243	001	Jun 20, 2000	Jan	CAHN	
AP		EQ 1MG BASE/ML		A075247	002	Jun 23, 2000	Jan	CAHN	
AP		EQ 1MG BASE/ML		A075324	001	Jun 20, 2000	Mar	CAHN	
AP		EQ 1MG BASE/ML		A075421	002	Jun 20, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075243	002	Jun 20, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075247	001	Jun 23, 2000	Jan	CAHN	
AP		EQ 5MG BASE/ML		A075324	002	Jun 20, 2000	Mar	CAHN	
AP		EQ 5MG BASE/ML		A075421	001	Jun 20, 2000	Jan	CAHN	
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE									
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML		A090315	001	Nov 29, 2010	May	CAHN	
AP		EQ 5MG BASE/ML		A090315	002	Nov 29, 2010	May	CAHN	
SYRUP;ORAL									
MIDAZOLAM HYDROCHLORIDE									
@	SUN PHARM INDS LTD	EQ 2MG BASE/ML		A076058	001	Mar 15, 2002	May	DISC	
<u>MIDODRINE HYDROCHLORIDE</u>									
TABLET;ORAL									
ORVATEN									
AB	UPSHER-SMITH LABS	2.5MG		A076725	001	Nov 03, 2004	Jun	CAHN	
AB		5MG		A076725	002	Nov 03, 2004	Jun	CAHN	
AB		10MG		A076725	003	Nov 03, 2004	Jun	CAHN	
PROAMATINE									
+ @	SHIRE LLC	2.5MG		N019815	001	Sep 06, 1996	Feb	CRLD	
+ @		5MG		N019815	002	Sep 06, 1996	Feb	CRLD	
+ @		10MG		N019815	003	Mar 20, 2002	Feb	CRLD	
<u>MIDOSTAURIN</u>									
CAPSULE;ORAL									
RYDAPT									
+!	NOVARTIS PHARMS CORP	25MG		N207997	001	Apr 28, 2017	Apr	NEWA	
<u>MILNACIPRAN HYDROCHLORIDE</u>									
TABLET;ORAL									
SAVELLA									
AB	+ ALLERGAN SALES LLC	12.5MG		N022256	001	Jan 14, 2009	Feb	CAHN	
AB	+	25MG		N022256	002	Jan 14, 2009	Feb	CAHN	
AB	+!	50MG		N022256	003	Jan 14, 2009	Feb	CAHN	
AB	+	100MG		N022256	004	Jan 14, 2009	Feb	CAHN	
<u>MILRINONE LACTATE</u>									
INJECTABLE;INJECTION									
MILRINONE LACTATE									
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML		A075530	001	May 28, 2002	Jan	CAHN	
AP		EQ 1MG BASE/ML		A075660	001	May 28, 2002	Jan	CAHN	
@		EQ 1MG BASE/ML		A075852	001	May 28, 2002	Mar	CAHN	
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER									
@	WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A075510	001	May 28, 2002	Mar	CAHN	
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A078113	001	May 21, 2008	Jan	CAHN	
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)		A078113	002	May 21, 2008	Jan	CAHN	
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER									
+ @	SANOFI AVENTIS US	EQ 10MG BASE/100ML		N020343	001	Aug 09, 1994	Jan	CRLD	

## INJECTABLE; INJECTION

## PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @		EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan	CRLD
+ @		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan	CRLD
+ @		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## MINOCYCLINE HYDROCHLORIDE

AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May	CAHN
	CAPSULE, EXTENDED RELEASE; ORAL						
	XIMINO						
	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CMFD

## TABLET, EXTENDED RELEASE; ORAL

## MINOCYCLINE HYDROCHLORIDE

@	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	NEWA
@		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	NEWA
@	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May	DISC
@		EQ 80MG BASE	A203443	002	Aug 22, 2014	May	DISC
@		EQ 90MG BASE	A090911	002	Jul 20, 2010	May	DISC
@		EQ 105MG BASE	A203443	003	Aug 22, 2014	May	DISC
@		EQ 135MG BASE	A090911	003	Jul 20, 2010	May	DISC
	MINOLIRA						
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May	NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May	NEWA

MIRABEGRON

## TABLET, EXTENDED RELEASE; ORAL

## MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
----	-------	------	---------	-----	--------------	-----	------

MIRTAZAPINE

## TABLET; ORAL

## MIRTAZAPINE

AB	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
AB	@	30MG	A076189	002	Jun 19, 2003	Jun	CAHN
		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
AB	@	45MG	A076189	003	Jun 19, 2003	Jun	CAHN
		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

## TABLET, ORALLY DISINTEGRATING; ORAL

## MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May	NEWA
AB		30MG	A205798	002	Jun 01, 2017	May	NEWA
AB		45MG	A205798	003	Jun 01, 2017	May	NEWA

MITOMYCIN

## INJECTABLE; INJECTION

## MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN

## MUTAMYCIN

+ @	BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
+ @		20MG/VIAL	N050450	002		Jan	CRLD

MODAFINIL

## TABLET; ORAL

## MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
AB		200MG	A202700	002	Oct 18, 2012	May	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A 077536	001	Nov 30, 2006	Apr	CAHN
AB		15MG	A 077536	002	Nov 30, 2006	Apr	CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A 090453 001 Mar 20, 2015 May CAHN

10MG

A 090453 002 Mar 20, 2015 May CAHN

!

25MG

A 090453 003 Mar 20, 2015 May CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

PERRIGO ISRAEL

0.1%

A 077180 001 Apr 06, 2005 Apr CAHN

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AMNEAL PHARMS

EQ 0.05MG BASE/SPRAY

A 207989 001 Apr 03, 2017 Mar NEWA

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

CSPC OUYI PHARM CO

EQ 10MG BASE

A 209012 001 Apr 24, 2017 Apr NEWA

PERRIGO R AND D

EQ 10MG BASE

A 206112 001 Apr 26, 2017 Apr NEWA

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

CSPC OUYI PHARM CO

EQ 4MG BASE

A 209011 001 Apr 18, 2017 Apr NEWA

AB

EQ 5MG BASE

A 209011 002 Apr 18, 2017 Apr NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

ACTAVIS ELIZABETH

30MG

A 079040 001 Jan 16, 2013 Apr CAHN

45MG

A 079040 002 Jan 16, 2013 Apr CAHN

60MG

A 079040 003 Jan 16, 2013 Apr CAHN

75MG

A 079040 004 Jan 16, 2013 Apr CAHN

90MG

A 079040 005 Jan 16, 2013 Apr CAHN

!

120MG

A 079040 006 Jan 16, 2013 Apr CAHN

AB UPSHER-SMITH LABS

10MG

A 202104 001 Jun 03, 2013 Jun CAHN

AB

20MG

A 202104 002 Jun 03, 2013 Jun CAHN

AB

30MG

A 202104 003 Jun 03, 2013 Jun CAHN

AB

50MG

A 202104 004 Jun 03, 2013 Jun CAHN

AB

60MG

A 202104 005 Jun 03, 2013 Jun CAHN

AB

80MG

A 202104 006 Jun 03, 2013 Jun CAHN

AB

100MG

A 202104 007 Jun 03, 2013 Jun CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

@ ICU MEDICAL INC

0.5MG/ML

N 019917 001 Oct 30, 1992 Jun CAHN

AP

+!

1MG/ML

N 019916 001 Oct 30, 1992 Apr CAHN

+!

5MG/ML

N 019916 002 Oct 27, 2006 Apr CAHN

@ MALLINCKRODT INC

1MG/ML

N 020631 001 Jul 03, 1996 Apr CAHN

@

2MG/ML

N 020631 002 Jul 03, 1996 Apr CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA HI-TECH PHARMACAL

100MG/5ML

A 208809 001 Jul 06, 2017 Jun NEWA

AA

RHODES PHARMS

10MG/5ML

A 206308 001 Jun 22, 2017 Jun NEWA

AA

AA + WEST-WARD PHARMS INT

100MG/5ML

A 206308 002 Jun 22, 2017 Jun NEWA

AA

+

10MG/5ML

N 022195 001 Mar 17, 2008 Jan CAHN

AA

+

20MG/5ML

N 022195 002 Mar 17, 2008 Jan CAHN

AA

+!

100MG/5ML

N 022195 003 Jan 25, 2010 Jan CAHN

TABLET;ORAL

MORPHINE SULFATE

+ WEST-WARD PHARMS INT

15MG

N 022207 001 Mar 17, 2008 Jan CAHN

+!

30MG

N 022207 002 Mar 17, 2008 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+ EGALET

15MG

N 208603 001 Jan 09, 2017 Jan NEWA

+

30MG

N 208603 002 Jan 09, 2017 Jan NEWA

+

60MG

N 208603 003 Jan 09, 2017 Jan NEWA

TABLET, EXTENDED RELEASE;ORAL  
MORPHABOND ER

+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan CTNA
+		30MG	N206544	002	Oct 02, 2015	Jan CTNA
+		60MG	N206544	003	Oct 02, 2015	Jan CTNA
+		100MG	N206544	004	Oct 02, 2015	Jan CTNA
MORPHINE SULFATE						
AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr CAHN
AB		30MG	A203849	002	Apr 06, 2015	Apr CAHN
AB		60MG	A203849	003	Apr 06, 2015	Apr CAHN
AB		100MG	A203849	004	Apr 06, 2015	Apr CAHN
AB		200MG	A203849	005	Apr 06, 2015	Apr CAHN
AB	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	May CAHN
AB		30MG	A091357	002	Jun 23, 2016	May CAHN
AB		60MG	A091357	003	Jun 23, 2016	May CAHN
AB		100MG	A091357	004	Jun 23, 2016	May CAHN
AB		200MG	A091357	005	Jun 23, 2016	May CAHN
AB	SUN PHARM INDS	15MG	A205634	001	Aug 25, 2016	Mar CAHN
AB		30MG	A205634	002	Aug 25, 2016	Mar CAHN
AB		60MG	A205634	003	Aug 25, 2016	Mar CAHN
AB		100MG	A205634	004	Aug 25, 2016	Mar CAHN
AB		200MG	A205634	005	Aug 25, 2016	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)  
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP	+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr CFTG
AP		MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
AP		MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1		APOTEX INC	EQ 0.5% BASE	A090080	001	Jun 30, 2017	Jun NEWA
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA

MUPIROCIN

OINTMENT;TOPICAL  
BACTROBAN

+	@	GLAXOSMITHKLINE	2%	N050591	001	Dec 31, 1987	May DISC
MUPIROCIN							
AB	!	PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003	May CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL  
MUPIROCIN

AB		GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	May CAHN
----	--	---------------------	------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb NEWA
AP		MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar NEWA

NABILONE

CAPSULE;ORAL  
CESAMET

+	!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar CAHN
---	---	---------------------	-----	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL  
NADOLOL

AB		AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
AB			40MG	A208832	002	Jun 02, 2017	May NEWA
AB			80MG	A208832	003	Jun 02, 2017	May NEWA
>A>	AB	ZYDUS PHARMS USA INC	20MG	A207761	001	Jul 28, 2017	Jul NEWA
>A>	AB		40MG	A207761	002	Jul 28, 2017	Jul NEWA
>A>	AB		80MG	A207761	003	Jul 28, 2017	Jul NEWA

NAFTIFINE HYDROCHLORIDECREAM; TOPICAL  
NAFTIFINE HYDROCHLORIDE

AB	TOLMAR	2%		A206960	001	Apr 10, 2017	Mar	NEWA
----	--------	----	--	---------	-----	--------------	-----	------

NALDEMEDINE TOSYLATETABLET; ORAL  
SYMPROIC

	+!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar	NEWA
--	----	--------------	---------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION  
NALOXONE

	@	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986	Jan	CAHN
	@		0.4MG/ML	A070496	001	Sep 24, 1986	Jan	CAHN

NALOXONE HYDROCHLORIDE

AP		AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb	NEWA
AP			0.4MG/ML	A208872	001	Mar 14, 2017	Feb	NEWA
>A>	AP	SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul	NEWA
>A>	AP		0.4MG/ML	A207634	001	Jul 26, 2017	Jul	NEWA

SPRAY, METERED; NASAL  
NARCAN

	+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan	NEWA
--	---	-------	-----------	---------	-----	--------------	-----	------

NALTREXONE HYDROCHLORIDETABLET; ORAL  
NALTREXONE HYDROCHLORIDE

>A>	AB	APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul	NEWA
-----	----	------------	------	---------	-----	--------------	-----	------

NANDROLONE DECANOATEINJECTABLE; INJECTION  
NANDROLONE DECANOATE

	!	LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun	CAHN
--	---	---------------------	----------	---------	-----	--------------	-----	------

NAPROXENTABLET; ORAL  
NAPROXEN

AB		AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB			375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB			500MG	A200429	003	Nov 08, 2011	Jan	CAHN
		@ CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May	CAHN
		@	375MG	A074410	002	Apr 28, 1995	May	CAHN
		@	500MG	A074410	003	Apr 28, 1995	May	CAHN
		@ HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May	DISC
		@	375MG	A076494	002	Jan 14, 2004	May	DISC
		@	500MG	A076494	003	Jan 14, 2004	May	DISC
		@ WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995	May	CAHN
		@	375MG	A074163	002	Feb 10, 1995	May	CAHN
		@	500MG	A074163	003	Feb 10, 1995	May	CAHN

NAPROXEN SODIUMTABLET; ORAL  
NAPROXEN SODIUM

AB		GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May	CAHN
AB			EQ 500MG BASE	A078314	002	Apr 27, 2007	May	CAHN

NATAMYCINSUSPENSION; OPHTHALMIC  
NATACYN

	+!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
--	----	----------------------	----	---------	-----	--	-----	------

NEBIVOLOL HYDROCHLORIDETABLET; ORAL  
NEBIVOLOL HYDROCHLORIDE

	@	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May	DISC
AB			EQ 2.5MG BASE	A203821	001	May 25, 2017	May	NEWA
	@		EQ 5MG BASE	A203821	002	May 25, 2017	May	DISC
AB			EQ 5MG BASE	A203821	002	May 25, 2017	May	NEWA
	@		EQ 10MG BASE	A203821	003	May 25, 2017	May	DISC
AB			EQ 10MG BASE	A203821	003	May 25, 2017	May	NEWA
	@		EQ 20MG BASE	A203821	004	May 25, 2017	May	DISC



	TABLET;ORAL							
	NEBIVOLOL HYDROCHLORIDE							
AB		EQ 20MG BASE	A203821	004	May 25, 2017		May	NEWA
	<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>							
	TABLET;ORAL							
	BYVALSON							
	+!	FOREST LABS LLC EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016		May	CRLD
	<u>NEDOCROMIL SODIUM</u>							
	AEROSOL, METERED;INHALATION							
	TILADE							
>D>	@	KING PHARMS 1.75MG/INH	N019660	001	Dec 30, 1992		Jul	CAHN
>A>	@	KING PHARMS LLC 1.75MG/INH	N019660	001	Dec 30, 1992		Jul	CAHN
	<u>NELFINAVIR MESYLATE</u>							
	POWDER;ORAL							
	VIRACEPT							
	@	AGOURON PHARMS EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997		Jan	CAHN
	TABLET;ORAL							
	VIRACEPT							
	+!	AGOURON PHARMS EQ 250MG BASE	N020779	001	Mar 14, 1997		Jan	CAHN
	+!	EQ 625MG BASE	N021503	001	Apr 30, 2003		Jan	CAHN
	<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
	SOLUTION;IRRIGATION							
	NEOSPORIN G.U. IRRIGANT							
AT	!	MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001			Apr	CAHN
	<u>NEOSTIGMINE METHYLSULFATE</u>							
	SOLUTION;INTRAVENOUS							
	NEOSTIGMINE METHYLSULFATE							
AP		PAR STERILE PRODUCTS 5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017		Apr	NEWA
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017		Apr	NEWA
>A>	<u>NERATINIB MALEATE</u>							
>A>	TABLET;ORAL							
>A>	NERLYNX							
>A>	+!	PUMA BIOTECH EQ 40MG BASE	N208051	001	Jul 17, 2017		Jul	NEWA
	<u>NEVIRAPINE</u>							
	SUSPENSION;ORAL							
	NEVIRAPINE							
>A>	AA	CIPLA LTD 50MG/5ML	A207684	001	Aug 03, 2017		Jul	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	NEVIRAPINE							
AB		AUROBINDO PHARMA LTD 400MG	A207698	001	Feb 28, 2017		Mar	CAHN
AB		AUROBINDO PHARMA USA 400MG	A207698	001	Feb 28, 2017		Feb	NEWA
>A>	AB	SCIEGEN PHARMS INC 100MG	A207467	001	Jul 31, 2017		Jul	NEWA
>A>	AB	400MG	A207467	002	Jul 31, 2017		Jul	NEWA
	<u>NIACIN</u>							
	TABLET;ORAL							
	NIACOR							
AA	!	UPSHER-SMITH LABS 500MG	A040378	001	May 03, 2000		Jun	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	NIACIN							
AB		LANNETT 500MG	A203899	001	Jun 16, 2017		Jun	NEWA
AB		1GM	A203899	002	Jun 16, 2017		Jun	NEWA
	<u>NICARDIPINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	NICARDIPINE HYDROCHLORIDE							
AP		WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009		Jan	CAHN
	INJECTABLE;INTRAVENOUS							
	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE							
		EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016		Feb	NEWA
		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016		Feb	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
AFEDITAB CR

AB1	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May	CAHN
	NIFEDIPINE						
	@ MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May	DISC
AB2		30MG	A090602	001	Sep 13, 2010	Mar	CAHN
	@	60MG	A090602	002	Sep 13, 2010	May	DISC
AB2		60MG	A090602	002	Sep 13, 2010	Mar	CAHN
	@	90MG	A090602	003	Sep 13, 2010	May	DISC
AB2		90MG	A090602	003	Sep 13, 2010	Mar	CAHN
AB2	OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun	CAHN

NIRAPARIB TOSYLATE

CAPSULE;ORAL  
ZEJULA

+	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar	NEWA
---	------------	---------------	---------	-----	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
SULAR

AB	+!	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May	CAHN
	+ @		10MG	N020356	001	Feb 02, 1995	May	CAHN
AB	+!		17MG	N020356	007	Jan 02, 2008	May	CAHN
	+ @		20MG	N020356	002	Feb 02, 1995	May	CAHN
	+ @		25.5MG	N020356	006	Jan 02, 2008	May	CAHN
	+ @		30MG	N020356	003	Feb 02, 1995	May	CAHN
AB	+!		34MG	N020356	005	Jan 02, 2008	May	CAHN
	+ @		40MG	N020356	004	Feb 02, 1995	May	CAHN

NITISINONE

>A> TABLET;ORAL  
>A> NITYR

>A>	+	CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017	Jul	NEWA
>A>	+		5MG	N209449	002	Jul 26, 2017	Jul	NEWA
>A>	+!		10MG	N209449	003	Jul 26, 2017	Jul	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	May	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
NITRO-DUR

AB1	+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun	CAHN
AB1	+!		0.2MG/HR	N020145	002	Apr 04, 1995	Jun	CAHN
	+!		0.3MG/HR	N020145	003	Apr 04, 1995	Jun	CAHN
AB1	+!		0.4MG/HR	N020145	004	Apr 04, 1995	Jun	CAHN
AB1	+!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CAHN
	+!		0.8MG/HR	N020145	006	Apr 04, 1995	Jun	CAHN

OINTMENT;TRANSDERMAL  
NITROGLYCERIN

!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Jan	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION  
NOREPINEPHRINE BITARTRATE

AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan	CAHN
----	----------------------	----------------	---------	-----	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL  
NORTRIPTYLINE HYDROCHLORIDE

	@ MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun	DISC
	@	EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun	DISC
	@	EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun	DISC
	@	EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun	DISC
AB	TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar	CAHN
AB		EQ 25MG BASE	A075520	003	May 08, 2000	Mar	CAHN
AB		EQ 50MG BASE	A075520	001	May 08, 2000	Mar	CAHN
AB		EQ 75MG BASE	A075520	002	May 08, 2000	Mar	CAHN

## SOLUTION;ORAL

## NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May	CAHN
----	---	-------------	------------------	---------	-----	--------------	-----	------

NYSTATIN

## PASTILLE;ORAL

## MYCOSTATIN

	@	DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987	Jun	CAHN
--	---	-------------------	---------------	---------	-----	--------------	-----	------

## POWDER;TOPICAL

## NYSTATIN

AT		LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May	NEWA
----	--	------	------------------	---------	-----	--------------	-----	------

AT		NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May	NEWA
----	--	---------------	------------------	---------	-----	--------------	-----	------

AT		UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun	CAHN
----	--	-------------------	------------------	---------	-----	--------------	-----	------

## SUSPENSION;ORAL

## NYSTATIN

>A>	@	ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN
-----	---	-------------------	------------------	---------	-----	--------------	-----	------

AA		FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN
----	--	--------------------	------------------	---------	-----	--------------	-----	------

AA		PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

>D>	@	ROXANE	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN
-----	---	--------	------------------	---------	-----	--------------	-----	------

AA		TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN
----	--	------------	------------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## NYSTATIN

	@	USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun	CAHN
--	---	------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM;TOPICAL

## MYCOLOG-II

	@	MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN
--	---	------------------	-----------------------	---------	-----	--------------	-----	------

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN
----	--	--------------------	-----------------------	---------	-----	--------------	-----	------

>A>	AT	PERRIGO UK FINCO	100,000 UNITS/GM;0.1%	A208479	001	Aug 14, 2017	Jul	NEWA
-----	----	------------------	-----------------------	---------	-----	--------------	-----	------

## OINTMENT;TOPICAL

## MYCOLOG-II

	@	MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN
--	---	------------------	-----------------------	---------	-----	--------------	-----	------

## NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A>	AT	AKORN	100,000 UNITS/GM;0.1%	A207217	001	Aug 04, 2017	Jul	NEWA
-----	----	-------	-----------------------	---------	-----	--------------	-----	------

AT		DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan	NEWA
----	--	--------------------	-----------------------	---------	-----	--------------	-----	------

AT		FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan	CAHN
----	--	--------------------	-----------------------	---------	-----	--------------	-----	------

OFLOXACIN

## SOLUTION/DROPS;OPHTHALMIC

## OFLOXACIN

AT		SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

## SOLUTION/DROPS;OTIC

## OFLOXACIN

AT		SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

OLANZAPINE

## TABLET;ORAL

## OLANZAPINE

AB		HIKMA PHARMS	2.5MG	A204866	001	Jun 16, 2017	Jun	NEWA
----	--	--------------	-------	---------	-----	--------------	-----	------

AB			5MG	A204866	002	Jun 16, 2017	Jun	NEWA
----	--	--	-----	---------	-----	--------------	-----	------

AB			7.5MG	A204866	003	Jun 16, 2017	Jun	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			10MG	A204866	004	Jun 16, 2017	Jun	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			15MG	A204866	005	Jun 16, 2017	Jun	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	A204866	006	Jun 16, 2017	Jun	NEWA
----	--	--	------	---------	-----	--------------	-----	------

	@	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun	DISC
--	---	------------------	-------	---------	-----	--------------	-----	------

AB			2.5MG	A076866	001	Apr 23, 2012	Mar	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

	@		5MG	A076866	002	Apr 23, 2012	Jun	DISC
--	---	--	-----	---------	-----	--------------	-----	------

AB			5MG	A076866	002	Apr 23, 2012	Mar	CAHN
----	--	--	-----	---------	-----	--------------	-----	------

	@		7.5MG	A076866	003	Apr 23, 2012	Jun	DISC
--	---	--	-------	---------	-----	--------------	-----	------

AB			7.5MG	A076866	003	Apr 23, 2012	Mar	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

	@		10MG	A076866	004	Apr 23, 2012	Jun	DISC
--	---	--	------	---------	-----	--------------	-----	------

AB			10MG	A076866	004	Apr 23, 2012	Mar	CAHN
----	--	--	------	---------	-----	--------------	-----	------

	@		15MG	A076866	005	Apr 23, 2012	Jun	DISC
--	---	--	------	---------	-----	--------------	-----	------

AB			15MG	A076866	005	Apr 23, 2012	Mar	CAHN
----	--	--	------	---------	-----	--------------	-----	------

	@		20MG	A076866	006	Apr 23, 2012	Jun	DISC
--	---	--	------	---------	-----	--------------	-----	------

AB			20MG	A076866	006	Apr 23, 2012	Mar	CAHN
----	--	--	------	---------	-----	--------------	-----	------

## TABLET, ORALLY DISINTEGRATING;ORAL

## OLANZAPINE

AB		AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May	NEWA
----	--	-------------------	-----	---------	-----	--------------	-----	------

AB			10MG	A204320	002	May 30, 2017	May	NEWA
----	--	--	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL  
OLANZAPINE

AB		15MG		A204320	003	May 30, 2017	May	NEWA
AB		20MG		A204320	004	May 30, 2017	May	NEWA

OLAPARIB

CAPSULE;ORAL  
LYNPARZA

+!	ASTRAZENECA PHARMS	50MG		N206162	001	Dec 19, 2014	Mar	CRLD
----	--------------------	------	--	---------	-----	--------------	-----	------

OLIVE OIL; SOYBEAN OIL

>D> INJECTABLE;INJECTION  
>D> CLINOLIPID 20%

>D>	+!	BAXTER HLTHCARE CORP	16% (160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul	DISC
>A>	+ @		16% (160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul	DISC

OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG		A207662	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A207662	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A207662	003	Apr 24, 2017	Apr	NEWA
AB	ALEMBIC PHARMS LTD	5MG		A203012	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A203012	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A203012	003	Apr 24, 2017	Apr	NEWA
AB	ALKEM LABS LTD	5MG		A206763	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A206763	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A206763	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	5MG		A204798	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A204798	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A204798	003	Apr 24, 2017	Apr	NEWA
AB	GLENMARK PHARMS LTD	5MG		A203281	001	May 25, 2017	May	NEWA
AB		20MG		A203281	002	May 25, 2017	May	NEWA
AB		40MG		A203281	003	May 25, 2017	May	NEWA
AB	JUBILANT GENERICS	5MG		A205482	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A205482	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A205482	003	Apr 24, 2017	Apr	NEWA
AB	LUPIN LTD	5MG		A206631	001	Apr 27, 2017	Apr	NEWA
AB		20MG		A206631	002	Apr 27, 2017	Apr	NEWA
AB		40MG		A206631	003	Apr 27, 2017	Apr	NEWA
AB	MACLEODS PHARMS LTD	5MG		A204814	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A204814	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A204814	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	5MG		A091079	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A091079	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A091079	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	5MG		A202375	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A202375	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A202375	003	Apr 24, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG		A205192	001	Apr 24, 2017	Apr	NEWA
AB		20MG		A205192	002	Apr 24, 2017	Apr	NEWA
AB		40MG		A205192	003	Apr 24, 2017	Apr	NEWA

OLOPATADINE HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## OLOPATADINE HYDROCHLORIDE

>A>	AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul	NEWA
	AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun	NEWA

## SPRAY, METERED;NASAL

## OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY		A202853	001	Jan 31, 2017	Jan	NEWA
----	----------------	---------------	--	---------	-----	--------------	-----	------

OLSALAZINE SODIUM

CAPSULE;ORAL  
DIPENTUM

+!	MYLAN SPECIALITY LP	250MG		N019715	001	Jul 31, 1990	Mar	CAHN
----	---------------------	-------	--	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATEPOWDER; SUBCUTANEOUS  
SYNRIBO

+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012 Apr CAHN

OMEGA-3-ACID ETHYL ESTERSCAPSULE; ORAL  
OMEGA-3-ACID ETHYL ESTERSAB AMNEAL PHARMS 1GM CONTAINS AT LEAST 900MG OF THE A204940 001 Nov 27, 2015 May CAHN  
ETHYL ESTERS OF OMEGA-3 FATTY  
ACIDSOMEPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL  
OMEPRAZOLEAB AUROBINDO PHARMA LTD 10MG A203270 001 Aug 19, 2015 Jan CAHN  
AB 20MG A203270 002 Aug 19, 2015 Jan CAHN  
AB 40MG A203270 003 Aug 19, 2015 Jan CAHN  
AB BRECKENRIDGE PHARM 10MG A203481 001 Jul 03, 2017 Jun NEWA  
AB 20MG A203481 002 Jul 03, 2017 Jun NEWA  
AB 40MG A203481 003 Jul 03, 2017 Jun NEWA  
AB TEVA PHARMS USA 20MG A204661 001 Jun 13, 2017 May NEWA  
AB 40MG A204661 002 Jun 13, 2017 May NEWAOMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE; ORAL  
PRILOSEC+ COVIS PHARMA BV EQ 2.5MG BASE/PACKET N022056 001 Mar 20, 2008 May CAHN  
+! EQ 10MG BASE/PACKET N022056 002 Mar 20, 2008 May CAHNOMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION; ORAL  
OMEPRAZOLE AND SODIUM BICARBONATEAB AJANTA PHARMA LTD 20MG/PACKET; 1.68GM/PACKET A205545 001 Jul 27, 2016 Jan CTEC  
AB 40MG/PACKET; 1.68GM/PACKET A205545 002 Jul 27, 2016 Jan CTEC  
AB PAR PHARM 20MG/PACKET; 1.68GM/PACKET A079182 001 Apr 19, 2013 Jan CMFD  
AB 40MG/PACKET; 1.68GM/PACKET A079182 002 Apr 19, 2013 Jan CMFD  
ZEGERID  
AB + SANTARUS INC 20MG/PACKET; 1.68GM/PACKET N021636 001 Jun 15, 2004 Jan CTEC  
AB +! 40MG/PACKET; 1.68GM/PACKET N021636 002 Dec 21, 2004 Jan CTECONDANSETRONTABLET, ORALLY DISINTEGRATING; ORAL  
ONDANSETRON@ CHARTWELL MOLECULES 4MG A076506 001 Dec 26, 2006 Mar CAHN  
@ 8MG A076506 002 Dec 26, 2006 Mar CAHN  
@ 16MG A077406 001 Dec 26, 2006 Mar CAHN  
@ 24MG A077406 002 Dec 26, 2006 Mar CAHNONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION  
ONDANSETRON HYDROCHLORIDE>A> AP MYLAN LABS LTD EQ 2MG BASE/ML A204906 001 Jul 31, 2017 Jul NEWA  
AP SANDOZ INC EQ 2MG BASE/ML A077430 001 Jun 27, 2007 Mar CAHN  
AP WEST-WARD PHARMS INT EQ 2MG BASE/ML A076967 001 Dec 26, 2006 Jan CAHN  
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE  
AP SANDOZ INC EQ 2MG BASE/ML A077551 001 Jun 27, 2007 Mar CAHN  
AP WEST-WARD PHARMS INT EQ 2MG BASE/ML A077011 001 Dec 26, 2006 Jan CAHN  
AP EQ 2MG BASE/ML A077541 001 Dec 26, 2006 Jan CAHN  
ZOFRAN  
+ @ NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 001 Jan 04, 1991 Mar CRLD  
ZOFRAN PRESERVATIVE FREE  
+ @ NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 003 Dec 10, 1993 Mar CRLDORPHENADRINE CITRATEINJECTABLE; INJECTION  
NORFLEX

@ TELIGENT 30MG/ML N013055 001 Apr CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May	NEWA
AB		EQ 45MG BASE	A209093	002	May 17, 2017	May	NEWA
AB		EQ 75MG BASE	A209093	003	May 17, 2017	May	NEWA
AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA
AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA

OSPEMIFENE

TABLET;ORAL

OSPHERA

+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Mar	CAHN
----	-----------	------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>A>	AP	WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul	NEWA

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

+	@	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD
---	---	-------------------	---------------------	---------	-----	--------------	-----	------

OXALIPLATIN

AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar	NEWA	
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar	NEWA	
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar	NEWA	
AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA	
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA	
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA	
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA	
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA	
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan	NEWA	
AP		50MG/VIAL	A207385	001	May 23, 2017	May	NEWA	
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan	NEWA	
AP		100MG/VIAL	A207385	002	May 23, 2017	May	NEWA	
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May	NEWA	
AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May	NEWA	
AP	!	QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan	CTEC

OXANDROLONE

TABLET;ORAL

OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Jun	CAHN
AB		10MG	A078033	001	Mar 22, 2007	Jun	CAHN

OXAPROZIN

TABLET;ORAL

OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May	CMS1
AB		15MG	A072253	003	Apr 14, 1988	May	CMS1
	@	WATSON LABS TEVA	A072952	001	Sep 28, 1990	May	CAHN

TABLET;ORAL

OXAZEPAM

@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jan	CAHN
---	----------------	------	---------	-----	--------------	-----	------

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May	CAHN
AB		300MG	A077802	002	Oct 09, 2007	May	CAHN
AB		600MG	A077802	003	Oct 09, 2007	May	CAHN
AB	JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Apr	CAHN
AB		300MG	A090239	002	Jan 25, 2010	Apr	CAHN

	TABLET;ORAL						
	OXCARBAZEPINE						
AB		600MG	A090239	003	Jan 25, 2010	Apr	CAHN
	<u>OXYBUTYNIN CHLORIDE</u>						
	SYRUP;ORAL						
	DITROPAN						
	+ @	ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan
	OXYBUTYNIN CHLORIDE						CRLD
AA		PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	May
	TABLET;ORAL						
	OXYBUTYNIN CHLORIDE						
AB		USL PHARMA	5MG	A074625	001	Jul 31, 1996	Jun
	TABLET, EXTENDED RELEASE;ORAL						
	OXYBUTYNIN CHLORIDE						
AB		ZYDUS PHARMS USA INC	5MG	A202332	001	Jun 26, 2017	Jun
AB			10MG	A202332	002	Jun 26, 2017	Jun
AB			15MG	A202332	003	Jun 26, 2017	Jun
	<u>OXYCODONE HYDROCHLORIDE</u>						
	SOLUTION;ORAL						
	OXYCODONE HYDROCHLORIDE						
>A>	AA	ABHAI LLC	5MG/5ML	A208593	001	Jul 21, 2017	Jul
>A>	AA		100MG/5ML	A208593	002	Jul 21, 2017	Jul
>A>	AA	HI-TECH PHARMACAL	5MG/5ML	A208817	001	Aug 10, 2017	Jul
>A>	AA		100MG/5ML	A208795	001	Aug 07, 2017	Jul
>A>	AA	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Jul
	TABLET;ORAL						
	OXYCODONE HYDROCHLORIDE						
>A>	AB	ASCENT PHARMS INC	15MG	A207418	001	Aug 07, 2017	Jul
>A>	AB		30MG	A207418	002	Aug 07, 2017	Jul
	AB	EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009	May
	AB		15MG	A090895	002	Aug 24, 2009	May
	AB		30MG	A090895	003	Aug 24, 2009	May
	AB	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	May
	AB		10MG	A204021	002	Jun 12, 2017	May
	AB		15MG	A204021	003	Jun 12, 2017	May
	AB		20MG	A204021	004	Jun 12, 2017	May
	AB		30MG	A204021	005	Jun 12, 2017	May
	ROXYBOND						
		INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Apr
			15MG	N209777	002	Apr 20, 2017	Apr
			30MG	N209777	003	Apr 20, 2017	Apr
	<u>OXYMETAZOLINE HYDROCHLORIDE</u>						
	CREAM;TOPICAL						
	RHOFADE						
	+!	ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan
	<u>OXYMETHOLONE</u>						
	TABLET;ORAL						
	ANADROL-50						
	+!	MYLAN SPECIALITY LP	50MG	N016848	001		Mar
	<u>OXYMORPHONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	OXYMORPHONE HYDROCHLORIDE						
AB		EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014	May
AB			10MG	A201187	002	Dec 15, 2014	May
	TABLET, EXTENDED RELEASE;ORAL						
	OXYMORPHONE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr
AB			7.5MG	A079046	001	Dec 13, 2010	Apr
AB			10MG	A079046	004	Jul 11, 2013	Apr
AB			15MG	A079046	002	Dec 13, 2010	Apr
AB			20MG	A079046	005	Jul 11, 2013	Apr
AB			30MG	A079046	006	Jul 11, 2013	Apr
AB			40MG	A079046	007	Jul 11, 2013	Apr
	@	PAR PHARM	5MG	A200792	001	Oct 24, 2014	May
	@		7.5MG	A200792	002	Oct 24, 2014	May
	@		10MG	A200792	003	Oct 24, 2014	May
	@		15MG	A200792	004	Oct 24, 2014	May

TABLET, EXTENDED RELEASE;ORAL  
 OXYMORPHONE HYDROCHLORIDE

@	20MG	A200792	005	Oct 24, 2014	May	DISC
@	30MG	A200792	006	Oct 24, 2014	May	DISC
@	40MG	A200792	007	Oct 24, 2014	May	DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
 TERRAMYCIN W/ POLYMYXIN B SULFATE

>A>	!	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001	Jul	CAHN
>D>	!	PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001	Jul	CAHN

PANTOPRAZOLE SODIUM

POWDER; IV (INFUSION)  
 PANTOPRAZOLE SODIUM

		EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jun	NEWA
--	--	----------------------	-------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL  
 PANTOPRAZOLE SODIUM

AB		SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar	CAHN
AB			EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar	CAHN

PARICALCITOL

CAPSULE;ORAL  
 PARICALCITOL

AB		AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May	CAHN
AB			2MCG	A204327	002	Jan 13, 2016	May	CAHN
AB			4MCG	A204327	003	Jan 13, 2016	May	CAHN

SOLUTION;INTRAVENOUS  
 PARICALCITOL

AP		AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb	NEWA
AP			0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb	NEWA
AP			0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb	NEWA
AP		SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr	CAHN
AP			0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr	CAHN
AP			0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr	CAHN

PAROXETINE HYDROCHLORIDE

TABLET;ORAL  
 PAROXETINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr	DISC
@		EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr	DISC
@		EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr	DISC
@		EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr	DISC
@	UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Jun	CAHN
@		EQ 20MG BASE	A075566	002	Mar 08, 2004	Jun	CAHN
@		EQ 30MG BASE	A075566	003	Mar 08, 2004	Jun	CAHN
@		EQ 40MG BASE	A075566	004	Mar 08, 2004	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL  
 PAROXETINE HYDROCHLORIDE

AB		LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan	NEWA
AB			EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan	NEWA
AB			EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan	NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL  
 BRISDELLE

AB	+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun	CFTG
AB		ACTAVIS LABS FL INC	EQ 7.5MG BASE	A207139	001	Jun 20, 2017	Jun	NEWA

PENCICLOVIR

CREAM;TOPICAL  
 DENAVIR

+	!	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan	CAHN
---	---	------------------	----	---------	-----	--------------	-----	------

PENICILLAMINE

TABLET;ORAL  
 DEPEN

+	!	MYLAN SPECIALITY LP	250MG	N019854	001		Mar	CAHN
---	---	---------------------	-------	---------	-----	--	-----	------



PENICILLIN G BENZATHINE

	INJECTABLE; INJECTION						
	BICILLIN L-A						
	+! KING PHARMS LLC	300,000 UNITS/ML		N050141	003		May CAHN
BC	+!	600,000 UNITS/ML		N050141	001		May CAHN
	PERMAPEN						
>A> BC	CASPER PHARMA LLC	600,000 UNITS/ML		A060014	001		Jul CAHN
>D> BC	PFIZER	600,000 UNITS/ML		A060014	001		Jul CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

	INJECTABLE; INJECTION						
	BICILLIN C-R						
	+! KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML		N050138	002		Apr CAHN
	+!	300,000 UNITS/ML; 300,000 UNITS/ML		N050138	001		Apr CAHN
	BICILLIN C-R 900/300						
	+! KING PHARMS LLC	900,000 UNITS/2ML; 300,000 UNITS/2ML		N050138	003		Apr CAHN

PENICILLIN G PROCAINE

	INJECTABLE; INJECTION						
	PENICILLIN G PROCAINE						
	! KING PHARMS LLC	300,000 UNITS/ML		A060101	002		Jun CAHN
	!	600,000 UNITS/ML		A060101	001		Jun CAHN

PENTOBARBITAL SODIUM

	INJECTABLE; INJECTION						
	PENTOBARBITAL SODIUM						
AP	SAGENT PHARMS	50MG/ML		A206404	001	May 23, 2016	Apr CAHN

PENTOXIFYLLINE

	TABLET, EXTENDED RELEASE; ORAL						
	PENTOXIL						
AB	UPSHER-SMITH LABS	400MG		A074962	001	Mar 31, 1999	Jun CAHN
	TRENTAL						
	+ @ US PHARM HOLDINGS	400MG		N018631	001	Aug 30, 1984	Jan CRLD

PERINDOPRIL ERBUMINE

	TABLET; ORAL						
	ACEON						
	+ @ SYMPLMED PHARMS LLC	2MG		N020184	001	Dec 30, 1993	May DISC
	+ @	4MG		N020184	002	Dec 30, 1993	May DISC
	+ @	8MG		N020184	003	Dec 30, 1993	May DISC
	PERINDOPRIL ERBUMINE						
AB	! AUROBINDO PHARMA	2MG		A079070	001	Nov 10, 2009	May CHRS
AB	!	4MG		A079070	002	Nov 10, 2009	May CHRS
AB	!	8MG		A079070	003	Nov 10, 2009	May CHRS

PERMETHRIN

	CREAM; TOPICAL						
	ELIMITE						
AB	+! MYLAN PHARMS INC	5%		N019855	001	Aug 25, 1989	Jan CAHN
	PERMETHRIN						
AB	ACTAVIS LABS	5%		A074806	001	Jan 23, 1998	May CAHN

PERPHENAZINE

	TABLET; ORAL						
	PERPHENAZINE						
AB	MYLAN PHARMS INC	2MG		A206691	001	Apr 14, 2017	Apr NEWA
AB		4MG		A206691	002	Apr 14, 2017	Apr NEWA
AB		8MG		A206691	003	Apr 14, 2017	Apr NEWA
AB		16MG		A206691	004	Apr 14, 2017	Apr NEWA

PHENDIMETRAZINE TARTRATE

	TABLET; ORAL						
	PHENDIMETRAZINE TARTRATE						
	@ USL PHARMA	35MG		A084399	001		Jun CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	PHENOXYBENZAMINE HYDROCHLORIDE						
AB	PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	PHENTERMINE HYDROCHLORIDE						
	@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997	May	CAHN
	@	30MG	A040448	001	Jan 22, 2003	May	CAHN
AA		37.5MG	A040228	001	Jun 19, 1997	May	CAHN
	@ UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982	Jun	CAHN
	@	30MG	A088430	001	Mar 27, 1984	Jun	CAHN
	TABLET;ORAL						
	PHENTERMINE HYDROCHLORIDE						
AA	ELITE LABS INC	37.5MG	A040190	001	May 30, 1997	May	CAHN
AA	KVK TECH INC	8MG	A203436	001	Mar 17, 2017	Mar	NEWA
AA	PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002	Feb	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	PHENTERMINE HYDROCHLORIDE						
	ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017	Jun	NEWA
		30MG	A204663	002	Jun 28, 2017	Jun	NEWA
		37.5MG	A204663	003	Jun 28, 2017	Jun	NEWA

PHENTOLAMINE MESYLATE

	INJECTABLE;INJECTION							
	PHENTOLAMINE MESYLATE							
>A>	AP	PRECISION DOSE INC	5MG/VIAL	A207686	001	Jul 14, 2017	Jul	NEWA
>D>	!	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Jul	CTEC
>A>	AP	!	5MG/VIAL	A040235	001	Mar 11, 1998	Jul	CTEC
		!	5MG/VIAL	A040235	001	Mar 11, 1998	May	CHRS
	REGITINE							
	+ @	NOVARTIS	5MG/VIAL	N008278	003		May	DISC

PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION;IV (INFUSION)							
	VAZCULEP							
	+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan	CAHN
	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan	CAHN
	+	!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan	CAHN

PHENYTOIN

	TABLET, CHEWABLE;ORAL							
	DILANTIN							
AB	!	PFIZER	50MG	A084427	001		Feb	CAHN
	PHENYTOIN							
AB		EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014	May	CAHN

PHENYTOIN SODIUM

	CAPSULE;ORAL							
	DILANTIN							
AB	!	PARKE-DAVIS	30MG EXTENDED	A084349	001		Feb	CAHN
AB	!		100MG EXTENDED	A084349	002		Feb	CAHN
	INJECTABLE;INJECTION							
	PHENYTOIN SODIUM							
AP		ACELLA PHARMS LLC	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN
	@	HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987	Mar	DISC

PHYTONADIONE

	INJECTABLE;INJECTION							
	AQUAMEPHYTON							
	+	@ TELIGENT	1MG/0.5ML	N012223	002		Apr	CAHN
	+	@	10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

	TABLET;ORAL						
	PILOCARPINE HYDROCHLORIDE						
AB	ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar	CAHN
AB		7.5MG	A076963	002	Feb 27, 2007	Mar	CAHN
AB	PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr	CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CMFD
AB		10MG	A073609	001	Mar 29, 1993	May	CMFD

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun	CAHN
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun	CAHN
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun	CAHN
AB	WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	May	CAHN
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	May	CAHN
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	May	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	NEWA
AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar	NEWA

PIRFENIDONE

TABLET; ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan	DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>A>	AB	HIKMA PHARMS	10MG	A209256	001	Aug 11, 2017	Jul	NEWA
>A>	AB		20MG	A209256	002	Aug 11, 2017	Jul	NEWA
>D>	AB	MYLAN	10MG	A074102	001	Jul 31, 1992	Jul	DISC
>A>		@	10MG	A074102	001	Jul 31, 1992	Jul	DISC
>D>	AB		20MG	A074102	002	Jul 31, 1992	Jul	DISC
>A>		@	20MG	A074102	002	Jul 31, 1992	Jul	DISC
	AB	PII	10MG	A206136	001	Jun 20, 2017	Jun	NEWA
	AB		20MG	A206136	002	Jun 20, 2017	Jun	NEWA
	AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr	NEWA
	AB		20MG	A208340	002	Apr 13, 2017	Apr	NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

>A>								
>A>	+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul	NEWA
>A>	+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul	NEWA
>A>	+		EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul	NEWA

PLECANATIDETABLET; ORAL  
TRULANCE

+! SYNERGY PHARMS 3MG N208745 001 Jan 19, 2017 Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A090409	001	Apr 02, 2010	Apr	DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A204559	001	Apr 13, 2015	Apr	CAHN
		.2GM/BOT					
		.2GM/BOT					
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Mar	CAHN
		.2GM/BOT					
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Feb	NEWA
		.2GM/BOT					
		.2GM/BOT					
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A076491	001	Feb 05, 2004	Mar	CAHN
		.2GM/BOT					

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar	CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar	CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar	CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar	CAHN
		ET					
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar	CAHN
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar	CAHN
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr	DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT SANDOZ INC 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun	CAHN
AB		10MEQ	A203106	002	Jul 10, 2015	Jun	CAHN
AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar	NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar	NEWA
	@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr	DISC
AP	+ ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
AP	+ ICU MEDICAL INC	745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN
AP	+! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
AP	+ ICU MEDICAL INC	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN
AP	+! ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN

INJECTABLE; INJECTION							
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER							
AP	+	ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN
TABLET, EXTENDED RELEASE; ORAL							
KLOR-CON							
AB2	+	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
AB2	+		10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
KLOR-CON M10							
AB1		UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
KLOR-CON M15							
		UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
KLOR-CON M20							
AB1	!	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN
<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>							
INJECTABLE; INJECTION							
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML; 450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML; 900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	298MG/100ML; 900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN
<u>POTASSIUM CITRATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
POTASSIUM CITRATE							
AB		IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Feb CAHN
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
TABLET; ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
	@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@		0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@		0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@		0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@		1MG	A091254	005	Nov 30, 2010	Jan DISC
	@		1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB		ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB			0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB			0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB			1MG	A078894	004	Oct 08, 2010	May CAHN
AB			1.5MG	A078894	005	Oct 08, 2010	May CAHN
TABLET, EXTENDED RELEASE; ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB			3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB		MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA
<u>PRASTERONE</u>							
INSERT; VAGINAL							
INTRAROSA							
	+	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May CAHN
<u>PRASUGREL HYDROCHLORIDE</u>							
TABLET; ORAL							
EFFIENT							
AB	+	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
AB	+		EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG
PRASUGREL							
AB		MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
AB			EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA
<u>PRAVASTATIN SODIUM</u>							
TABLET; ORAL							
PRAVASTATIN SODIUM							
AB		AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB			20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB			40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB			80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

IDT AUSTRALIA LTD

EQ 1MG BASE  
EQ 5MG BASE

A072577 002 May 16, 1989 May CMS1  
A072577 003 May 16, 1989 May CMS1

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA PHARM ASSOC  
AA VISTAPHARM

15MG/5ML  
15MG/5ML

A040399 001 Mar 05, 2003 May CAHN  
A040323 001 May 13, 1999 Mar CAHN

TABLET;ORAL

PREDNISOLONE

@ CHARTWELL RX

5MG

A084542 001 Apr CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ AMNEAL PHARMS

EQ 15MG BASE/5ML

A078345 001 Mar 10, 2009 May DISC

AA CHARTWELL RX

EQ 5MG BASE/5ML

A075988 001 May 25, 2004 Jun CAHN

@ PHARM ASSOC

EQ 5MG BASE/5ML

A076123 001 Dec 23, 2002 May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT ! BAUSCH AND LOMB  
AT SANDOZ INC

EQ 0.23% PHOSPHATE;10%  
EQ 0.23% PHOSPHATE;10%

A074449 001 Dec 29, 1995 Feb CAHN  
A073630 001 May 27, 1993 Feb CAHN

PREDNISONE

TABLET;ORAL

METICORTEN

+ @ SCHERING  
+ @

1MG  
5MG

N009766 002 Mar CMS1  
N009766 001 Mar CMS1

PREDNISONE

@ CHARTWELL RX

5MG

A083059 001 Apr CAHN

@ CONTRACT PHARMACAL

5MG

A080209 001 Mar DISC

AB MYLAN PHARMS INC

5MG

A080292 001 Jan CAHN

AB

10MG

A088832 001 Dec 04, 1985 Jan CAHN

AB

20MG

A083677 001 Jan CAHN

AB SUN PHARM INDS

10MG

A089246 001 Dec 04, 1985 May CAHN

@ UPSHER SMITH

5MG

A087471 001 Jun CAHN

@

20MG

A087470 001 Jun CAHN

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

AB ACTAVIS LABS FL INC

1MG

A204867 001 Apr 25, 2017 Apr NEWA

AB

2MG

A204867 002 Apr 25, 2017 Apr NEWA

AB

5MG

A204867 003 Apr 25, 2017 Apr NEWA

RAYOS

AB + HORIZON PHARMA

1MG

N202020 001 Jul 26, 2012 Apr CFTG

AB

2MG

N202020 002 Jul 26, 2012 Apr CFTG

AB

+

5MG

N202020 003 Jul 26, 2012 Apr CFTG

PROBENECID

TABLET;ORAL

BENEMID

+ @ MERCK

500MG

N007898 004 Jan CRLD

PROBENECID

AB WATSON LABS TEVA

500MG

A084442 004 Mar 29, 1983 May CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

@ WEST-WARD PHARMS INT

100MG/ML

A089029 001 Apr 17, 1986 Jan CAHN

@

500MG/ML

A089030 001 Apr 17, 1986 Mar CAHN

<u>PROCARBAZINE HYDROCHLORIDE</u>										
CAPSULE; ORAL										
MATULANE										
	+	LEADIANT BIOSCI INC	EQ 50MG BASE		N016785	001			Feb	CAHN
<u>PROCHLORPERAZINE EDISYLATE</u>										
INJECTABLE; INJECTION										
PROCHLORPERAZINE EDISYLATE										
	@	ATHENEX INC	EQ 5MG BASE/ML		A040540	001	May 28, 2004		Mar	CAHN
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML		A089523	001	May 03, 1988		Jan	CAHN
AP			EQ 5MG BASE/ML		A089903	001	Aug 29, 1989		Jan	CAHN
<u>PROCYCLIDINE HYDROCHLORIDE</u>										
TABLET; ORAL										
KEMADRIN										
	@	MONARCH PHARMS	2MG		N009818	005			Apr	CAHN
	@		5MG		N009818	003			Apr	CAHN
<u>PROGESTERONE</u>										
CAPSULE; ORAL										
PROGESTERONE										
AB		DR REDDYS LABS INC	100MG		A208801	001	Feb 28, 2017		Feb	NEWA
AB			200MG		A208801	002	Feb 28, 2017		Feb	NEWA
INJECTABLE; INJECTION										
PROGESTERONE										
AO	+	ACTAVIS LABS UT INC	50MG/ML		N017362	002			Feb	CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>										
SUPPOSITORY; RECTAL										
PHENERGAN										
	+	@ MYLAN PHARMS INC	50MG		N011689	001			Jan	CAHN
TABLET; ORAL										
PROMETHAZINE HYDROCHLORIDE										
AB		PRINSTON INC	12.5MG		A040622	001	Jul 18, 2006		Feb	CAHN
AB			25MG		A040622	002	Jul 18, 2006		Feb	CAHN
AB			50MG		A040622	003	Jul 18, 2006		Feb	CAHN
AB		STRIDES PHARMA	12.5MG		A209177	001	Jun 30, 2017		Jun	NEWA
AB			25MG		A209177	002	Jun 30, 2017		Jun	NEWA
AB			50MG		A209177	003	Jun 30, 2017		Jun	NEWA
<u>PROPIOMAZINE HYDROCHLORIDE</u>										
INJECTABLE; INJECTION										
LARGON										
	@	WEST-WARD PHARMS INT	20MG/ML		N012382	002			Jan	CAHN
<u>PROPRANOLOL HYDROCHLORIDE</u>										
CAPSULE, EXTENDED RELEASE; ORAL										
INNOPRAN XL										
BX		ANI PHARMS INC	80MG		N021438	001	Mar 12, 2003		Mar	CAHN
BX			120MG		N021438	002	Mar 12, 2003		Mar	CAHN
PROPRANOLOL HYDROCHLORIDE										
BX		UPSHER SMITH	60MG		A078311	001	Mar 06, 2009		Apr	CMFD
	@		60MG		A078311	001	Mar 06, 2009		Feb	DISC
BX			80MG		A078311	002	Mar 06, 2009		Apr	CMFD
	@		80MG		A078311	002	Mar 06, 2009		Feb	DISC
BX			120MG		A078311	003	Mar 06, 2009		Apr	CMFD
	@		120MG		A078311	003	Mar 06, 2009		Feb	DISC
BX			160MG		A078311	004	Mar 06, 2009		Apr	CMFD
	@		160MG		A078311	004	Mar 06, 2009		Feb	DISC
BX		UPSHER-SMITH LABS	60MG		A078311	001	Mar 06, 2009		Jun	CAHN
BX			80MG		A078311	002	Mar 06, 2009		Jun	CAHN
BX			120MG		A078311	003	Mar 06, 2009		Jun	CAHN
BX			160MG		A078311	004	Mar 06, 2009		Jun	CAHN
INJECTABLE; INJECTION										
PROPRANOLOL HYDROCHLORIDE										
AP		ATHENEX INC	1MG/ML		A075792	001	Aug 29, 2000		Mar	CAHN
	@	SANDOZ INC	1MG/ML		A076400	001	Feb 26, 2003		Mar	CAHN
TABLET; ORAL										
INDERAL										
	+	@ WYETH PHARMS INC	40MG		N016418	002			Jan	CRLD

## TABLET;ORAL

## PROPRANOLOL HYDROCHLORIDE

@	WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May	CAHN
@		20MG	A070549	001	Apr 11, 1986	May	CAHN
@		40MG	A070550	001	Apr 11, 1986	May	CAHN

PROPYLTHIOURACIL

## TABLET;ORAL

## PROPYLTHIOURACIL

@	CHARTWELL RX	50MG	A084543	001		Apr	CAHN
---	--------------	------	---------	-----	--	-----	------

PROTAMINE SULFATE

## INJECTABLE;INJECTION

## PROTAMINE SULFATE

@	WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN
@		10MG/ML	A089475	001	Nov 05, 1986	Jan	CAHN

PYRIDOSTIGMINE BROMIDE

## INJECTABLE;INJECTION

## REGONOL

AP	SANDOZ INC	5MG/ML	N017398	001		May	CAHN
----	------------	--------	---------	-----	--	-----	------

## TABLET;ORAL

## PYRIDOSTIGMINE BROMIDE

@	IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb	CAHN
---	----------------	------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE;ORAL

## PYRIDOSTIGMINE BROMIDE

>A>	AB	KINEDEXE UK	180MG	A205464	001	Aug 15, 2017	Jul	NEWA
-----	----	-------------	-------	---------	-----	--------------	-----	------

PYRIMETHAMINE

## TABLET;ORAL

## DARAPRIM

+	!	TURING PHARMS LLC	25MG	N008578	001		May	CAHN
---	---	-------------------	------	---------	-----	--	-----	------

QUETIAPINE FUMARATE

## TABLET;ORAL

## QUETIAPINE FUMARATE

@	MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	May	DISC
---	------------------	--------------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE;ORAL

## QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	EQ 150MG BASE	A090681	001	May 09, 2017	Apr	NEWA
AB			EQ 200MG BASE	A090681	002	May 09, 2017	Apr	NEWA
AB			EQ 300MG BASE	A090681	003	May 09, 2017	Apr	NEWA
AB			EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN
AB		INTELLIPHARMACEUTICS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	NEWA
AB			EQ 150MG BASE	A202939	002	May 09, 2017	Apr	NEWA
AB			EQ 200MG BASE	A202939	003	May 09, 2017	Apr	NEWA
AB			EQ 300MG BASE	A202939	004	May 09, 2017	Apr	NEWA
AB			EQ 400MG BASE	A202939	005	May 09, 2017	Apr	NEWA
AB		LUPIN LTD	EQ 50MG BASE	A204203	001	May 17, 2017	May	NEWA
AB			EQ 150MG BASE	A204203	002	May 17, 2017	May	NEWA
AB			EQ 200MG BASE	A204203	003	May 17, 2017	May	NEWA
AB			EQ 300MG BASE	A204203	004	May 17, 2017	May	NEWA
AB			EQ 400MG BASE	A204203	005	May 17, 2017	May	NEWA
AB		PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
AB			EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
AB			EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
AB			EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
AB			EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
AB		PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
AB			EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
AB			EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
AB			EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
AB			EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
		SEROQUEL XR						
AB	+	ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
AB	+	!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC





REPAGLINIDE

TABLET; ORAL

PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb	CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb	CAHN
AB	+	!	2MG	N020741	003	Dec 22, 1997	Feb	CAHN
REPAGLINIDE								
AB		BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Jun	CAHN
AB			1MG	A091517	002	Apr 24, 2015	Jun	CAHN
AB			2MG	A091517	003	Apr 24, 2015	Jun	CAHN

RESERPINE

TABLET; ORAL

RESERPINE

	+	@ SANDOZ	0.1MG	N009838	001		Apr	DISC
	+	@	0.25MG	N009838	002		Apr	DISC

RIBAVIRIN

CAPSULE; ORAL

RIBASPHERE

AB		KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan	CAHN
TABLET; ORAL								
RIBAVIRIN								
AB		KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan	CAHN
AB			400MG	A077456	002	Dec 05, 2005	Jan	CAHN
AB		!	600MG	A077456	003	Dec 05, 2005	Jan	CAHN

RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

	+	!	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar	NEWA
--	---	---	----------------------	---------------	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	CAHN
AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan	CAHN

RILUZOLE

TABLET; ORAL

RILUZOLE

AB		GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May	CAHN
----	--	---------------------	------	---------	-----	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

	@	IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb	CAHN
--	---	----------------	-------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

	@	JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr	CAHN
	@		0.5MG	A078828	002	Mar 23, 2009	Apr	CAHN
	@		1MG	A078828	003	Mar 23, 2009	Apr	CAHN
	@		2MG	A078828	004	Mar 23, 2009	Apr	CAHN
	@		3MG	A078828	005	Mar 23, 2009	Apr	CAHN
	@		4MG	A078828	006	Mar 23, 2009	Apr	CAHN
AB		PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB			0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB			1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB			2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB			3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB			4MG	A078707	006	Dec 29, 2008	Feb	CAHN

RITONAVIR

POWDER; ORAL

NORVIR

	+	!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017	Jun	NEWA
--	---	---	------------	--------------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan	NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan	NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan	NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan	NEWA
AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar	CAHN
AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar	CAHN
AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar	CAHN
AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar	CAHN
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb	NEWA
AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May	CAHN
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May	CAHN
AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan	NEWA
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan	NEWA
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb	NEWA
AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar	NEWA
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
AP	!	100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb	NEWA
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr	CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr	CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr	CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr	CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr	CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr	CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr	CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb	NEWA
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb	NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb	NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb	NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb	NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb	NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb	NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May	CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May	CAHN
	@	EQ 1MG BASE	A078230	003	May 20, 2008	May	CAHN
	@	EQ 2MG BASE	A078230	004	May 20, 2008	May	CAHN
	@	EQ 3MG BASE	A078230	005	May 20, 2008	May	CAHN
	@	EQ 4MG BASE	A078230	006	May 20, 2008	May	CAHN
	@	EQ 5MG BASE	A078230	007	May 20, 2008	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May	CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May	CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May	CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May	CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May	CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun	CDFR
----	-----------	---------------------	---------	-----	--------------	-----	------

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar	CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar	CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar	CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar	CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar	NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar	NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar	NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar	NEWA
>A>	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Jul	NEWA
>A>		10MG	A205587	002	Jul 31, 2017	Jul	NEWA
>A>		20MG	A205587	003	Jul 31, 2017	Jul	NEWA
>A>		40MG	A205587	004	Jul 31, 2017	Jul	NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr	CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr	CAHN
AB		20MG	A201619	003	Oct 31, 2016	Apr	CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr	CAHN

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May	NEWA
---	---------------------	---------------	---------	-----	--------------	-----	------

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar	NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar	NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr	CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr	CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May	CAHN
	@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan	CAHN
	@	5MG	A074641	001	Aug 02, 1996	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN
---	-------------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun	CAHN
@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun	CAHN
@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun	CAHN
@	ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
@	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
@		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
@		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
@	WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May	CAHN
@		EQ 50MG BASE	A077663	002	Feb 06, 2007	May	CAHN
@		EQ 100MG BASE	A077663	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May	CFTG
AB	+	!	2.4GM/PACKET	N022318	002	Feb 18, 2009	May	CFTG
AB		SEVELAMER CARBONATE						
AB		AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May	NEWA

	FOR SUSPENSION;ORAL						
	SEVELAMER CARBONATE						
AB		2.4GM/PACKET	A207624	002	Jun 13, 2017	May	NEWA
	TABLET;ORAL						
	RENVELA						
>D>	+	GENZYME	800MG	N022127	001	Oct 19, 2007	Jul CFTG
>A>	AB	+	800MG	N022127	001	Oct 19, 2007	Jul CFTG
>A>	SEVELAMER CARBONATE						
>A>	AB	AUROBINDO PHARMA LTD	800MG	A207179	001	Jul 17, 2017	Jul NEWA
	<u>SILDENAFIL CITRATE</u>						
	TABLET;ORAL						
	VIAGRA						
	+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	May CAHN
	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May CAHN
	+		EQ 100MG BASE	N020895	003	Mar 27, 1998	May CAHN
	<u>SILODOSIN</u>						
	CAPSULE;ORAL						
	RAPAFLO						
AB	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar CFTG
AB	+		8MG	N022206	002	Oct 08, 2008	Mar CFTG
	SILODOSIN						
AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar NEWA
AB			8MG	A204726	002	Mar 31, 2017	Mar NEWA
	<u>SIMVASTATIN</u>						
	SUSPENSION;ORAL						
	SIMVASTATIN						
	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan CAHN
	+		40MG/5ML	N206679	002	Apr 21, 2016	Jan CAHN
	TABLET;ORAL						
	SIMVASTATIN						
	@	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May DISC
	@		10MG	A090868	002	Jun 08, 2010	May DISC
	@		20MG	A090868	003	Jun 08, 2010	May DISC
	@		40MG	A090868	004	Jun 08, 2010	May DISC
	@		80MG	A090868	005	Jun 08, 2010	May DISC
AB		WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May CAHN
AB			10MG	A076685	002	Dec 20, 2006	May CAHN
AB			20MG	A076685	003	Dec 20, 2006	May CAHN
AB			40MG	A076685	004	Dec 20, 2006	May CAHN
AB			80MG	A076685	005	Dec 20, 2006	May CAHN
	<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>						
	SOLUTION;IV (INFUSION)						
	SODIUM PHENYLACETATE AND SODIUM BENZOATE						
>A>	AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul CAHN
>D>	AP	AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul CAHN
	<u>SODIUM BICARBONATE</u>						
	INJECTABLE;INJECTION						
	SODIUM BICARBONATE						
AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb NEWA
	<u>SODIUM CHLORIDE</u>						
	INJECTABLE;INJECTION						
	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb CAHN
		SODIUM CHLORIDE 0.9%					
>A>	AP	SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jul NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN
		SODIUM CHLORIDE 0.9%					
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May NEWA

INJECTABLE; INJECTION							
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr CAHN
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER							
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER							
>D>		@ B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988	Jul CMFD
>A>	AP		3GM/100ML	N019635	003	Mar 09, 1988	Jul CMFD
>D>	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Jul CTEC
>A>	AP	+	3GM/100ML	N019022	001	Nov 01, 1983	Jul CTEC
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER							
>D>		@ B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988	Jul CMFD
>A>	AP		5GM/100ML	N019635	004	Mar 09, 1988	Jul CMFD
>D>	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983	Jul CTEC
>A>	AP	+	5GM/100ML	N019022	002	Nov 01, 1983	Jul CTEC
SODIUM CHLORIDE IN PLASTIC CONTAINER							
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar CRLD
SOLUTION; IRRIGATION							
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AT		ICU MEDICAL INC	900MG/100ML	N017514	001		Feb CAHN
AT			900MG/100ML	N018314	001		Feb CAHN
<u>SODIUM NITROPRUSSIDE</u>							
INJECTABLE; INJECTION							
SODIUM NITROPRUSSIDE							
AP		AKORN	25MG/ML	A208635	001	May 04, 2017	Apr NEWA
AP		NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May NEWA
SOLUTION; IV (INFUSION)							
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%							
	+	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar NEWA
<u>SODIUM OXYBATE</u>							
SOLUTION; ORAL							
SODIUM OXYBATE							
AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan NEWA
XYREM							
AA	+	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan CFTG
<u>SODIUM PHENYLBUTYRATE</u>							
TABLET; ORAL							
SODIUM PHENYLBUTYRATE							
AB		ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr CAHN
<u>SODIUM POLYSTYRENE SULFONATE</u>							
POWDER; ORAL, RECTAL							
SODIUM POLYSTYRENE SULFONATE							
AA		CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr CAHN
AA		ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar CAHN
SUSPENSION; ORAL, RECTAL							
SPS							
AA	!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr CAHN
>A>	<u>SOFOBUVIR; VELPATASVIR; VOXILAPREVIR</u>						
>A>	TABLET; ORAL						
>A>	VOSEVI						
>A>	+	GILEAD SCIENCES INC	400MG; 100MG; 100MG	N209195	001	Jul 18, 2017	Jul NEWA
<u>SOMATROPIN RECOMBINANT</u>							
INJECTABLE; INJECTION							
VALTROPIN							
BX		LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
<u>SONIDEGIB PHOSPHATE</u>							
CAPSULE; ORAL							
ODOMZO							
	+	SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
	+	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB1	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May	CAHN
AB1	+		120MG	N019865	005	Apr 20, 1994	May	CAHN
AB1	+	!	160MG	N019865	002	Oct 30, 1992	May	CAHN
AB1	+		240MG	N019865	003	Oct 30, 1992	May	CAHN
		@	320MG	N019865	004	Oct 30, 1992	May	CAHN

BETAPACE AF

		@	COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May	CAHN
		@		60MG	N021151	007	Apr 02, 2003	May	CAHN
AB2	+		80MG	N021151	001	Feb 22, 2000	May	CAHN	
		@	100MG	N021151	005	Mar 14, 2003	May	CAHN	
AB2	+		120MG	N021151	002	Feb 22, 2000	May	CAHN	
AB2	+	!	160MG	N021151	003	Feb 22, 2000	May	CAHN	

SORINE

AB1		UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001	Jun	CAHN
AB1			120MG	A075500	004	Apr 27, 2001	Jun	CAHN
AB1			160MG	A075500	002	Apr 27, 2001	Jun	CAHN
AB1			240MG	A075500	003	Apr 27, 2001	Jun	CAHN

SOTALOL HYDROCHLORIDE

		@	MYLAN	80MG	A075237	001	May 01, 2000	Jun	DISC
		@		80MG	A075725	001	Dec 19, 2000	Jun	DISC
		@		120MG	A075237	002	May 01, 2000	Jun	DISC
		@		120MG	A075725	002	Dec 19, 2000	Jun	DISC
		@		160MG	A075237	003	May 01, 2000	Jun	DISC
		@		160MG	A075725	003	Dec 19, 2000	Jun	DISC
		@		240MG	A075237	004	May 01, 2000	Jun	DISC
		@		240MG	A075725	004	Dec 19, 2000	Jun	DISC
		@	TEVA	80MG	A076883	001	Jul 26, 2004	Apr	DISC
		@		120MG	A076883	002	Jul 26, 2004	Apr	DISC
		@		160MG	A076883	003	Jul 26, 2004	Apr	DISC
AB1			UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Jun	CAHN
AB1				120MG	A075366	002	May 01, 2000	Jun	CAHN
AB1				160MG	A075366	003	May 01, 2000	Jun	CAHN
AB1				240MG	A075366	004	May 01, 2000	Jun	CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB		ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar	CAHN	
AB			50MG	A203512	002	Sep 19, 2016	Mar	CAHN	
AB			100MG	A203512	003	Sep 19, 2016	Mar	CAHN	
AB		AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010	May	CAHN	
AB			25MG	A091426	001	Jul 02, 2010	May	CMS1	
AB			50MG	A091426	002	Jul 02, 2010	May	CAHN	
AB			50MG	A091426	002	Jul 02, 2010	May	CMS1	
AB			100MG	A091426	003	Jul 02, 2010	May	CAHN	
AB			100MG	A091426	003	Jul 02, 2010	May	CMS1	
		@	UPSHER SMITH	25MG	A087554	001		Jun	CAHN

STAVUDINE

CAPSULE; ORAL

STAVUDINE

		@	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May	DISC
AB				30MG	A078775	001	Jan 05, 2009	Mar	CAHN
		@		40MG	A078775	002	Jan 05, 2009	May	DISC
AB				40MG	A078775	002	Jan 05, 2009	Mar	CAHN

FOR SOLUTION; ORAL

STAVUDINE

>D>	AA	AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008	Jul	DISC	
>A>		@		1MG/ML	A077774	001	Dec 29, 2008	Jul	DISC

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP		WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan	CAHN	
AP	+	!	ICU MEDICAL INC	100%	N018233	001		Feb	CAHN
AP	+	!		100%	N019869	001	Dec 26, 1989	Apr	CAHN
AP			TARO	100%	A077393	001	Aug 11, 2006	Apr	CAHN

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	100%		N017513	001			Feb	CAHN
AT		100%		N018313	001			Feb	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP	+	SANDOZ INC	20MG/ML		N008453	002			May	CAHN
		@	50MG/ML		N008453	003			May	CAHN
		@	500MG/VIAL		N008453	001			May	CAHN
		@	1GM/VIAL		N008453	004			May	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AT		SANDOZ INC	10%		A089560	001	Oct 18, 1988		Feb	CAHN
----	--	------------	-----	--	---------	-----	--------------	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SEPTRA

AB		MONARCH PHARMS	400MG; 80MG		N017376	001			May	CAHN
		SEPTRA DS								
AB		MONARCH PHARMS	800MG; 160MG		N017376	002			May	CAHN
		SULFAMETHOXAZOLE AND TRIMETHOPRIM								
AB		CHARTWELL MOLECULES	400MG; 80MG		A078060	002	Jan 25, 2007		Mar	CAHN
AB			800MG; 160MG		A078060	001	Jan 25, 2007		Mar	CAHN
AB		CHARTWELL PHARMS LLC	400MG; 80MG		A078060	002	Jan 25, 2007		Jan	CAHN
AB			800MG; 160MG		A078060	001	Jan 25, 2007		Jan	CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	!	MYLAN SPECIALITY LP	15%		N006530	003	Jan 27, 1987		Mar	CAHN
		SUPPOSITORY; VAGINAL								
		AVC								
		@ MYLAN SPECIALITY LP	1.05GM		N006530	004	Jan 27, 1987		Mar	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

		@ SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		A078067	002	Feb 06, 2009		Mar	CAHN
		@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A078067	001	Feb 06, 2009		Mar	CAHN
AP		WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A079123	001	Feb 06, 2009		Jan	CAHN
		SYSTEM; IONTOPHORESIS								
		ZECUITY								
+	@	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR		N202278	001	Jan 17, 2013		Jan	DISC

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

+		CPPI CV	EQ 12.5MG BASE		N021938	001	Jan 26, 2006		Mar	CTEC
+			EQ 25MG BASE		N021938	002	Jan 26, 2006		Mar	CTEC
+			EQ 37.5MG BASE		N021938	004	Mar 31, 2009		Mar	CTEC
+	!		EQ 50MG BASE		N021938	003	Jan 26, 2006		Mar	CTEC

TALC

POWDER; INTRAPLEURAL

STERITALC

+		NOVATECH SA	2GM/VIAL		N205555	001	May 01, 2017		Apr	NEWA
+			3GM/VIAL		N205555	002	May 01, 2017		Apr	NEWA
+	!		4GM/VIAL		N205555	003	May 01, 2017		Apr	NEWA



TAMSULOSIN HYDROCHLORIDE

	CAPSULE; ORAL							
	TAMSULOSIN HYDROCHLORIDE							
AB	MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan	NEWA	
	TAMSULOSIN HYDROCHLORIDE							
>A> AB	ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul	NEWA	

TAZAROTENE

	AEROSOL, FOAM; TOPICAL							
	FABIOR							
	+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan	CAHN
	CREAM; TOPICAL							
	AVAGE							
AB	+!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar	CFTG
	TAZAROTENE							
AB		TARO	0.1%	A208258	001	Apr 03, 2017	Mar	NEWA
	TAZORAC							
AB	+!	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar	CFTG

TECHNETIUM TC-99M MEDRONATE KIT

	INJECTABLE; INJECTION							
	MDP-BRACCO							
AP	CARDINAL HEALTH 414	N/A	N018107	001		Apr	CAHN	

TECHNETIUM TC-99M SESTAMIBI KIT

	INJECTABLE; INJECTION							
	TECHNETIUM TC 99M SESTAMIBI							
AP	JUBILANT DRAXIMAGE	N/A	A078806	001	Apr 29, 2009	Jun	CAHN	

TECHNETIUM TC-99M TETROFOSMIN KIT

	INJECTABLE; INJECTION							
	MYOVIEV							
>D>	+!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Jul	DISC
>A>	+ @		N/A	N020372	001	Feb 09, 1996	Jul	DISC
>D>	MYOVIEV 30ML							
>D>	+!	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005	Jul	DISC
>A>	+ @		N/A	N020372	002	Jul 07, 2005	Jul	DISC

TECHNETIUM TC-99M TILMANOCEPT

	INJECTABLE; INJECTION							
	LYMPHOSEEK KIT							
	+!	CARDINAL HLTH 414	N/A	N202207	001	Mar 13, 2013	Mar	CAHN

TELAVANCIN HYDROCHLORIDE

	POWDER; IV (INFUSION)							
	VIBATIV							
	+	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May	CAHN
	+!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May	CAHN

TELMISARTAN

	TABLET; ORAL							
	TELMISARTAN							
>A> AB	CADILA PHARMS LTD	20MG	A208605	001	Jul 25, 2017	Jul	NEWA	
>A> AB		40MG	A208605	002	Jul 25, 2017	Jul	NEWA	
>A> AB		80MG	A208605	003	Jul 25, 2017	Jul	NEWA	
AB	GLENMARK PHARMS LTD	20MG	A090032	001	Jul 07, 2014	May	CAHN	
AB		40MG	A090032	002	Jul 07, 2014	May	CAHN	
AB		80MG	A090032	003	Jul 07, 2014	May	CAHN	
AB	PRINSTON INC	20MG	A207882	001	May 03, 2017	Apr	NEWA	
AB		40MG	A207882	002	May 03, 2017	Apr	NEWA	
AB		80MG	A207882	003	May 03, 2017	Apr	NEWA	

TELOTTRISTAT ETIPRATE

	TABLET; ORAL							
	XERMELO							
	+!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Feb	NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	ACTAVIS ELIZABETH	15MG	A 071620	002	Aug 07, 1987	May CMS1
AB	PRINSTON INC	7.5MG	A 201781	001	Jun 04, 2015	Feb CAHN
AB		15MG	A 201781	002	Jun 04, 2015	Feb CAHN
AB		22.5MG	A 201781	003	Jun 04, 2015	Feb CAHN
AB		30MG	A 201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A 201528	001	Feb 27, 2017	Feb NEWA	
AB		20MG	A 201528	002	Feb 27, 2017	Feb NEWA	
AB		100MG	A 201528	003	Feb 27, 2017	Feb NEWA	
AB		140MG	A 201528	004	Feb 27, 2017	Feb NEWA	
AB		180MG	A 201528	005	Feb 27, 2017	Feb NEWA	
AB		250MG	A 201528	006	Feb 27, 2017	Feb NEWA	
AB	DEVA HOLDING AS	5MG	A 207658	001	Apr 26, 2017	Apr NEWA	
AB		20MG	A 207658	002	Apr 26, 2017	Apr NEWA	
AB		100MG	A 207658	003	Apr 26, 2017	Apr NEWA	
AB		140MG	A 207658	004	Apr 26, 2017	Apr NEWA	
AB		180MG	A 207658	005	Apr 26, 2017	Apr NEWA	
AB		250MG	A 207658	006	Apr 26, 2017	Apr NEWA	
AB	WATSON LABS TEVA	5MG	A 203959	001	Apr 18, 2017	Apr NEWA	
AB		20MG	A 203959	002	Apr 18, 2017	Apr NEWA	
AB		100MG	A 203959	003	Apr 18, 2017	Apr NEWA	
AB		140MG	A 203959	004	Apr 18, 2017	Apr NEWA	
AB		250MG	A 203959	005	Apr 18, 2017	Apr NEWA	
>A>	AB	ZYDUS PHARMS USA INC	5MG	A 206750	001	Jul 31, 2017	Jul NEWA
>A>	AB		20MG	A 206750	002	Jul 31, 2017	Jul NEWA
>A>	AB		100MG	A 206750	003	Jul 31, 2017	Jul NEWA
>A>	AB		140MG	A 206750	004	Jul 31, 2017	Jul NEWA
>A>	AB		180MG	A 206750	005	Jul 31, 2017	Jul NEWA
>A>	AB		250MG	A 206750	006	Jul 31, 2017	Jul NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Mar CAHN
AB		EQ 2MG BASE	A 075140	003	Feb 11, 2000	Mar CAHN
AB		EQ 5MG BASE	A 075140	001	Feb 11, 2000	Mar CAHN
AB		EQ 10MG BASE	A 075140	004	Feb 11, 2000	Mar CAHN

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP	! ATHENEX INC	1MG/ML	A 076770	001	Apr 23, 2004	Mar CAHN
	TABLET;ORAL					
	BRETHINE					
	+ @ ANI PHARMS INC	2.5MG	N 017849	001		Feb CAHN
	+ @	5MG	N 017849	002		Feb CAHN
	TERBUTALINE SULFATE					
	! LANNETT	5MG	A 077152	002	Mar 25, 2005	Jan CHRS

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

AB2	+ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N 022309	002	Sep 07, 2012	Jun CFTG
AB2	+!	1.62% (40.5MG/2.5GM PACKET)	N 022309	003	Sep 07, 2012	Jun CFTG
	TESTIM					
AB2	+! AUXILIUM PHARMS LLC	50MG/5GM PACKET	N 021454	001	Oct 31, 2002	May CAHN
	TESTOSTERONE					
AB2	PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A 205781	001	Jul 12, 2017	Jun NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A 205781	002	Jul 12, 2017	Jun NEWA
	VOGELXO					
AB2	UPSHER-SMITH LABS	50MG/5GM PACKET	N 204399	002	Jun 04, 2014	Jun CAHN
	GEL, METERED;TRANSDERMAL					
	TESTOSTERONE					
AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A 204571	001	Aug 05, 2015	Mar CAHN

	GEL, METERED;TRANSDERMAL						
	VOGELXO						
BX	UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	CAHN
	SOLUTION, METERED;TRANSDERMAL						
	AXIRON						
AT	+! ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb	CFTG
	TESTOSTERONE						
>A>	ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION	A205328	001	Aug 07, 2017	Jul	NEWA
AT	PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb	NEWA
	TABLET, EXTENDED RELEASE;BUCCAL						
	STRIANT						
	+! AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May	CAHN
	<u>TESTOSTERONE CYPIONATE</u>						
	INJECTABLE;INJECTION						
	TESTOSTERONE CYPIONATE						
AO	LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun	NEWA
AO	SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar	CAHN
AO		200MG/ML	A040615	002	Aug 10, 2006	Mar	CAHN
AO	WATSON PHARMS INC	200MG/ML	A086030	001		Feb	CAHN
AO	WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan	CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jan	CAHN
	<u>TESTOSTERONE ENANTHATE</u>						
	INJECTABLE;INJECTION						
	TESTOSTERONE ENANTHATE						
AO	WATSON PHARMS INC	200MG/ML	A085598	001		Feb	CAHN
	<u>TETRABENAZINE</u>						
	TABLET;ORAL						
	TETRABENAZINE						
AB	ACTAVIS LABS FL INC	25MG	A206686	001	Jul 07, 2017	Jun	NEWA
AB	APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan	NEWA
AB		25MG	A207682	002	Jan 31, 2017	Jan	NEWA
	<u>TETRACYCLINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	ACHROMYCIN V						
AB	+ HERITAGE PHARMA	250MG	N050278	003		Jan	CAHN
AB	+!	500MG	N050278	001		Jan	CAHN
	TETRACYCLINE HYDROCHLORIDE						
AB	CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr	CAHN
AB		500MG	A062752	002	Aug 12, 1988	Apr	CAHN
>D>	IMPAX LABS	100MG	A060469	002		Jul	DISC
>A>	@	100MG	A060469	002		Jul	DISC
>D>	AB	250MG	A060469	001		Jul	DISC
>A>	@	250MG	A060469	001		Jul	DISC
>D>	AB	500MG	A060469	003		Jul	DISC
>A>	@	500MG	A060469	003		Jul	DISC
	<u>THEOPHYLLINE</u>						
	ELIXIR;ORAL						
	THEOPHYLLINE						
	@ CHARTWELL RX	80MG/15ML	A085952	001		Apr	CAHN
	@ PHARM ASSOC	80MG/15ML	A086720	001		May	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	THEOCHRON						
AB	NOSTRUM PHARMS LLC	100MG	A088320	001	Feb 21, 1985	May	CAHN
AB		200MG	A088321	001	Feb 21, 1985	May	CAHN
	@	300MG	A087400	002	Jan 11, 1983	May	CAHN
	THEOPHYLLINE						
	! ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr	CHRS
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May	CAHN
	!	450MG	A090430	002	Oct 27, 2010	May	CAHN
	<u>THIAMINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	THIAMINE HYDROCHLORIDE						
	@ WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan	CAHN

THIORIDAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC	30MG/ML	A 089602	001	Nov 09, 1987	Jan CAHN
@ PHARM ASSOC	30MG/ML	A 040187	001	Aug 28, 1997	May CAHN
@	100MG/ML	A 040213	001	May 29, 1998	May CAHN

## TABLET; ORAL

## THIORIDAZINE HYDROCHLORIDE

@ WATSON LABS TEVA	15MG	A 088477	001	Nov 08, 1983	May CAHN
@	25MG	A 088567	001	May 11, 1984	May CAHN
@	200MG	A 088872	001	Apr 26, 1985	May CAHN

THIOTEPA

## POWDER; IV (INFUSION)

## TEPADINA

+! ADIENNE SA	15MG/VIAL	N 208264	001	Jan 26, 2017	Jan NEWA
+!	100MG/VIAL	N 208264	002	Jan 26, 2017	Jan NEWA

TICAGRELOR

## TABLET; ORAL

## BRILINTA

+ ASTRAZENECA PHARMS	60MG	N 022433	002	Sep 03, 2015	Jan CAHN
+!	90MG	N 022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

## POWDER; IV (INFUSION)

## TIGECYCLINE

AP	SANDOZ INC	50MG/VIAL	A 091620	001	May 27, 2015	Feb CDFR
AP	+! PF PRISM CV	50MG/VIAL	N 021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATE

## SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

## TIMOLOL MALEATE

AB	SANDOZ INC	EQ 0.25% BASE	N 020963	001	Oct 21, 1998	Feb CAHN
AB		EQ 0.5% BASE	N 020963	002	Oct 21, 1998	Feb CAHN

## SOLUTION/DROPS; OPHTHALMIC

## TIMOLOL MALEATE

AT	! ALCON RES LTD	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Jan CHRS
AT1	!	EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Jan CHRS
AT	! SANDOZ INC	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Feb CAHN
AT1	!	EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Feb CAHN
	TIMOPTIC					
	+ @ ATON	EQ 0.25% BASE	N 018086	001		Jan DISC
	+ @	EQ 0.5% BASE	N 018086	002		Jan DISC

TINIDAZOLE

## TABLET; ORAL

## TINIDAZOLE

AB	UNIQUE PHARM LABS	250MG	A 202489	001	Oct 09, 2013	Jan CTEC
AB		500MG	A 202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

## CAPSULE; ORAL

## TIZANIDINE HYDROCHLORIDE

>A>	AB	JUBILANT GENERICS	EQ 2MG BASE	A 209605	001	Aug 04, 2017	Jul NEWA
>A>	AB		EQ 4MG BASE	A 209605	002	Aug 04, 2017	Jul NEWA
>A>	AB		EQ 6MG BASE	A 209605	003	Aug 04, 2017	Jul NEWA
	AB	PAR PHARM INC	EQ 2MG BASE	A 207199	001	Mar 14, 2017	Feb NEWA
	AB		EQ 4MG BASE	A 207199	002	Mar 14, 2017	Feb NEWA
	AB		EQ 6MG BASE	A 207199	003	Mar 14, 2017	Feb NEWA
	AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A 208622	001	Mar 03, 2017	Feb NEWA
	AB		EQ 4MG BASE	A 208622	002	Mar 03, 2017	Feb NEWA
	AB		EQ 6MG BASE	A 208622	003	Mar 03, 2017	Feb NEWA

## TABLET; ORAL

## TIZANIDINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 2MG BASE	A 076347	001	Oct 11, 2002	May CAHN
AB		EQ 4MG BASE	A 076347	002	Oct 11, 2002	May CAHN
AB	PAR PHARM INC	EQ 2MG BASE	A 207170	001	Jan 26, 2017	Jan NEWA
AB		EQ 4MG BASE	A 207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May	CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar	NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun	NEWA
AT	TOBEX						
AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@ SUN PHARM INDS

EQ 200MG BASE

A073310 001 Nov 27, 1991 Apr DISC

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun	CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun	CAHN
+		100MG	N205122	003	Mar 11, 2014	Jun	CAHN
+		150MG	N205122	004	Mar 11, 2014	Jun	CAHN
+	!	200MG	N205122	005	Mar 11, 2014	Jun	CAHN

TABLET; ORAL

TOPIRAMATE

@ MYLAN

25MG

A076314 001 Mar 27, 2009 May DISC

@

50MG

A076314 002 Mar 27, 2009 May DISC

@

100MG

A076314 003 Mar 27, 2009 May DISC

@

200MG

A076314 004 Mar 27, 2009 May DISC

AB	UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun	CAHN
AB		50MG	A078499	002	Jan 07, 2010	Jun	CAHN
AB		100MG	A078499	003	Jan 07, 2010	Jun	CAHN
AB		200MG	A078499	004	Jan 07, 2010	Jun	CAHN

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun	NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun	NEWA

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan	CAHN
---	---	-------------	--------------	---------	-----	--------------	-----	------

TORSEMIDE

TABLET; ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar	CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar	CAHN
AB	+	!	20MG	N020136	003	Aug 23, 1993	Mar	CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar	CAHN
AB	AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

+	@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CRLD
+	@		200MG	N021692	002	Sep 08, 2005	Mar	CRLD
+	@		300MG	N021692	003	Sep 08, 2005	Mar	CRLD

TRAMETINIB DIMETHYL SULFOXIDETABLET; ORAL  
MEKINIST

>D>	+	NOVARTIS PHARMS CORP	EQ 1MG	N204114	002	May 29, 2013	Jul	DISC
>A>	+	@	EQ 1MG	N204114	002	May 29, 2013	Jul	DISC

TRANDOLAPRILTABLET; ORAL  
TRANDOLAPRIL

	@	EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007	May	CAHN
	@		2MG	A077256	002	Jun 12, 2007	May	CAHN
	@		4MG	A077256	003	Jun 12, 2007	May	CAHN
	@	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007	Jun	DISC
BX			1MG	A078320	001	Jun 12, 2007	Apr	CTEC
	@		2MG	A078320	002	Jun 12, 2007	Jun	DISC
BX			2MG	A078320	002	Jun 12, 2007	Apr	CTEC
	@		4MG	A078320	003	Jun 12, 2007	Jun	DISC
BX			4MG	A078320	003	Jun 12, 2007	Apr	CTEC
	@	MYLAN	1MG	A078346	001	Apr 28, 2008	May	DISC
	@		2MG	A078346	002	Apr 28, 2008	May	DISC
	@		4MG	A078346	003	Apr 28, 2008	May	DISC

TRANEXAMIC ACIDINJECTABLE; INJECTION  
TRANEXAMIC ACID

AP		AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb	NEWA
AP		GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan	NEWA
AP		MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Jun	NEWA
>A>	AP	ZYDUS PHARMS USA INC	100MG/ML	A205228	001	Jul 17, 2017	Jul	NEWA

TRAVOPROSTSOLUTION/DROPS; OPHTHALMIC  
TRAVOPROST

AT		MYLAN PHARMS INC	0.004%	A205050	001	Jul 07, 2017	Jun	NEWA
----	--	------------------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDETABLET; ORAL  
TRAZODONE HYDROCHLORIDE

	@	MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	May	DISC
	@		100MG	A090514	002	Jun 02, 2009	May	DISC
	@		150MG	A090514	003	Jun 02, 2009	May	DISC
	@		300MG	A090514	004	Jun 02, 2009	May	DISC

TRETINOINCAPSULE; ORAL  
TRETINOIN

AB		GLENMARK PHARMS LTD	10MG	A208279	001	Dec 23, 2016	Jun	CAHN
	+	@ CHEPLAPHARM	10MG	N020438	001	Nov 22, 1995	May	CAHN

CREAM; TOPICAL  
TRETINOIN

AB2		ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN
-----	--	----------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL  
TRETINOIN

AB		MYLAN PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN
AB			0.05%	A207955	001	Aug 13, 2015	Jun	CAHN
AB			0.1%	A202026	001	Jul 17, 2013	Jun	CAHN

TRIAMCINOLONE ACETONIDECREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA
AT			0.1%	A208763	002	Feb 01, 2017	Jan	NEWA
AT			0.5%	A208763	003	Feb 01, 2017	Jan	NEWA
AT	+	MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN
AT	+		0.1%	N011601	006		Jan	CAHN
	@	TARO	0.025%	A040038	001	Oct 26, 1994	Apr	CAHN
AT			0.1%	A040039	001	Nov 26, 1997	Apr	CAHN
AT			0.1%	A040039	001	Nov 26, 1997	Mar	CAHN

	INJECTABLE; INJECTION							
	KENALOG-10							
	+	APOTHECON	10MG/ML	N012041	001		Jun CRLD	
		TRIAMCINOLONE ACETONIDE						
	@	SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr CAHN	
	@		40MG/ML	A090164	001	Jun 01, 2009	Apr CAHN	
	OINTMENT; TOPICAL							
	KENALOG							
AT		MYLAN PHARMS INC	0.025%	N011600	003		Jan CAHN	
AT			0.1%	N011600	001		Jan CAHN	
		TRIAMCINOLONE ACETONIDE						
	@	TARO	0.025%	A040040	001	Sep 30, 1994	Apr CAHN	
AT			0.1%	A040037	001	Sep 30, 1994	Apr CAHN	
AT		TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb NEWA	
		TRIAMCINOLONE ACETONIDE	IN ABSORBASE					
	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr CAHN	
	PASTE; DENTAL							
		TRIAMCINOLONE ACETONIDE						
AT		G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan NEWA	
	SPRAY, METERED; NASAL							
		TRIAMCINOLONE ACETONIDE						
	@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN	
	<u>TRIAMCINOLONE DIACETATE</u>							
	INJECTABLE; INJECTION							
	ARISTOCORT							
	@	SANDOZ INC	25MG/ML	N011685	003		Jun CAHN	
	+	@	40MG/ML	N012802	001		Jun CAHN	
	<u>TRIAMCINOLONE HEXACETONIDE</u>							
	INJECTABLE; INJECTION							
	ARISTOSPAN							
	+	!	SANDOZ INC	5MG/ML	N016466	001	Jun CAHN	
	+	!		20MG/ML	N016466	002	Jun CAHN	
	<u>TRIFLURIDINE</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	TRIFLURIDINE							
>A>	AT	HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017	Jul NEWA	
	AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb CAHN	
	VIOPTIC							
	AT	+	!	MONARCH PHARMS	1%	N018299	001	Feb CAHN
	<u>TRIHXYPHENIDYL HYDROCHLORIDE</u>							
	ELIXIR; ORAL							
	TRIHXYPHENIDYL HYDROCHLORIDE							
AA	!	PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May CAHN	
	TABLET; ORAL							
	TRIHXYPHENIDYL HYDROCHLORIDE							
AA		VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar CAHN	
AA			5MG	A040254	002	Dec 24, 1998	Mar CAHN	
	<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	TIGAN							
AB	+	!	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May CAHN
	<u>TRIMIPRAMINE MALEATE</u>							
	CAPSULE; ORAL							
	TRIMIPRAMINE MALEATE							
AB		ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May CAHN	
AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	May CAHN	
AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	May CAHN	
	<u>TRIPTORELIN PAMOATE</u>							
	FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
	TRIPTODUR KIT							
	+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun NEWA

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC  
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001			Feb	CAHN
----	---	------------	------	---------	-----	--	--	-----	------

TROSPIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
TROSPIUM CHLORIDE

	@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015		Jun	CAHN
--	---	-------------------	------	---------	-----	--------------	--	-----	------

ULIPRISTAL ACETATETABLET;ORAL  
ELLA

AB	+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010		Jan	CFTG
----	---	----------------	------	---------	-----	--------------	--	-----	------

AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017		Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	--	-----	------

URSODIOLCAPSULE;ORAL  
URSODIOL

	@	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006		May	DISC
BX			300MG	A077895	001	Jul 27, 2006		Apr	CTEC
AB			300MG	A077895	001	Jul 27, 2006		Feb	CAHN

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL  
VALACYCLOVIR HYDROCHLORIDE

	@	MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010		Jun	DISC
	@		EQ 1GM BASE	A078070	002	May 24, 2010		Jun	DISC

VALBENAZINE TOSYLATECAPSULE;ORAL  
INGREZZA

	+	NEUROCRINE	40MG	N209241	001	Apr 11, 2017		Apr	NEWA
--	---	------------	------	---------	-----	--------------	--	-----	------

VALPROATE SODIUMINJECTABLE;INJECTION  
VALPROATE SODIUM

AP		ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002		Mar	CAHN
----	--	-------------	------------------	---------	-----	--------------	--	-----	------

VALPROIC ACIDCAPSULE;ORAL  
VALPROIC ACID

	@	USL PHARMA	250MG	A070631	001	Jun 11, 1987		Jun	CAHN
--	---	------------	-------	---------	-----	--------------	--	-----	------

SYRUP;ORAL

AA		ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010		Mar	CAHN
----	--	----------------	-----------	---------	-----	--------------	--	-----	------

AA		PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000		May	CAHN
----	--	-------------	-----------	---------	-----	--------------	--	-----	------

AA		VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000		Feb	CAHN
----	--	------------	-----------	---------	-----	--------------	--	-----	------

VALSARTANTABLET;ORAL  
VALSARTAN

AB		AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016		May	CAHN
AB			80MG	A204011	002	Jan 11, 2016		May	CAHN
AB			160MG	A204011	003	Jan 11, 2016		May	CAHN
AB			320MG	A204011	004	Jan 11, 2016		May	CAHN
AB		MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015		Feb	CAHN
AB			80MG	A090866	002	Jan 05, 2015		Feb	CAHN
AB			160MG	A090866	003	Jan 05, 2015		Feb	CAHN
AB			320MG	A090866	004	Jan 05, 2015		Feb	CAHN

VARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL  
STAXYN

	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010		Jun	CTEC
--	---	----------------	------	---------	-----	--------------	--	-----	------



VASOPRESSIN

SOLUTION;IV (INFUSION)

VASOSTRICT

	+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May	CMFD
	+	@	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	DISC
	+	!	20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr	NEWA
	+	!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May	NEWA

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

		@	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar	CAHN
AP				10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
		@		20MG/VIAL	A075218	002	Aug 23, 1999	Mar	CAHN
AP				20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb	CAHN
AB				EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb	CAHN
AB				EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb	CAHN
AB				EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb	CAHN
AB				EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar	NEWA
AB				EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar	NEWA
AB	+		OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar	CFTG

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPTIN

	+	@	MT ADAMS	2.5MG/ML	N018485	001		Apr	CRLD
--	---	---	----------	----------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

	+	@	PFIZER	180MG	N019152	002	Dec 15, 1989	Jan	CRLD
			COVERA-HS						
		@	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan	DISC
		@		240MG	N020552	002	Feb 26, 1996	Jan	DISC

VERAPAMIL HYDROCHLORIDE

AB			CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr	NEWA
AB				240MG	A206173	002	May 05, 2017	Apr	NEWA

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+	!	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CFTG
	+	!		500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN

VIGABATRIN

AA			PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr	NEWA
----	--	--	---------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

SABRIL

	+	!	LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN
--	---	---	---------------------	-------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP			WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar	CAHN
AP				EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN

VORICONAZOLE

POWDER;IV (INFUSION)

VORICONAZOLE

			XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar	NEWA
--	--	--	-------------------	------------	---------	-----	--------------	-----	------

VORTIOXETINE HYDROBROMIDETABLET; ORAL  
TRINTELLIX

+ @ TAKEDA PHARMS USA EQ 15MG BASE N204447 003 Sep 30, 2013 Mar DISC

WARFARIN SODIUMTABLET; ORAL  
JANTOVEN

AB	USL PHARMA	1MG	A 040416	001	Oct 02, 2003	Jun	CAHN
AB		2MG	A 040416	002	Oct 02, 2003	Jun	CAHN
AB		2.5MG	A 040416	003	Oct 02, 2003	Jun	CAHN
AB		3MG	A 040416	004	Oct 02, 2003	Jun	CAHN
AB		4MG	A 040416	005	Oct 02, 2003	Jun	CAHN
AB		5MG	A 040416	006	Oct 02, 2003	Jun	CAHN
AB		6MG	A 040416	007	Oct 02, 2003	Jun	CAHN
AB		7.5MG	A 040416	008	Oct 02, 2003	Jun	CAHN
AB		10MG	A 040416	009	Oct 02, 2003	Jun	CAHN

WARFARIN SODIUM

	@ MYLAN	1MG	A 040415	001	Sep 27, 2004	Apr	DISC
	@	2MG	A 040415	002	Sep 27, 2004	Apr	DISC
	@	2.5MG	A 040415	003	Sep 29, 2004	Apr	DISC
	@	3MG	A 040415	004	Sep 27, 2004	Apr	DISC
	@	4MG	A 040415	005	Sep 27, 2004	Apr	DISC
	@	5MG	A 040415	006	Sep 27, 2004	Apr	DISC
	@	6MG	A 040415	007	Sep 27, 2004	Apr	DISC
	@	7.5MG	A 040415	008	Sep 27, 2004	Apr	DISC
	@	10MG	A 040415	009	Sep 27, 2004	Apr	DISC
AB	TARO PHARM	1MG	A 040301	002	Jul 15, 1999	Mar	CAHN
AB		2MG	A 040301	003	Jul 15, 1999	Mar	CAHN
AB		2.5MG	A 040301	004	Jul 15, 1999	Mar	CAHN
AB		3MG	A 040301	005	Jul 15, 1999	Mar	CAHN
AB		4MG	A 040301	006	Jul 15, 1999	Mar	CAHN
AB		5MG	A 040301	007	Jul 15, 1999	Mar	CAHN
AB		6MG	A 040301	008	Jul 15, 1999	Mar	CAHN
AB		7.5MG	A 040301	009	Jul 15, 1999	Mar	CAHN
AB		10MG	A 040301	001	Jul 15, 1999	Mar	CAHN

ZALEPLONCAPSULE; ORAL  
ZALEPLON

>D>	AB	MYLAN	5MG	A 077238	001	Jun 06, 2008	Jul	DISC
>A>		@	5MG	A 077238	001	Jun 06, 2008	Jul	DISC
>D>	AB		10MG	A 077238	002	Jun 06, 2008	Jul	DISC
>A>		@	10MG	A 077238	002	Jun 06, 2008	Jul	DISC
		@ UPSHER-SMITH LABS	5MG	A 078095	001	Jun 06, 2008	Jun	CAHN
		@	5MG	A 078706	001	Jun 06, 2008	Jun	CAHN
		@	10MG	A 078095	002	Jun 06, 2008	Jun	CAHN
		@	10MG	A 078706	002	Jun 06, 2008	Jun	CAHN

ZIDOVUDINETABLET; ORAL  
ZIDOVUDINE

@ HEC PHARM USA INC 300MG A202058 001 Oct 07, 2011 May CAHN

ZILEUTONTABLET, EXTENDED RELEASE; ORAL  
ZILEUTON

AB	PACK PHARMS LLC	600MG	A 204929	001	Mar 17, 2017	Mar	NEWA
AB	RISING PHARMS INC	600MG	A 204929	001	Mar 17, 2017	Mar	CAHN
	ZYFLO CR						
AB	+! CHIESI USA INC	600MG	N 022052	001	May 30, 2007	Mar	CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A 204375	001	Feb 17, 2017	Feb	NEWA
AB		EQ 40MG BASE	A 204375	002	Feb 17, 2017	Feb	NEWA
AB		EQ 60MG BASE	A 204375	003	Feb 17, 2017	Feb	NEWA
AB		EQ 80MG BASE	A 204375	004	Feb 17, 2017	Feb	NEWA

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)  
ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May	CAHN

ZOLMITRIPTANTABLET;ORAL  
ZOLMITRIPTAN

AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun	NEWA
AB		5MG	A206973	002	Jun 30, 2017	Jun	NEWA
AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb	NEWA

ZOLPIDEM TARTRATETABLET;ORAL  
ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar	CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar	CAHN

TABLET;SUBLINGUAL  
EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar	CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL  
ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA
	@ SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	DISC
	@	12.5MG	A078483	002	Jun 06, 2011	Apr	DISC

ZONISAMIDECAPSULE;ORAL  
ZONISAMIDE

@	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May	CAHN
@		50MG	A077876	002	Feb 21, 2007	May	CAHN
@		100MG	A077876	003	Feb 21, 2007	May	CAHN
@	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun	DISC
@		50MG	A077647	002	Dec 22, 2005	Jun	DISC
@		100MG	A077647	003	Dec 22, 2005	Jun	DISC
@	UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun	CAHN
@		50MG	A077644	002	Dec 22, 2005	Jun	CAHN
@		100MG	A077644	003	Dec 22, 2005	Jun	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL  
SHADE UVAGUARD

+ @ BAYER HEALTHCARE LLC 3%;7.5%;3% N020045 001 Dec 07, 1992 Jun DISC

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A> STRIDES PHARMA 10MG A205291 001 Jul 21, 2017 Jul NEWA

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ALLIED PHARMA INC 5MG/5ML A091327 001 Oct 17, 2011 Apr CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ALLIED PHARMA INC 5MG/5ML A091327 002 Oct 17, 2011 Apr CAHN

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT CADISTA 5MG A078933 001 Jun 15, 2010 Apr CAHN

10MG A078933 002 Jun 15, 2010 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

JUBILANT CADISTA 5MG A078933 003 Jun 15, 2010 Apr CAHN

10MG A078933 004 Jun 15, 2010 Apr CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL MULTI-SYMPOM COLD & FLU

+! PFIZER 4MG;200MG;10MG N022113 002 Apr 28, 2017 Apr NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

L PERRIGO CO 200MG A075285 001 Oct 29, 1998 Apr CAHN

@ SANDOZ INC 100MG A075122 001 Jun 19, 1998 Mar CAHN

@ 200MG A075122 002 Jun 19, 1998 Mar CAHN

@ WATSON LABS TEVA 200MG A075425 001 Jul 29, 1999 May CAHN

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

L PERRIGO CO 1.34MG A074512 001 Nov 22, 1995 Apr CAHN

TAVIST-1

+! GLAXOSMITHKLINE CONS 1.34MG N020925 001 Aug 21, 1992 Apr CAHN

CLOTTRIMAZOLE

CREAM; VAGINAL

CLOTTRIMAZOLE

! ACTAVIS MID ATLANTIC 1% A074165 001 Jul 16, 1993 Jun CHRS

TARO 1% A072641 001 Dec 04, 1995 Apr CAHN

GYNE-LOTRIMIN

+ @ BAYER HEALTHCARE LLC 1% N018052 002 Nov 30, 1990 Jun DISC

GYNE-LOTRIMIN 3

+ @ BAYER HEALTHCARE LLC 2% N020574 001 Nov 24, 1998 Jun DISC

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ @ BAYER HEALTHCARE LLC 1%,200MG N020526 002 Jul 29, 1996 Jun DISC

GYNE-LOTRIMIN COMBINATION PACK

+ @ BAYER HEALTHCARE LLC 1%,100MG N020289 002 Apr 26, 1993 Jun DISC

TABLET; VAGINAL

GYNE-LOTRIMIN

+ @ BAYER HEALTHCARE LLC 100MG N017717 002 Nov 30, 1990 Jun DISC

GYNE-LOTRIMIN 3

+ @ BAYER HEALTHCARE LLC 200MG N020525 001 Jul 29, 1996 Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL 30MG;600MG A091070 001 Aug 31, 2015 Mar CAHN

60MG;1.2GM A091070 002 Aug 31, 2015 Mar CAHN

AUROBINDO PHARMA LTD 30MG;600MG A206941 001 Mar 17, 2017 Mar NEWA

60MG;1.2GM A206941 002 Mar 17, 2017 Mar NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL  
 DEXTROMETHORPHAN POLISTIREX  
 >A> AMNEAL PHARMS LLC EQ 30MG HBR/5ML A203133 001 Jul 28, 2017 Jul NEWA

FAMOTIDINE

TABLET;ORAL  
 FAMOTIDINE  
 PERRIGO R AND D 20MG A077351 001 Sep 25, 2006 Apr CAHN

FLUTICASONE FUROATE

SPRAY, METERED;NASAL  
 FLONASE SENSIMIST ALLERGY RELIEF  
 +! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY N022051 002 Aug 02, 2016 Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
 GUAIFENESIN  
 ACTAVIS LABS FL 1.2GM A091009 002 Sep 03, 2015 Mar CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE  
 ACTAVIS LABS FL 600MG;60MG A091071 001 May 27, 2015 Mar CAHN  
 1.2GM;120MG A091071 002 May 27, 2015 Mar CAHN

IBUPROFEN

CAPSULE;ORAL  
 IBUPROFEN  
 AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM A202300 001 Dec 23, 2011 May CAHN  
 SALT  
 SUSPENSION;ORAL  
 IBUPROFEN  
 TARO 100MG/5ML A209207 001 Jun 27, 2017 Jun NEWA  
 SUSPENSION/DROPS;ORAL  
 IBUPROFEN  
 L PERRIGO CO 40MG/ML A075217 001 Dec 16, 1998 Apr CAHN  
 TABLET;ORAL  
 IBUPROFEN  
 AIPING PHARM INC 200MG A207095 001 May 05, 2017 Apr NEWA  
 AMNEAL PHARMS 200MG A079233 001 Mar 18, 2014 Apr CAHN  
 STRIDES PHARMA 200MG A207052 001 May 30, 2017 Jun CMS2  
 200MG A207052 001 May 30, 2017 May NEWA  
 JUNIOR STRENGTH IBUPROFEN  
 L PERRIGO CO 100MG A075367 001 Apr 22, 1999 Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL  
 XYZAL ALLERGY 24HR  
 + SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML) N209090 001 Jan 31, 2017 Feb CAHN  
 + UCB INC 2.5MG/5ML (0.5MG/ML) N209090 001 Jan 31, 2017 Jan NEWA  
 TABLET;ORAL  
 XYZAL ALLERGY 24HR  
 + SANOFI-AVENTIS US 5MG N209089 001 Jan 31, 2017 Feb CAHN  
 + UCB INC 5MG N209089 001 Jan 31, 2017 Jan NEWA

LEVONORGESTREL

TABLET;ORAL  
 LEVONORGESTREL  
 RECKITT BENCKISER 1.5MG A202246 001 Jun 05, 2015 Apr CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL  
 LOPERAMIDE HYDROCHLORIDE  
 ALLIED PHARMA INC 1MG/5ML A073079 001 Apr 30, 1992 Mar CAHN  
 TABLET;ORAL  
 LOPERAMIDE HYDROCHLORIDE  
 L PERRIGO CO 2MG A075232 001 Jan 06, 2000 Apr CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE  
 ! PERRIGO 2MG;125MG A076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL  
 LORATADINE  
 TARO PHARM 1MG/ML A201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL  
 MICONAZOLE NITRATE  
 TARO 2% A074444 001 Jan 13, 1997 Apr CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL  
 M-ZOLE 3 COMBINATION PACK  
 ACTAVIS MID ATLANTIC 2%,200MG A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL  
 MICONAZOLE NITRATE  
 ACTAVIS PHARMA 100MG A073507 001 Nov 19, 1993 May CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL  
 MINOXIDIL (FOR MEN)  
 WATSON LABS INC 5% A208092 001 Feb 17, 2017 Feb NEWA

>A>

MINOXIDIL (FOR WOMEN)  
 WATSON LABS INC 5% A208092 002 Jul 27, 2017 Jul NEWA

SOLUTION;TOPICAL  
 MINOXIDIL (FOR MEN)  
 L PERRIGO CO 2% A075357 001 Jul 30, 1999 Apr CAHN

MINOXIDIL (FOR WOMEN)  
 L PERRIGO CO 2% A075357 002 Jul 30, 1999 Apr CAHN

NAPROXEN SODIUM

TABLET;ORAL  
 NAPROXEN SODIUM  
 LNK INTL INC EQ 200MG BASE A204872 001 Jan 23, 2017 Jan NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
 HABITROL  
 + DR REDDYS LABS SA 7MG/24HR N020076 004 Nov 12, 1999 Jun CAHN  
 + 14MG/24HR N020076 005 Nov 12, 1999 Jun CAHN  
 +! 21MG/24HR N020076 006 Nov 12, 1999 Jun CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL  
 NICOTINE POLACRILEX  
 L PERRIGO CO EQ 2MG BASE A076775 001 Sep 16, 2004 Apr CAHN  
 EQ 2MG BASE A076776 001 Sep 16, 2004 Apr CAHN  
 EQ 2MG BASE A076777 001 Sep 16, 2004 Apr CAHN  
 EQ 4MG BASE A076778 001 Sep 16, 2004 Apr CAHN  
 EQ 4MG BASE A076779 001 Sep 16, 2004 Apr CAHN  
 EQ 4MG BASE A076789 001 Sep 16, 2004 Apr CAHN

OMEPRAZOLE

>A>

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

>A>

OMEPRAZOLE

>A>

+ DEXCEL PHARMA 20MG N209400 001 Jul 05, 2017 Jul NEWA

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 OCUCLEAR  
 @ BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 May DISC

PERMETHRIN

LOTION; TOPICAL  
PERMETHRIN

ACTAVIS MID ATLANTIC 1%

A075014 001 Mar 28, 2000 May CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 120MG  
L PERRIGO CO 120MG

A209008 001 Jun 09, 2017 May NEWA  
A075153 001 Feb 26, 1999 Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 150MG BASE  
ZANTAC 150

A200536 001 Jun 28, 2011 Jan CAHN

+! SANOFI US EQ 150MG BASE

N021698 001 Aug 31, 2004 Mar CAHN

+ ZANTAC 75 EQ 150MG BASE

N021698 002 Mar 13, 2007 Mar CAHN

ZANTAC 75

SANOFI US EQ 75MG BASE

N020520 001 Dec 19, 1995 Mar CAHN

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

>A> +! GLAXOSMITHKLINE 1%

N020980 001 Mar 09, 1999 Jul CAHN

>D> +! NOVARTIS 1%

N020980 001 Mar 09, 1999 Jul CAHN

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT-1

>A> +! COMBE 6.5%

N020676 001 Feb 11, 1997 Jul CAHN

>D> +! NOVARTIS 6.5%

N020676 001 Feb 11, 1997 Jul CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2017**

NO JULY 2017 APPROVALS



## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790 001					>A> PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Sep 17, 2022	DS DP U-1167			
	6967208	Sep 17, 2022	DS DP U-1200			
	6967208	Sep 17, 2022	DS DP U-1301			
	6967208	Sep 17, 2022	DS DP U-1302			
	6967208	Sep 17, 2022	DS DP U-1323			
	6967208	Sep 17, 2022	DS DP U-1501			
	6967208	Sep 17, 2022	DS DP U-1502			
	6967208	Sep 17, 2022	DS DP U-1729			
	6967208	Sep 17, 2022	DS DP U-1730			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Sep 17, 2022	DS DP U-1200			
	6967208	Sep 17, 2022	DS DP U-1301			
	6967208	Sep 17, 2022	DS DP U-1302			
	6967208	Sep 17, 2022	DS DP U-1323			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					>A> I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					>A> I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					>A> I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					>A> I-746	Jul 27, 2020
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030		U-543		
	9034867	Nov 07, 2032		DP U-543		
	9193685	Oct 24, 2033		DP U-543		
	9452131	Mar 19, 2035		U-543		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					>A> M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					>A> M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 003					>A> M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 004					>A> M-204	Jun 23, 2020
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
	>A> 9695122	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9655907	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	>A> 6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	>A> 6376515	Sep 15, 2020	DS DP U-1502			
	>A> 6376515	Sep 15, 2020	DS DP U-2029			
	>A> 6376515	Sep 15, 2020	DS DP U-2030			
	>A> 6835739	Sep 15, 2020	DS DP			
	>A> 7598276	Nov 08, 2026	DS			
	>A> 8404724	Mar 29, 2031	DP U-2034			
	>A> 8518977	Sep 15, 2020	DS			
	>A> 8557852	Sep 08, 2028	U-1167			
	>A> 8557852	Sep 08, 2028	U-2030			
	>A> 8691847	Sep 15, 2020	DS DP U-2029			
	>A> 8691847	Sep 15, 2020	DS DP U-2035			
	>A> 8987463	Dec 28, 2030	DP			
	>A> 9555023	Nov 07, 2026	U-1502			
	>A> 9629831	Sep 15, 2020	U-1167			
	>A> 9629831	Sep 15, 2020	U-1502			
	>A> 9629831	Sep 15, 2020	U-2030			
	>A> 9629831	Sep 15, 2020	U-2035			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	>A> 6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	>A> 6376515	Sep 15, 2020	DS DP U-1502			
	>A> 6376515	Sep 15, 2020	DS DP U-2029			
	>A> 6376515	Sep 15, 2020	DS DP U-2030			
	>A> 6835739	Sep 15, 2020	DS DP			
	>A> 7598276	Nov 08, 2026	DS			
	>A> 8404724	Mar 29, 2031	DP U-2034			
	>A> 8518977	Sep 15, 2020	DS			
	>A> 8557852	Sep 08, 2028	U-1167			
	>A> 8557852	Sep 08, 2028	U-2030			
	>A> 8691847	Sep 15, 2020	DS DP U-2029			
	>A> 8691847	Sep 15, 2020	DS DP U-2035			
	>A> 8987463	Dec 28, 2030	DP			
	>A> 9555023	Nov 07, 2026	U-1502			
	>A> 9629831	Sep 15, 2020	U-1167			
	>A> 9629831	Sep 15, 2020	U-1502			
	>A> 9629831	Sep 15, 2020	U-2030			
	>A> 9629831	Sep 15, 2020	U-2035			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029		U-1927	ODE	Apr 28, 2024
	9611283	Apr 10, 2034		U-1927		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033		U-1933		
	9561277	Jan 16, 2024		U-1933		
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	7367333	Nov 11, 2018	DP		PED	Jul 27, 2020
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211*PED	Mar 09, 2019				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	>A> 9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	>A> 9687454	Aug 07, 2029	DP U-1464			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	>A> 9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	>A> 9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			PED	Nov 17, 2020
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030		U-1630		
	8927592*PED	Apr 27, 2031				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 9700575	Jul 10, 2035	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028		U-2004		
	9629797	Nov 10, 2028		U-2005		
	9629797	Nov 10, 2028		U-2006		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					>A> PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
					NCE	Nov 05, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE NPP	Aug 27, 2017 Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	>A> 9682092	Feb 16, 2027	U-1932			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	>A> 9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	>A> 7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> ODE	Jun 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-1406			
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8835443	Sep 13, 2025	U-2026			
	>A> 8835443	Sep 13, 2025	U-2027			
	>A> 8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	>A> 7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> ODE	Jun 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-1406			
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8835443	Sep 13, 2025	U-2026			
	>A> 8835443	Sep 13, 2025	U-2027			
	>A> 8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					NPP	Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE	Feb 09, 2022
					ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE	Feb 09, 2022
					ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE	Feb 09, 2022
					ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE	Feb 09, 2022
					ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE	Feb 09, 2022
					ODE	Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	>A> 7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	>A> 8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	>A> 8273892	Aug 06, 2026	DS			
	>A> 8497378	Dec 28, 2029	DS			
	>A> 8648093	Oct 07, 2025	DP U-2028			
	>A> 8871938	Sep 23, 2029	DS			
	>A> 8969569	Oct 07, 2025	DP U-2028			
	>A> 9539250	Oct 07, 2025	DS DP U-2028			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	>A> 7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	>A> 8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	>A> 8273892	Aug 06, 2026	DS			
	>A> 8497378	Dec 28, 2029	DS			
	>A> 8648093	Oct 07, 2025	DP U-2028			
	>A> 8871938	Sep 23, 2029	DS			
	>A> 9539250	Oct 07, 2025	DS DP U-2028			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 001				>A>	PC	Jan 25, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 002				>A>	PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 003				>A>	PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9592242	Oct 20, 2020		U-1989		
	9592242	Oct 20, 2020		U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029		U-1482		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027		U-1614		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027		U-620		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001 >A>	7560122	Jan 25, 2019	DP			
	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8598185	Apr 28, 2029	DP			
	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026		U-1281		
	8183274	Aug 24, 2026		U-1588		
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035		U-1829		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 5753646	Jun 27, 2021	DS DP	U-2041		
	9566244	Oct 23, 2028		DP		
	9643929	Apr 21, 2026		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 5753646	Jun 27, 2021	DS DP	U-2041		
	9566244	Oct 23, 2028		DP		
	9643929	Apr 21, 2026		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 5753646	Jun 27, 2021	DS DP	U-2041		
	9566244	Oct 23, 2028		DP		
	9643929	Apr 21, 2026		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 5753646	Jun 27, 2021	DS DP	U-2041		
	9566244	Oct 23, 2028		DP		
	9643929	Apr 21, 2026		DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001					>A> NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002					>A> NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	>A> 9701712	Jul 29, 2030	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	>A> 9701712	Jul 29, 2030	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	>A> 9701712	Jul 29, 2030	DS DP U-2014			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	>A> 6239124	Jul 29, 2017	U-1049			
	>A> 6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	>A> 6239124	Jul 29, 2017	U-1049			
	>A> 6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	>A> 6239124	Jul 29, 2017	U-1049			
	>A> 6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004					ODE	Feb 26, 2023
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001				M-202 NCE	May 15, 2020 May 10, 2018
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002				M-202 NCE	May 15, 2020 May 10, 2018
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	003	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9616024	Sep 01, 2024	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	6446627	Dec 18, 2017	DP	NP	Jan 27, 2020
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8714149	Feb 25, 2032	DP		
		8978966	Jan 13, 2032	DP		
		9066957	Oct 06, 2034	DP U-645		
		9216260	Jun 28, 2031	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP	Apr 28, 2020
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
>A>	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1491		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	>A> 9707176	Nov 11, 2030	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	9670163	Dec 28, 2026	DP	U-1311		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					>A> I-748	Jul 07, 2020
					>A> ODE	Jul 07, 2024
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	>A> 7169780	Oct 03, 2023	DS DP			
	>A> 7169780*PED	Apr 03, 2024				
	>A> 7217713	Oct 21, 2022		U-1663		
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022		U-1663		
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP	U-1663		
	>A> 7754731*PED	Sep 11, 2029				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP	Apr 07, 2020
					ODE	Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001 >A>	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001 >A>	9708371	Aug 16, 2033	DP U-1515			
	>A> 9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002 >A>	9708371	Aug 16, 2033	DP U-1515			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
>A>	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	>A> 9707176	Nov 11, 2030	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	>A> 9707176	Nov 11, 2030	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	>A> 9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	>A> 5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		>A> ODE	Apr 25, 2024
					>A> ODE	Apr 25, 2024
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9669096	Apr 08, 2024	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	>A> 9724343	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	>A> 8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	>A> 9072680	Jun 28, 2032	DP			
	>A> 9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	>A> 8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	>A> 9072680	Jun 28, 2032	DP			
	>A> 9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	>A> 8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	>A> 9072680	Jun 28, 2032	DP			
	>A> 9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	>A> 9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	>A> 6288082	Sep 24, 2019	DS DP U-2043		>A> NCE	Jul 17, 2022
	>A> 7399865	Dec 29, 2025	DS DP			
	>A> 7982043	Oct 08, 2025	U-2043			
	>A> 8518446	Nov 20, 2030	DP U-2043			
	>A> 8790708	Nov 05, 2030	DP U-2043			
	>A> 9139558	Oct 15, 2028	U-2043			
	>A> 9211291	Mar 24, 2030	U-2043			
	>A> 9630946	Oct 15, 2028	U-2043			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018	U-1942			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	>A> 9682061	Apr 26, 2030	U-1569			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007 >A>	9675610	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	>A> 7566729	Apr 22, 2029	U-2077		NCE	Oct 16, 2019
	>A> 7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	>A> 7635707	Apr 22, 2029	U-2072			
	>A> 7635707	Apr 22, 2029	U-2073			
	>A> 7635707	Apr 22, 2029	U-2074			
	>A> 7635707	Apr 22, 2029	U-2075			
	>A> 7635707	Apr 22, 2029	U-2076			
	>A> 7635707	Apr 22, 2029	U-2083			
	>A> 7767700	Dec 18, 2027	U-2080			
	>A> 7816383	Jan 08, 2030	U-2042			
	>A> 7816383	Jan 08, 2030	U-2050			
	>A> 7910610	Jan 08, 2030	U-2048			
	>A> 7910610	Jan 08, 2030	U-2049			
	>A> 8013002	Jan 08, 2030	U-2047			
	>A> 8013002	Jan 08, 2030	U-2082			
	>A> 8084475	Jan 08, 2030	U-2052			
	>A> 8084475	Jan 08, 2030	U-2054			
	>A> 8318780	Jan 08, 2030	U-2046			
	>A> 8318780	Jan 08, 2030	U-2081			
	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8420674	Dec 18, 2017	U-2079			
	>A> 8592462	Apr 22, 2029	U-2055			
	>A> 8592462	Apr 22, 2029	U-2056			
	>A> 8592462	Apr 22, 2029	U-2057			
	>A> 8592462	Apr 22, 2029	U-2058			
	>A> 8592462	Apr 22, 2029	U-2059			
	>A> 8592462	Apr 22, 2029	U-2060			
	>A> 8592462	Apr 22, 2029	U-2061			
	>A> 8592462	Apr 22, 2029	U-2062			
	>A> 8592462	Apr 22, 2029	U-2063			
	>A> 8609701	Apr 22, 2029	U-2064			
	>A> 8609701	Apr 22, 2029	U-2065			
	>A> 8609701	Apr 22, 2029	U-2066			
	>A> 8609701	Apr 22, 2029	U-2067			
	>A> 8609701	Apr 22, 2029	U-2068			
	>A> 8609701	Apr 22, 2029	U-2069			
	>A> 8609701	Apr 22, 2029	U-2070			
	>A> 8648098	Jan 08, 2030	U-2051			
	>A> 8648098	Jan 08, 2030	U-2052			
	>A> 8754109	Jan 08, 2030	U-2053			
	>A> 8778947	Aug 30, 2033	U-2044			
	>A> 8778947	Aug 30, 2033	U-2045			
	>A> 9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE	Oct 16, 2019
					ODE	Oct 15, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	>A> 7566729	Apr 22, 2029	U-2077		NCE	Oct 16, 2019
	>A> 7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	>A> 7635707	Apr 22, 2029	U-2072			
	>A> 7635707	Apr 22, 2029	U-2073			
	>A> 7635707	Apr 22, 2029	U-2074			
	>A> 7635707	Apr 22, 2029	U-2075			
	>A> 7635707	Apr 22, 2029	U-2076			
	>A> 7635707	Apr 22, 2029	U-2083			
	>A> 7767700	Dec 18, 2027	U-2080			
	>A> 7816383	Jan 08, 2030	U-2042			
	>A> 7816383	Jan 08, 2030	U-2050			
	>A> 7910610	Jan 08, 2030	U-2048			
	>A> 7910610	Jan 08, 2030	U-2049			
	>A> 8013002	Jan 08, 2030	U-2047			
	>A> 8013002	Jan 08, 2030	U-2082			
	>A> 8084475	Jan 08, 2030	U-2052			
	>A> 8084475	Jan 08, 2030	U-2054			
	>A> 8318780	Jan 08, 2030	U-2046			
	>A> 8318780	Jan 08, 2030	U-2081			
	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8420674	Dec 18, 2017	U-2079			
	>A> 8592462	Apr 22, 2029	U-2055			
	>A> 8592462	Apr 22, 2029	U-2056			
	>A> 8592462	Apr 22, 2029	U-2057			
	>A> 8592462	Apr 22, 2029	U-2058			
	>A> 8592462	Apr 22, 2029	U-2059			
	>A> 8592462	Apr 22, 2029	U-2060			
	>A> 8592462	Apr 22, 2029	U-2061			
	>A> 8592462	Apr 22, 2029	U-2062			
	>A> 8592462	Apr 22, 2029	U-2063			
	>A> 8609701	Apr 22, 2029	U-2064			
	>A> 8609701	Apr 22, 2029	U-2065			
	>A> 8609701	Apr 22, 2029	U-2066			
	>A> 8609701	Apr 22, 2029	U-2067			
	>A> 8609701	Apr 22, 2029	U-2068			
	>A> 8609701	Apr 22, 2029	U-2069			
	>A> 8609701	Apr 22, 2029	U-2070			
	>A> 8648098	Jan 08, 2030	U-2051			
	>A> 8648098	Jan 08, 2030	U-2052			
	>A> 8754109	Jan 08, 2030	U-2053			
	>A> 8778947	Aug 30, 2033	U-2044			
	>A> 8778947	Aug 30, 2033	U-2045			
	>A> 9561217	Jan 25, 2022	DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	>A> 7169780	Oct 03, 2023	DS DP		>A> D-167	May 26, 2020
	>A> 7169780*PED	Apr 03, 2024			>A> PED	Nov 26, 2020
	>A> 7217713	Oct 21, 2022	U-257			
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022	U-257			
	>A> 7435734	Oct 21, 2022	U-900			
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP U-257			
	>A> 7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	>A> 7169780	Oct 03, 2023	DS DP		>A> NS	May 26, 2020
	>A> 7169780*PED	Apr 03, 2024			>A> PED	Nov 26, 2020
	>A> 7217713	Oct 21, 2022	U-257			
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022	U-257			
	>A> 7435734	Oct 21, 2022	U-900			
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP U-257			
	>A> 7754731*PED	Sep 11, 2029				
	>A> 9649311	Oct 21, 2030	DP			
	>A> 9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	>A> 7169780	Oct 03, 2023	DS DP			
	>A> 7169780*PED	Apr 03, 2024				
	>A> 7217713	Oct 21, 2022	U-257			
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022	U-257			
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP U-257			
	>A> 7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	>A> 7169780	Oct 03, 2023	DS DP			
	>A> 7169780*PED	Apr 03, 2024				
	>A> 7217713	Oct 21, 2022	U-257			
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022	U-257			
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP U-257			
	>A> 7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	>A> 7169780	Oct 03, 2023	DS DP			
	>A> 7169780*PED	Apr 03, 2024				
	>A> 7217713	Oct 21, 2022	U-257			
	>A> 7217713*PED	Apr 21, 2023				
	>A> 7435734	Oct 21, 2022	U-257			
	>A> 7435734*PED	Apr 21, 2023				
	>A> 7754731	Mar 11, 2029	DS DP U-257			
	>A> 7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823	002				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	001				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	002				PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001				M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001	7351834	Jun 28, 2022	DS	I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001	8324225	Jun 17, 2028	DS DP	NCE	Mar 13, 2022
		8415355	Feb 19, 2031	DS DP		
		8685980	May 25, 2030	DS DP		
		8962630	Dec 09, 2029	U-1981		
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029	U-1981		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	9629828	Jul 24, 2029		U-1994	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1956	
		9539218	Feb 17, 2034		U-1957	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1956	
		9539218	Feb 17, 2034		U-1957	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1957	
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	8404702	Apr 04, 2027		U-1741	
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	001				M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	002				M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	003				M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008	004				M-203	Mar 23, 2020



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SIMEPREVIR SODIUM - OLYSTO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	>A> 7964580	Mar 26, 2029	DS DP U-2039		>A> NCE	Dec 06, 2018
	>A> 7964580	Mar 26, 2029	DS DP U-2040		>A> NCE	Jun 28, 2021
	>A> 8334270	Mar 21, 2028	DS DP U-2039		>A> NCE	Jul 18, 2022
	>A> 8334270	Mar 21, 2028	DS DP U-2040			
	>A> 8575135	Nov 05, 2033	DS DP U-2039			
	>A> 8575135	Nov 05, 2033	DS DP U-2040			
	>A> 8580765	Mar 21, 2028	DS DP U-2039			
	>A> 8580765	Mar 21, 2028	DS DP U-2040			
	>A> 8618076	Dec 11, 2030	DS DP U-2039			
	>A> 8618076	Dec 11, 2030	DS DP U-2040			
	>A> 8633309	Mar 26, 2029	DS DP U-2039			
	>A> 8633309	Mar 26, 2029	DS DP U-2040			
	>A> 8735372	Mar 21, 2028	DS DP U-2039			
	>A> 8735372	Mar 21, 2028	DS DP U-2040			
	>A> 8889159	Mar 26, 2029	DS DP U-2039			
	>A> 8889159	Mar 26, 2029	DS DP U-2040			
	>A> 8921341	Nov 16, 2032	DS DP U-2039			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	>A> 8921341	Nov 16, 2032	DS DP U-2040			
	>A> 8940718	Nov 16, 2032	DS DP U-2039			
	>A> 8940718	Nov 16, 2032	DS DP U-2040			
	>A> 9085573	Mar 21, 2028	DS DP U-2039			
	>A> 9085573	Mar 21, 2028	DS DP U-2040			
	>A> 9284342	Sep 13, 2030	DS DP U-2039			
	>A> 9284342	Sep 13, 2030	DS DP U-2040			
	>A> 9296782	Jul 17, 2034	DS DP			
	>A> 9585906	Mar 21, 2028	DS DP U-2039			
	>A> 9585906	Mar 21, 2028	DS DP U-2040			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	RE46363	Aug 03, 2026	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	9561251	Jan 23, 2030	DP U-1468			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TALC - STERITALC</u>						
N 205555 001				>A> ODE		May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002				>A> ODE		May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003				>A> ODE		May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002 >A>	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003 >A>	9662340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					>A> I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					>A> I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	>A> RE46276	Oct 30, 2024	DS DP U-1935			
	>A> RE46276	Oct 30, 2024	DS DP U-1936			
	>A> RE46276	Oct 30, 2024	DS DP U-1937			
	>A> RE46276	Oct 30, 2024	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	>A> RE46276	Oct 30, 2024	DS DP U-1935			
	>A> RE46276	Oct 30, 2024	DS DP U-1936			
	>A> RE46276	Oct 30, 2024	DS DP U-1937			
	>A> RE46276	Oct 30, 2024	DS DP U-1938			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001 >A>	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	>A> 8703781	Oct 15, 2030	DS DP U-2033		>A> ODE	Jun 22, 2024
	>A> 8835443	Sep 13, 2025	U-1581			
	>A> 8835443	Sep 13, 2025	U-1582			
	>A> 8835443	Sep 13, 2025	U-2020			
	>A> 8835443	Sep 13, 2025	U-2037			
	>A> 8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	>A> 8703781	Oct 15, 2030	DS DP U-2033		>A> ODE	Jun 22, 2024
	>A> 8835443	Sep 13, 2025	U-1581			
	>A> 8835443	Sep 13, 2025	U-1582			
	>A> 8835443	Sep 13, 2025	U-2020			
	>A> 8835443	Sep 13, 2025	U-2037			
	>A> 8952018	Oct 15, 2030	U-2020			
	>A> 9155706	Jan 28, 2032	DP			
	>A> 9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	>A> 8703781	Oct 15, 2030	DS DP U-2033		>A> ODE	Jun 22, 2024
	>A> 8835443	Sep 13, 2025	U-1581			
	>A> 8835443	Sep 13, 2025	U-1582			
	>A> 8835443	Sep 13, 2025	U-2020			
	>A> 8835443	Sep 13, 2025	U-2037			
	>A> 8952018	Oct 15, 2030	U-2020			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	>A> 9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	>A> 9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	>A> 9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	>A> 9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP >A> ODE	Jun 29, 2020 Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					NCE NCE	May 10, 2018 Dec 18, 2018
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035		U-1857		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035		U-1857		
	9687526	Jan 30, 2035		U-1857		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	>A> 9707270	Oct 01, 2024		U-2084		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002 >A>	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003 >A>	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004 >A>	9707270	Oct 01, 2024	U-2084			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)